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ABSTRACT
The ability of human articular cartilage to respond to injury is poor. Once
cartilage damage has occurred, an irreversible degenerative process can occur and will
often lead to osteoarthritis (OA). An estimated 26.9 million of U.S. adults are affected by
OA. Osteochondral grafting is currently used to treat OA and osteochondral defects;
however, complications can develop at the donor site and defect area. Osteochondral
tissue engineering provides a potential treatment option and alternative to osteochondral
grafting. The long term goal of this work is to develop a tissue engineered mesenchymal
stem cell (MSC) based osteochondral construct to repair cartilage damage.
The first set of studies evaluated the interactions between skeletal tissue cells and
the effectiveness of conditioned media (CM) to modulate mesenchymal stem cell
differentiation. The results showed that CM can enhance the differentiation of MSCs
towards several different cell types depending on the type of CM.
The next set of studies involved the design and characterization of a novel
biphasic osteochondral tissue engineered construct. The osteochondral constructs were
designed to address some of the current limitations that osteochondral tissue engineering
currently faces; i.e., providing an alternate method of anchoring the construct and
providing the ability to generate large viable constructs. Based on the results of several
studies, a composite of polylactide/polycaprolactone and hydroxyapatite was used for the
bone phase, a barbed pin was used to create a stable implant, and agarose was chosen for
use in the cartilage phase. In addition, capillary channel fibers were incorporated in the
bone phase to provide nutrient and cell delivery. The bundles of capillary channel fibers
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embedded in large tissue engineering scaffolds were shown to facilitate a uniform cell
distribution through large volume scaffolds.
In the next study, a modified bioreactor was designed and incorporated a
pneumatically controlled syringe to generate hydrostatic pressure (HP) on both phases of
the biphasic construct. The bioreactor was used to demonstrate synergistic effects of CM
and HP on the chondrogenic and osteogenic differentiation of MSCs.
Ultimately, in a final study, the combination of CM, bioreactor cultivation, and
the unique construct design generated a biphasic construct with a cartilage-like upper
phase attached to a bone-like bottom phase.
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PREFACE
Adult articular cartilage has only a very limited capacity to heal and even small
initially injuries will not only fail to heal, but will often enlarge with time. Left untreated
these defects frequently lead to a debilitating state such as osteoarthritis (OA). OA, the
most common form of arthritis, affects approximately 14% of adults aged 25 and older
and 34% of those 65 and older. An estimated 26.9 million U.S. adults were affected by
OA in 2005, an increase from 21 million in 1990 [1]. Osteochondral grafting is currently
used to treat OA and osteochondral defects; however, complications can develop at the
donor site and defect area. Osteochondral tissue engineering provides a potential
treatment option and alternative to osteochondral grafting.
The long term goal of this work is to develop a tissue engineered mesenchymal
stem cell (MSC) based osteochondral construct. The studies described in this dissertation
are focused on three different aspects of developing an osteochondral construct: 1) Using
conditioned media (CM) to examine cellular interactions and enhance stem cell
differentiation 2) Examining the construct design and the biomaterials used to make the
constructs 3) Employing bioreactor technology to generate an in vitro modeling system
and provide advantageous culturing environments.
Chapter 1 provides an overview of the anatomy and physiology of cartilage and
bone. A discussion on the significance of the problem, including OA and traumatic
injury, is also included, followed by an overview of the current treatment options. Also
included in this chapter is a review of the current osteochondral tissue engineering
strategies and finally the use of bioreactors in tissue engineering is discussed.
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Chapter 2 describes two studies, both aimed at the evaluation of the interactions
between skeletal tissue cells and the effectiveness of CM to modulate MSC
differentiation. The first study was detailed in the peer reviewed journal, Journal of
Tissue Engineering and Regenerative Medicine, Volume 2 in 2008. The results were also
presented at the 2007 Annual Fall Meeting for the Biomedical Engineering Society in
Los Angeles, CA. Results from the first study showed that CM from differentiating
adipocytes can enhance the differentiation of MSCs toward osteoblasts and that CM from
differentiating osteoblasts can enhance the differentiation of MSCs toward adipocytes.
The second study is detailed in the Journal of Biomaterials Science – Polymer Edition;
the manuscript is currently in press. The results were also presented at the Society For
Biomaterials 2009 Annual Meeting and Exposition in San Antonio, TX. Results from the
second study suggest that CM from differentiating chondrocytes can enhance the
differentiation of MSCs toward osteoblasts and that CM from differentiating osteoblasts
can enhance the differentiation of MSCs toward chondrocytes.
Chapter 3 overviews the design and characterization of a novel biphasic
osteochondral tissue engineered construct. Two novel constructs for osteochondral tissue
engineering were developed. The osteochondral constructs were designed to address
some of the current limitations that osteochondral tissue engineering currently faces,
including the need to provide an alternative method of anchoring the construct and the
need to generate large viable constructs. The melting point and glass transition
temperatures of the biomaterials were evaluated before and after the various construct
production steps. The molecular weight and molecular weight distribution were also
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determined before and after the different production steps. Finally, the effectiveness of
the anchoring system was evaluated by testing the pull-out strength of the constructs.
Chapter 4 describes three studies that were conducted to evaluate individual
features of the biphasic construct in an effort to optimize the design. Based on the results
of the studies, a composite of polylactide/polycaprolactone and hydroxyapatite was used
for the bone phase of a barbed pin design to support osteogenic differentiation. In
addition, capillary channel fibers were incorporated in the bone phase of the barbed pin
design to allow for the development of larger constructs. Finally, agarose was chosen for
use in the cartilage phase of both designs as it enhanced chondrogenic differentiation,
showed better cell viability, and has better handling properties. The work from both
Chapter 3 and 4 resulted in a US patent application in 2009.
Chapter 5 overviews work to modify a bioreactor to improve a method of
producing hydrostatic pressure and to allow hydrostatic pressure to be administered to a
biphasic construct. The previous method of producing hydrostatic pressure failed 50% of
the time, resulting in samples being lost. The new design incorporates a pneumatically
controlled syringe that generates the hydrostatic pressure. The design was also modified
to allow hydrostatic pressure to be administered to a biphasic construct. An additional
biochamber was added to the setup, providing a chamber for each phase of a biphasic
construct; pressure chambers connected to pneumatically controlled syringes were
attached to each biochamber. In addition, the bioreactors were constructed out of
aluminum to avoid cracking problems that were seen with the previous design.
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Chapter 6 investigated the synergistic effects of CM and hydrostatic pressure
(HP) on the chondrogenic and osteogenic differentiation of mesenchymal stem cells. The
results showed that both osteoblast CM and intermittent HP individually enhanced the
chondrogenic differentiation of MSCs. In addition, there is evidence of a synergistic
interaction between CM and HP on chondrogenic differentiation. The results also
suggested that the combination of chondrocyte CM and HP significantly enhanced the
osteogenic differentiation of MSCs, while the individual stimuli did not have a significant
effect.
Chapter 7 presents work designed to evaluate the effectiveness of constructs
containing capillary channel fibers to facilitate large tissue constructs. The work was
split into two different phases, focusing first on evaluating the initial cell infiltration into
the scaffold, then investigating the cell viability and osteogenic differentiation after 3
weeks of culture. The results suggest that bundles of capillary channel fibers embedded
in large tissue engineering scaffolds as well as large fiber bundles can produce a uniform
cell distribution through the thickness of the large scaffolds. In addition, the cells are
able to remain viable after 21 days of culture and underwent osteogenic differentiation.
This work led to a second US patent application in 2010.
Chapter 8 combined the information gained in the previous studies in an effort to
generate and characterize a novel tissue engineered osteochondral construct. Human
MSCs were seeded on the newly designed osteochondral construct and cultured in the
modified bioreactor with conditioned media. Results showed that the combination of all
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these factors generated a biphasic construct with a cartilage-like upper phase attached to a
bone-like bottom phase.
The work presented in this dissertation details the preliminary steps toward the
development of a biphasic tissue engineered osteochondral graft. It serves to increase the
knowledge base and can aid in future work towards the potential clinical implementation
of osteochondral tissue engineering.
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CHAPTER 1
LITERATURE REVIEW
Native Osteochondral Tissue
Articular Cartilage
Cartilage is an avascular specialized connective tissue consisting of cells
dispersed in a matrix of collagen and/or elastic fibers and ground substance that consists
primarily of proteoglycans. Cartilage can be classified into three different types: elastic
cartilage, fibrocartilage, and hyaline cartilage. Hyaline cartilage, the most common type
of cartilage and the type that will be focused on here, is a glassy white tissue which
contains a high concentration of proteoglycans in a net like structure of Type II collagen
fibers [1]. This type of cartilage can be found as the precursor to bones in the fetus, in
the epiphysis growth plate, in the trachea, nose, or at the end of the ribs [2].
Hyaline cartilage is also found on the bone surface of articulating joints, and as
such this cartilage is called articular cartilage. After endochondral ossification, a region
of hyaline cartilage remains over the surface of the epiphysis and is termed the articular
cartilage. Articular cartilage has an incredibly low coefficient of friction, as well as an
ability to bear very large compressive loads, making it ideal for placement in joints. In
human joints, the thickness of the articular cartilage layer varies from 0.5 to 1.5 mm in
upper extremity joints, such as the hand and the shoulder, and from 1 to 6 mm in lower
extremity joints, such as the hip, knee, and ankle [3-5]. It is a highly hydrated tissue,
with a porosity varying from 68 to 85 per cent in adult joints [6]. As articular cartilage is
located on the ends of articulating bones, it has two main functions. The first function is
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load carriage, which includes shock absorbance and load distribution. Secondly,
articular cartilage acts as a lubricant for the bearing surface. As a result, articular
cartilage provides a wear-resistant, nearly frictionless, load-bearing surface.

The Cells
The only type of cell that is found within adult articular cartilage is the
chondrocyte, with its primary responsibility being the maintenance of the extracellular
matrix (ECM). Mature articular chondrocytes, which are completely incased in matrix,
are unable to proliferate [7]. In humans, only 1-10% of the cartilage volume is occupied
by chondrocytes [8, 9]. Electron micrographs of articular cartilage chondrocytes reveal a
cell with a pair of centrioles, a well developed golgi apparatus, and elongated
mitochondria in the surrounding cytoplasm [10]. The chondrocytes are positioned in
small cavities within the ECM called lacunae. Articular cartilage is often divided into
four zones: the superficial zone, the transitional zone, the deep zone, and the calcified
zone [6]. The cells in the superficial zone, nearest to the articular surface, tend to become
elongated and align parallel to the cartilage surface. However, these cells appear to have
a round shape when viewed in a section that is cut tangential to the surface. This means
that the chondrocytes in this superficial zone are actually discoidal. In the transitional
zone the cells are spherical occurring as single cells in the upper portion, then occurring
as groups of two or more called chondrons in the deeper portions. In the deep zone, the
chondrocytes are also spherical, but tend to be arranged in vertical columns [6]
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Chondrocytes originate from mesenchymal stem cells (MSCs), through a series of

differentiation pathways, which have received extensive study. It has been shown that a
number of cytokines and transcription factors are involved in chondrocyte maturation and
cartilage formation; however, the specific mechanisms regulating these processes are not
yet fully understood [11-14]. Chondrogenesis during embryo development starts with
the condensation of MSCs. The expression of a number of cartilage-specific molecules
signals the process. The transcription factor Sox-9 is one of those signals. Following the
expression of Sox-9, Col2A, which encodes the chondrocyte-specific protein Type II
collagen, becomes involved in the chondrogenesis pathway and regulates the threshold of
the next phase. Sox-9 binds to and activates a consensus sequence in the Col2A enhancer
region, then up regulates Col2A expression [10]. Chondrocytes may further experience a
dedifferentiation with the expression of the hypotrophic chondrocyte unique marker Type
X collagen [11]. Cartilage matrix calcification progressively follows the apoptosis of
hypotrophic chondrocytes. The final stage of dedifferentiation occurs in the
chondrocytes that are in the cartilage that is to turn into bone. This also happens to the
chondrocytes in the deep zone as a person ages [10].
While chondrocytes produce a large amount of cartilage during skeletal
development, they have relatively low metabolic activity in adult articular cartilage. This
is due, in most part, to the avascular nature of the tissue, though chondrocytes can possess
a prominent golgi complex and a fairly large endoplasmic reticulum which allows for
some synthesis activity [8]. The supply of glucose and other components necessary for
the chondrocytes‟ survival, such as oxygen, is limited to slow processes like diffusion.
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These processes taking place in the synovial fluid are adequate to supply the cells in the
superficial zone, but will not reach the deeper zones. The fluid movement through the
tissue caused by joint loading and movement are vital to supply the chondrocytes in the
deeper zones [9]. This means that the movement of joints is essential for the health of the
tissue. As a result of the nutrient supply being limited to these slower processes, the
chondrocyte metabolism occurs at low oxygen tensions within the cartilage matrix,
ranging from 10% oxygen tension at the surface to less than 1% in the deep zones [8].

The Extracellular Matrix
The ECM of articular cartilage consists (as wet mass) of about 60–85% water and
dissolved electrolytes. The rest is a complex solid framework with 10-30% collagens, 3–
10% proteoglycans and small amounts of noncollagenous proteins [9]. The collagen
fibers form a mesh in which the proteoglycans and chondrocytes reside, as shown in
Figure 1.1. The proteoglycans are retained within the collagen network by binding sites
in the core protein and hyaluronan. The strand of hyaluronan weaves into the collagen
network and docks several times.
Articular cartilage contains seven different known collagen types. Types II, IX
and XI form the basic architecture and types III, VI, XII, and XIV are found in small
fractions in the tissue [15]. An amount of 90–95% of the collagen in the ECM of
articular cartilage is formed by collagen Type II fibrils, which contribute to the tensile
strength of the tissue [6]. Together with Type IX collagen, Type II fibrils form a mesh
where Type IX collagen is covalently linked to the surfaces of the Type II fibrils. Type
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VI collagen can be found in the pericellular region that surrounds the surface of the
chondrocytes of the middle zone and throughout the ECM in small amounts of up to 1%
[16]. Collagen Type III has been isolated on the surface of the collagen Type II fibril
network of adult human cartilage [17]. Collagen Type X can be observed in a mineralized
form in the calcified zone of articular cartilage, and is predominantly associated with
hypertrophic cartilage and has often been seen as unique to that tissue[9].

Figure 1.1: Schematic showing the relative positions of the various components of
cartilage [9].

The arrangement and thickness of the collagen fibrils vary with the thickness of
the cartilage. The outer 10-20 % layer contains fine collagen fibrils arranged parallel to
the surface. In the middle 40-60% zone the collagen fibers are larger and arranged more
randomly. In the deep zone the collagen fibers are woven together, aligned perpendicular
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to the articulating surface, and are on average the thickest collagen fibers in the tissue
[18].
Proteoglycans (PGS) consist of a core protein with one or more covalently
attached glycosaminoglycan (GAG) chains, aligned in a bottle brush fashion. These
GAG chains are long, linear carbohydrate polymers that are negatively charged under
physiological conditions, due to the occurrence of carboxyl and sulfate groups [19].
The majority (50–85%) of the overall PG content in articular cartilage is in the
form of large aggregating PGs like the major biomolecule, aggrecan [20] (Figure 1.2).
The proteoglycan aggrecan is the most abundant PG and the high content is often used to
characterize articular cartilage. Aggrecan molecules do not exist in isolation within the
extracellular matrix, but as proteoglycan aggregates [21]. Each aggregate is composed of
a central filament of hyaluronan (HA) with up to 100 aggrecan molecules radiating from
it, with each interaction stabilized by the presence of a link protein [6].
GAGs such as keratan sulfate (KS) and chondroitin sulfate (CS) are covalently
bound to the core protein [9]. The KS chains are located primarily near the HA strand,
whereas the CS chains are more distant from the HA strand [21]. The distribution of both
types of GAGs depends on the zone of the cartilage source. Typically the concentration
of PGs increases with increasing depth. The superficial zone contains almost no PGs,
while the deep zone contains the highest concentration [9]. The proteoglycan aggregates
are responsible for the swollen nature of the cartilage and provide the osmotic properties
needed to resist compressive loads [6].
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Figure 1.2: Schematic showing the basic structure of aggrecan [20].

Osteochondral Junction
As one observes articular cartilage regions closely adjacent to bone regions, a few
different zones and demarcations can be noted. As illustrated in Figure 1.3, the
osteochondral junction region of diarthrodial joints can be considered to consist of: 1) the
deepest layer of non-calcified cartilage, 2) the tidemark, 3) the layer of calcified cartilage,
4) the thin subchondral plate of cortical bone, and 5) the trabecular bone [22]. The
tidemark is a clearly defined boundary, delineating uncalcified cartilage from calcified
cartilage with a thickness of 5-10 μm. The tidemark does not form a straight line across a
joint, but rather, is a complex 3D structure that follows uncalcified cartilage
prolongations, dipping down through the calcified cartilage to abut the subchondral bone
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at a few points. The tidemark consists of dense bands of collagen running parallel to the
surface, intersected at right angles by fibers coming from the overlying radial zone [23].
The organization of the tidemark may aid in resistance to shear stresses. This region is
postulated to be involved in joint nutrition, mineralization and the transfer of forces from
hyaline cartilage to bone [22].

Figure 1.3: Schematic of the various layers that can be found in the transition from articular
cartilage to the subchondral bone [22].

The zone of calcified cartilage lies between the tidemark and the underlying
subchondral bone and is composed of short columns of hypertrophic chondrocytes
separated by thin bars of cartilage. Vascular invasion in the bone side of the zone, with
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bars of calcified cartilage occurs in the vicinity of the capillaries. As a person ages, the
cells lose their columnar organization and the cartilage bars calcify progressively [23].
The zone of calcified cartilage is supported by the subchondral bony end plate, where the
end plate is composed of dense cortical bone and is supported by numerous small
connecting trabeculae.

Bone
Bone is a complex, highly organized, specialized connective tissue and comprises
a structured extracellular matrix composed principally of collagen Type I impregnated
with a mineral phase in the form of hydroxyapatite [24]. Bone has several different
functions in the body. Probably the most obvious function is providing a framework that
supports the body and gives it its shape. Secondly, bones interact with skeletal muscles,
tendons, ligaments and cartilage to generate and transfer forces so that individual body
parts can be moved relative to each other. The bones are integral in this process by
providing ridged links and muscle attachment sites. Bones also form protective barriers
that protect vital internal organs, such as the skull which protects the brain, the vertebrae
which protect the spinal cord, and the ribs which protect the heart and lungs. Another
important function that the bones contribute to is blood production. The marrow, located
within the medullar cavity of long bones, produces blood cells in a process called
haematopoiesis. The last major function of bone is mineral storage, as bones act as
reserves of important minerals such as calcium and phosphorus [25].
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Cells
Bone contains several types of cells that are responsible for its upkeep and are
responsive to various signals [26]. Osteoblasts are mononucleated cells that are
responsible for bone formation [2]. Osteoblasts produce osteoid, which is the
nonmineralized component of the bone matrix and is composed mainly of Type I
collagen. In addition, osteoblasts produce osteocalcin and bone morphogenic proteins.
Osteoblasts are also most likely responsible for mineralization of the osteoid matrix by
modulating electrolyte flux between the extracellular fluid and the osseous fluid [24].
Osteoblasts are derived from mesenchymal progenitor cells from either the bone
marrow or periosteum [27]. Expression of the transcription factors runt-related
transcription factor-2 (Runx2), distal-less homeobox-5 (Dlx5), and msh homeobox
homologue-2 (Msx2) is required to push the precursor cells toward the osteoblast lineage
[28]. The committed preosteoblast expresses type I collagen and bone sialoprotein.
Further differentiation of the preosteoblast into a mature osteoblast phenotype requires
the expression of Runx2, osterix (Osx), and several other components of the signaling
pathway [29-31]. The mature osteoblast expresses Type I collagen and osteocalcin and a
key enzyme in the mineralization process, alkaline phosphatase [27]. The sequences of
events involved in osteogenesis can be seen in Figure 1.4.
Osteoblasts range in size from 20 – 30 μm and, as would be expected, are
characteristically found where new bone is laid down [2]. Osteoblasts that are actively
laying down osteoid are usually rounded or rectangular cells, with their long axes
perpendicular to the bone surface. When active these cells contain an abundance of
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rough-surfaced endoplasmic reticulum, a characteristic of cells that manufacture protein
for export from the cell [23]. Inactive osteoblasts assume a flattened morphology and
frequently polarize so the nucleus lies at the end of the cell opposite the bone surface [2].
Usually osteoblasts cover the bone surface in a single layer. Numerous cytoplasmic
processes extend from osteoblasts, especially on the side next to the bone matrix and
extend through the matrix [27]. Once osteoblasts have fulfilled their function, they either
revert back to undifferentiated mesenchymal cells, or enclose themselves in the bone
matrix becoming osteocytes.

Figure 1.4: Schematic of the steps involved in osteogenesis. Factors in the boxes are
needed for the corresponding step to take place, while the factors not enclosed by a box
are expressed by the cell at that stage [27].
When the osteoblasts enclose themselves in the bone matrix they are then
considered osteocytes. The osteocytes lie in lacunae that are uniformly oriented with
respect to the longitudinal axis of the bone lamellae [24]. Osteocytes comprise about
90% of all the cells in mature bone and are responsible for maintaining the bone [32]. As
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would be expected, young osteocytes that have recently been incorporated in the matrix
still closely resemble osteoblasts. As they age, they lose their cytoplasm and have a
higher nucleus to cytoplasm ratio [2]. The pericellular space surrounding the osteocytes
contains protein, lipids, and collagen fibers. Osteocytes also have processes that extend
into canaliculi and connect to processes of surrounding osteocytes [33]. It is thought that
this connection is used to transmit biophysical information to cells throughout the bone.
Osteocytes play an essential role in controlling the calcium exchange between the bone
mineral and the extracellular fluid, which in turn controls the concentration of calcium in
the serum [27]. The control of calcium is important as it has a vital role in cell membrane
transport, muscle contraction, and nerve function. It is also likely that osteocytes play an
important role in bone remodeling and adaptation as they can sense the mechanical
stresses present in various areas of the bone and detect microfractures with in the matrix
[27].
Osteoclasts are responsible for the removal of bone; a process called bone
resorption. Osteoclasts are formed by the fusion of cells of the monocyte-macrophage
cell line [34] and are characterized by high expression of tartrate resistant acid
phosphatase (TRAP) and cathepsin K. An osteoclast is a large cell with multiple nuclei
and a cytoplasm with a "foamy" appearance. This appearance is due to a high
concentration of vesicles and vacuoles [35, 36]. At a site of active bone resorption, the
osteoclast‟s cell membrane forms a "ruffled border", which touches the surface of the
bone tissue [34]. The ruffled border facilitates removal of the bony matrix and increases
surface area interface for bone resorption.
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The osteoclasts are derived from hematopoetic stem cells residing mainly in the
marrow and spleen [27]. Osteoclastogenesis begins when a hematopoetic stem cell is
stimulated to generate mononuclear cells, which then become committed preosteoclasts
and are introduced into the blood stream. Once activated, osteoclasts move by
chemotaxis to areas of the bone that need to be removed, such as microfractures [36].
Osteoclasts lie in small cavities called Howship's lacunae, formed from the digestion of
the underlying bone. The sealing zone is the area of attachment of the osteoclast's plasma
membrane to the underlying bone. Sealing zones are bounded by belts of specialized
adhesion structures called podosomes [23]. Attachment to the bone matrix is facilitated
by integrin receptors. The osteoclast releases hydrogen ions through the ruffled border
into the cavity, acidifying and dissolving the mineralized bone matrix [34]. The calcium
and phosphate ions of the bone matrix are absorbed into small vesicles which move
across the cell and eventually are released into the extracellular fluid, thus increasing
levels of the ions in the blood [34]. In addition, several hydrolytic enzymes, such as
members of the cathepsin and matrix metalloprotease (MMP) groups, are released to
digest the organic components of the matrix. Of these hydrolytic enzymes, cathepsin K is
of most importance [27].

Extracellular Matrix
The organic portion of the bone matrix makes up about 30-40% of the dry weight
and is mainly composed of Type I collagen [24]. Osteocalcin makes up about 10-20% of
the noncollagenous proteins. It plays a role in attracting osteoclasts to an area that will be
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resorbed [24], osteonectin plays a role in the regulation of calcium [23] and osteopotin
mediates the attachment of the cells to the matrix [27]. Other factors present include
glycosaminoglycans, bone sialoprotein, growth factors and cytokines.
The inorganic portion of the matrix makes up 60-70% of the dry weight of bone
and is mainly crystalline mineral salts and calcium, which are present in the form of
hydroxyapatite [24]. This version of calcium phosphate has a unit cell that contains
Ca10(PO4)6(OH)2 [24]. However, the crystals are not completely pure as 4-6% of the
phosphate groups are replaced by carbonate. This substitution takes place largely near
the edges of the bone, near vasculature, and marrow spaces [24]. The individual crystals
tend to be plate like in shape.
The mechanisms that initiate and propagate mineralization of newly formed
osteoid are not completely understood. It is widely accepted that the particular
arrangement of the collagen molecule allows it to serve as a nucleation site, permitting
the precipitation of lumps of mineral that, without the presence of an energetically
favorable site, would not occur. One likely location for a nucleation site in collagen is
the gap between the heads and tails of tropocollagen molecules [24]. Other investigations
into the nucleation sites of hydroxyapatite crystals on collagen fibers have suggested that
the binding of calcium ions on the negatively charged carboxylate groups of collagen is
one of the key factors for the first-step nucleation of hydroxyapatite crystals [37]. These
sites are present in about 11% of the amino acid residues of collagen molecules [38].
After the mineral is deposited on the nucleation sites it continues to grow along
the length of the collagen fibers. As the plate like crystals grow they tend to form large
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lumps and the individual crystals tend to be oriented in the direction of the collagen
fibrils [24].
Cortical bone, also known as compact bone, is dense and forms the surface of
bones, contributing about 80% of the weight of a human skeleton [33]. It is extremely
hard and formed of multiple stacked layers with few gaps (lamellar bone). The very
dense matrix of cortical bone is arranged in a regular circular pattern around blood
vessels supplying nutrients. Each unit is composed of concentric rings of bone matrix
and osteocytes around a central canal called a Haversion canal [2]. The entire system
consisting of the Haversion canal and the surrounding rings of bone matrix is called an
osteon. Numerous osteons make up the structure of compact bone and tend to parallel the
long axis of the bone [24]. Blood vessels in the Haversian canals supply the cells of the
osteon with nutrients while canals that run perpendicular to them termed Volkmann
canals carry blood between osteons [2]. The arrangement of cortical bone and the
Haversian canals can be seen in Figure 1.5.
Trabecular bone, also called cancellous bone, is a three dimensional lattice
of bony plates and rods that makes up 20% of the human skeleton by weight [33]. The
basic architecture of trabecular bone includes sheets or plates of lamellar bone that are
oriented in a fairly uniform direction and interconnected by rods running perpendicular to
the plates [23]. This system provides support for transmitting applied loads as the
trabeculae are oriented to provide maximum strength while using a minimal amount of
material [24]. The structure of trabecular bone can be seen in a femur in Figure 1.5a and
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10d. Trabecular bone is typically found in the epiphysis (the ends of long bones) as well
as in short and irregular bones such as the vertebrae and the pelvis.

Figure 1.5: Schematic illustrating trabecular bone (A), osteocytes and their
corresponding canaliculi (B), Haversian canals and osteons of cortical bone (C), and
the interface between cortical and trabecular bone typically seen in a long bone (D) [25].

Significance of Problem
Osteoarthritis
Osteoarthritis (OA) is a disease with many complex etiologies, affecting cartilage
and all adjacent tissues in diarthrodial joints. Morphological, biochemical, structural, and
biomechanical changes of the extracellular matrix and the cells are manifested in OA,
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which leads to the degeneration of the articular cartilage with softening, fibrillation,
ulceration, and cartilage loss [39]. However, it has been demonstrated that OA is not
exclusively a disorder of articular cartilage [40]. Multiple components of the joint are
adversely affected by OA, including the subchondral bone, synovial joint lining, and
adjacent supporting connective tissue elements [41]. The pathological characteristics of
OA are loss of cartilage, with associated underlying bony changes consisting of sclerosis,
subchondral bone collapse, bone cysts, and osteophyte formation [42]. The most
frequently affected sites are the hands, feet/ankles, knees, and hips [1]. OA affects 14%
of adults aged 25 and older and 34% of those 65+. A conservative estimate of 26.9
million US adults in affected by OA 2005 increased from an estimated 21 million adults
in 1990 [1].
The symptoms of OA are often associated with significant functional impairment,
as well as signs and symptoms of inflammation, including pain, stiffness, and loss of
mobility [43]. The cardinal symptom of OA is pain, which occurs with joint use and is
relieved by rest. The pain is usually aching and poorly located [44]. No strict correlation
exists between joint symptoms and the extent or degree of pathological or radiographic
changes. Only 30% of patients with radiographic evidence of OA complain of pain at
relevant sites [45]. Articular gelling, a transient stiffness lasting only for several flexion
extension cycles, is extremely common in elderly patients, especially in the lower
extremity joints. Limited motion develops as OA progresses because of joint-surface
incongruity, capsular contracture, and mechanical blockage due to osteophytes or loose
bodies [46]. Late stages of the disease are associated with gross deformity and
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subluxation due to cartilage loss, the collapse of subchondral bone, the formation of bone
cysts, and gross bony overgrowth [45].
OA is often classified into primary and secondary variations [6]. Primary OA is
the case where the cause or causes are unknown. Primary OA develops in a joint
previously free from diseases, obvious mechanical abnormalities, or injuries. It is likely
that there may be several different forms of primary OA and that several different
etiologies are responsible [6]. In contrast, secondary OA means that the major factors
can be determined [6]. Secondary OA is caused by another disease or condition and the
actual OA that develops is “secondary” to the disease or condition [6]. Conditions that
can lead to secondary osteoarthritis include obesity, repeated trauma or surgery to the
joint structures, abnormal joint anatomy, gout, diabetes and other hormone disorders [47].

Traumatic Injuries
Articular cartilage injuries can be classified into two different groups. The
injuries are either classified as partial thickness defects, termed chondral defects, or fullthickness defects, termed osteochondral defects. The former lie entirely within the
confines of cartilage tissue itself and do not penetrate beyond the calcified cartilage into
subchondral bone. The latter penetrate through the entire thickness of the articular
cartilage, the calcified cartilage, and into the subchondral bone [48]. The differences
between the two defect types have large implications on the natural healing processes that
take place.
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A chondral defect cannot be accessed by blood, nor by macrophages or
mesenchymal stem cells located within the bone-marrow space. Hence, when a partialthickness defect is created in articular cartilage, no fibrin clot forms within its void and
there is little or no evidence of cell migration therein. Chondrocytes directly in the path
of the injury are killed, and the matrix architecture is disrupted [49]. However, some
cells may temporarily increase metabolic activity. The lesion does not heal [49-51], and
its appearance several months after injury is similar to that observed when the injury
occurred, and the site appears to be inert [51-53]. Furthermore, the native articular
cartilage adjacent to the defect site often becomes necrotic [50, 54]. Partial-thickness
lesions are analogous to the clefts and fissures seen during the early stages of
osteoarthritis, and are often the cause of osteoarthritis [55]. The absence of a repair can
lead to disintegration of the articular surface and exposure of subchondral bone. The
exposed bone does not result in cartilage regeneration. Rather, the bone becomes even
stiffer and may attempt to increase its thickness in response to higher mechanical loads
[53].
Osteochondral defects penetrate the subchondral bone and are therefore accessible
to a number of stem cells located within the bone marrow. Spontaneous repair of
osteochondral defects consistently follows the same course that has been well described
by Shapiro and coworkers [53, 54]. The void of a full thickness defect becomes filled
with a fibrin clot almost immediately after its creation. Two days later, the clot adheres
strongly to the wound edges in the bony compartment, but not to those in the cartilage.
Parallel strands of fibrin extend horizontally across the entire width of the defect.
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Mesenchymal cells begin to penetrate the fibrin clot and by approximately the fifth day
completely fill the clot, adopting a corresponding orientation to the fibrin strands. After
approximately one week, the fibrin clot becomes almost completely resorbed, and the
defect is filled with mesenchymal cells. Between ten and fourteen days, the
mesenchymal cells differentiate into chondrocytes, which lay down a proteoglycan-rich
extracellular matrix. After approximately eight weeks, the repair tissue usually resembles
hyaline cartilage; however, it is not and is actually more similar to fibrocartilage. After
approximately 24 weeks, the surface of the healed tissue is continuous with that of the
surrounding native cartilage. By approximately 48 weeks, however, signs of degeneration
are apparent, and the degeneration progresses with the advance of time. Within the bony
compartments, osteogenesis proceeds in parallel with chondrogenic activity in the
cartilaginous compartments. Subchondral bone is initially deposited along the surfaces of
the defect, but progressive layers gradual fill the void. By 48 weeks, this process is
complete. The junction between the repair tissue and the surrounding articular cartilage
frequently contains points of discontinuity between the two tissues. Additionally, even at
sites of continuity, there exists no true integration between the repair and native articular
cartilage, and the collagen fibrils within each compartment fail to intermingle with one
another [53, 54].

Current treatment options
In both cases of OA and chondral/osteochondral defects, the ultimate goal is to reestablish a structurally and functionally competent repair tissue of an enduring nature
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[48]. However, this event is not usually immediately possible, and the principal clinical
objectives of treatment, especially for OA, are to control pain adequately, improve
function, and reduce disability [45]. Two main goals exist for articular cartilage
treatments, in addition to those listed above. The first goal is to fill the defect with a
material that will have the same mechanical properties as articular cartilage. Ideally this
material would be new articular cartilage. The second goal is the integration of this
material with the native articular cartilage. Even with small chondral defects, failure to
accomplish these goals may lead to osteoarthritis [56].

Debridement
Debridement involves the mechanical removal of diseased or damaged tissue and
free bodies from the joint. There is no evidence of beneficial biological effects or
regenerative effects derived from debridement [48]. The clinical findings are highly
variable, ranging from good with pain relief in 65% of patients, [57] to moderate with
pain relief in less than 50% of patients [58] to very poor with pain relief in less than15%
of patients [59]. Even when the results are reportedly good, the effects are always
temporary. Accordingly, debridement is typically used as a temporary treatment to
postpone an arthroplasty [57]-[59].

Micro-fracture, Abrasion Chondroplasty, and Pridie Drilling
Micro-fracture, abrasion chondroplasty, and pridie drilling all involve surgical
access to the bone-marrow spaces. These procedures lead to a spontaneous repair
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response, which is based upon therapeutically-induced bleeding from the subchondral
bone spaces and subsequent blood-clot formation. The results of the procedure are highly
variable, non-reproducible and the tissue formed is fibrous in nature [60] and not durable
[54]. Although the repair tissue contains most of the matrix components found in hyaline
cartilage, significant quantities of fibrous constituents are also present [60]. The repair
tissue also tends to degrade over time and a long-term cure cannot be expected from these
procedures. The success rates are variable [48, 61] and depend on many factors, such as
the patient‟s age, activity level, the severity of the arthritic condition, and the follow-up
period. These techniques have the best results in young athletes and in young patients in
general. In such individuals, good results of improved joint functionality and relief from
pain in 75% of cases have been reported [62].
Of the three similar techniques, micro-fracture appears to be the most
advantageous. Since the holes are considerably smaller, approximately 0.5–1.0 mm in
diameter, than those created by Pridie drilling, which are approximately 2.0–2.5 mm in
diameter, perforation of the subchondral bone plate impacts the plate biomechanics to a
lesser extent [48]. Additionally, the micro-fracture technique can be performed by a
minimally invasive arthroscopic approach, which induces only minimal surrounding
tissue damage and reduces the thermal damage to subchondral bone [63].

Osteochondral Grafts
Allogeneic osteochondral grafts have been used to fill articular cartilage defects
for several decades, and much clinical experience has thus been gathered. The approach
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does not attempt to induce a cartilage repair response, but represents a means of
substituting failed or lost tissue with healthy articular cartilage derived from cadavers
[48]. Patients with large osteochondral defects, such as those generated by tumor
resection, osteonecrosis, extensive trauma, broad focal OA or osteochondritis dissecans,
have benefited from this procedure [48]. Clinical experience with this treatment protocol
has been quite good. Studies show that human osteochondral transplants can survive for
long periods [64, 65]. Success rates range between 65% and 85%, even after follow-up
periods of up to 10 years [66, 67].
Drawbacks associated with this methodology include the scarcity of fresh donor
material and problems connected with the handling and storage of frozen tissue [48].
Immunological problems will inevitably be present [68]. Despite the relative
immunologically privileged position of articular cartilage due to a lack of a blood supply,
an immune response is still a potential problem with this approach, especially with in the
subchondral bone section [68, 69]. Also, cryopreservation of tissue can lead to the death
of cells [70, 71]. Fresh tissue has better structural and mechanical stability as well as a
longer life span than cryopreserved or lyophilized material [70, 71].
Autologous osteochondral grafts involve the removal of cylindrical plugs of
osteochondral tissue from nonload bearing regions of the articular cartilage and are
transplanted to the debrided full depth defect (Figure 1.6). This procedure can be carried
out either on an open joint or by arthroscopy [72]. Osteochondral transfer is most
commonly referred to as mosaicplasty. There are numerous studies that pertain to the
short-term clinical experience with this procedure in human patients [73-75]. These
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studies have revealed results to be good to very good with pain relief and improved joint
functionality in 60–90% of cases. However, no prospective, double-blinded clinical trials
have been conducted to assess whether the long term results of this technique are indeed
superior to others.
As with all of these treatments there are drawbacks. First, in removing
osteochondral plugs from normal sites of a joint, the surgeon is destroying almost as
much healthy tissue as he/she is attempting to treat [56]. Moreover, the translocation of
tissue from a low-weight-bearing area to a high-weight-bearing one can lead to its
degeneration, as a consequence of mechanical overloading in the new position [56].
Marginal cell death occurs with the removal of osteochondral plugs, thereby reducing the
filling of the defect by about 24% [76].

Figure 1.6: Depiction of an autologous osteochondral graft[77].
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Joint Replacement
When articular cartilage is severely damaged because of a trauma or
osteoarthritis, the joint replacement is the most widely used treatment method. Prognosis
is good to excellent in 95% of major joint replacements (hips and knees) [78]. Pain relief
is especially reliable, however full recovery of range of motion is not always
accomplished. The most common joints to be replaced are the knee and hip, but elbow,
shoulder, ankle, and finger joint replacements are also clinically available [78].
Fixation of the implant is either accomplished with bone cements, porous surfaces
that allow bone ingrowth, or press fitting. There are numerous designs of implants and
numerous materials that are employed. Common metals that are used are titanium alloys,
stainless steel and Co-Cr alloys. Titanium is not used for the bearing surfaces. Ceramics
such as alumina and zirconia are also used for the bearing surfaces and are used more
often in the hip. One of the most common bearing surface is ultra high molecular weight
polyethylene (UHMWPE) [78].
The average life time of a hip or knee replacement is between 13 and 15 years.
Factors such as physical activity, age, vocation, and weight will impact the life of an
implant. The procedure is typically not recommended for younger patients, because they
are typically more active and will likely have to go through several revisions [78]. Even
with significant improvements of the material properties and design of new implants over
the decades, loosening, wear, stress shielding, and implant breaking due to either fatigue
or over loading are all complications associated with joint replacements [79-81].
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Osteochondral Tissue Engineering
Tissue engineering involves the regeneration of biological tissues by seeding the
patient‟s own tissue-forming cells onto biodegradable scaffolds. It is an interdisciplinary
field that encompasses the combination of cells, materials, and biochemical and physiochemical factors to generate replacement tissue for missing or damaged tissue [82, 83].
Osteochondral tissue engineering provides a potential mechanism to produce viable tissue
replacements.

Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are highly replicative cells that have
multilineage differentiation capacity. These cells can differentiate into multiple tissue
forming cell lineages such as osteoblasts, adipocytes, chondrocytes, tenocytes, and
myocytes [83, 84]. In addition, they are capable of self-renewal and can be readily
expanded ex vivo for several passages without losing their self-renewal capacity [85, 86].
MSCs have been found in many tissues including bone marrow, tooth pulp, adipose
tissue, umbilical cord blood, synovium, brain, blood vessels and blood [86]. Stem cells
of the bone marrow are the most commonly studied and used in osteochondral tissue
engineering [87]. The major advantage to using MSCs is that they enable the use of one
cell type for both the cartilage phase and the bone phase.
Numerous cytokines, growth factors, and non-protein chemical compounds have
been used in chondrogenic differentiation cocktails to induce MSCs to differentiate to
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chondrocytes in vitro. It is not clear which additives or combination of additives are the
most effective in inducing chondrogenic differentiation. Among the most potent inducers
of chondrogenic differentiation are members of the transforming growth factor beta
(TGF-β) family [86, 88]. A study reported in the literature showed that TGF- β2 and
TGF- β 3 caused production of significantly more proteoglycans and collagen II than
TGF- β1, but that all three produced more matrix than cultures without TGF- β [86].
Another cytokine that plays an important role in chondrogenesis is fibroblast growth
factor (FGF). FGF has been shown to cause increased expression of the transcription
factor Sox9, which is the master regulator of chondrogenesis [89]. Insulin like growth
factor-1 (IGF-1) has also been shown to have stimulatory effects on chondrogenic
differentiation [90]. The combination of TGF-β1 with IGF-1 was reported to have a
synergistic effect on chondrogenic differentiation in vitro [91]. Some non-protein
chemical compounds that are known to promote chondrogenic differentiation in vitro are
dexamethasone, thyroid hormone, and ascorbic acid. The components used in osteogenic
differentiation cocktails are fairly consistent throughout the literature. The typical
osteogenic differentiation cocktail contains β-glycerophosphate, dexamethasone, and Lascorbic acid. Additive β-glycerophosphate provides a phosphate source used by the
cells in the production of hydroxyapatite [92]. Dexamethasone is a glycocorticoid that
binds with a hormone receptor on the cell that modulates genetic response [93]. Lascorbic acid (vitamin C) is crucial to cells in the production of collagen [6, 94].
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Configurations
A closer look at the studies that involve osteochondral tissue engineering reveals
that there are four configurations of scaffolds that have been assessed. The first
configuration includes a scaffold for the bone phase; cells for the cartilage phase are
seeded on top of the bone phase without a scaffold. This approach was taken by Wang
and coworkers [95], Tuli and coworkers [96], and Kandal and coworkers [97]. The
second configuration employs separate scaffolds for the bone and the cartilage portions
that are integrated after cultivation. This method was employed by Gao and coworkers
[98] and by Schaefer and coworkers [99, 100]. The next configuration is a single
scaffold that has separate phases for each tissue. Examples of this system are shown in
the studies of Hung and coworkers [101], Chang and coworkers [102], and Schek and
coworkers [103]. The final configuration is a single homogeneous scaffold that is the
same for both tissues which was applied by Solchaga and coworkers [104].

Bioreactors in Tissue Engineering
The use of bioreactors for osteochondral tissue engineering is a potential way to
improve the quality of tissue that is formed and aid in the development of functional
tissue engineered osteochondral grafts. It is well known that physical stimuli can
modulate the metabolism of chondrocytes and osteoblasts, and when applied with
specific magnitudes and frequencies, may up regulate the production of extracellular
matrix components [105]. The use of bioreactors leverages this response. Ideally, a
bioreactor should provide an in vitro like environment for rapid and orderly tissue
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development, starting from isolated cells and three-dimensional scaffolds [106]. With
few exceptions, bioreactors used for cultivating osteochondral tissue attempt to mimic the
mechanical loading experienced in vivo which results from the motion and forces in
joints [9]. Those mechanical loads include interstitial fluid flow, shear, hydrostatic
pressure, compression, and stretch [106]. In addition to physical stimuli, bioreactors can
control conditions in culture medium such as temperature, pH, osmolality, oxygen levels,
nutrients, metabolites, regulatory molecules, as well as facilitate mass transfer between
the cells and the culture environment.
Two types of bioreactors are generally used to impart shear forces on tissue
engineered constructs: a spinner flask/vessel with a stirring bar or a rotating vessel
reactor [9]. Depending on whether solid or porous scaffolds are used, shear forces reach
the entire cell population or only cells growing on the construct surface [9]. Chang and
coworkers [102] developed a double chamber stirring bioreactor to cultivate biphasic
osteochondral grafts in a single apparatus. The bioreactor consisted of two tubular-shape
glass chambers, each with a magnetic bar stirrer and ports for media exchange, gas
ventilation, and sample aspiration. The chambers were separated by a silicon rubber
septum that contained several holes to hold the biphasic composite scaffolds. This design
allowed one side to be cultivated in chondrogenic medium and the other in osteogenic
medium, while both were exposed to shear forces caused by the stir bars. A perfusion
fluid flow system is a third type of bioreactor that can also be classified as facilitating
shear forces. The shear force is generated by the media being pumped through the
scaffold within the bioreactor. The amount of shear that the cells are exposed to is
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dependent on several variables including flow rate, port size, and pore size [107, 108].
An advantage of a perfusion flow system is the ability to continuously deliver nutrients
and remove waste products.
Hydrostatic pressure is often experienced by the cells of the osteochondral region
in vivo, and this condition can be replicated with bioreactors. One way of creating
hydrostatic pressure is to connect the gas phase above the culture medium directly with
another pressure chamber. The in and out flow of the gas is controlled and is therefore
able to provide various pressure protocols. The gas phase transmits pressure on the
culture medium and the sample within [109]. Other systems put the culture medium
directly under pressure without transmitting it from a gas phase above. The chamber
containing the sample is connected to a syringe that is capable of creating intermittent
pressure protocols. When the syringe moves, it transmits the hydrostatic pressure to the
culture volume and sample [110]. A third design to create hydrostatic pressure involves
the use of a flexible membrane. The sample in culture medium is sealed with a gas and
fluid-impermeable flexible membrane. A positive pressure is created on the opposite side
of the membrane and is transmitted by the flexible membrane to the culture medium and
sample. Computer controlled valves that control the positive pressure enable the precise
application of various pressure protocols [9].
Other bioreactor systems employ a combination of perfusion fluid flow and
hydrostatic pressure. One such design involves perfusing medium through constructs in a
glass column that is connected in a closed loop to the medium reservoir, a single-piston
cylinder pump, and a back pressure regulator connected to the control device [111].
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When the back pressure is released, perfusion flow is active, but when the back pressure
is engaged, hydrostatic pressure is created as the pump continues to run. Another design
is a vessel in which constructs are cultured in culture medium and a peristaltic pump
perfuses the constructs. Valves can be opened or closed at the ends of the vessel creating
an isolated volume of medium in the vessel when they are closed. The second part of the
system is an air-driven cylinder with a piston capable of hydrostatic pressure on the
culture volume when the valves are closed [112-114]. Both of these bioreactor systems
either apply hydrostatic pressure or perfusion fluid flow, but not both at the same time.
There is a need for designs that allow the combination of stimuli to be applied to
osteochondral constructs, but also allow separate culture media to be used for the two
different phases and different loading regimen to be applied to the opposite phases.
References
1.

Lawrence, R.C., D.T. Felson, and C.G. Helmick, Estimates of the prevalence of
arthritis and other rheumatic conditions in the United States. Part II. Arthritis
Rheum 2008. 58(1): p. 26-35.

2.

Ross, M.H., L.J. Romrell, and G.I. Kaye, Histology : a text and atlas 3ed. 1995,
Baltimore ; Philadelphia Williams & Wilkins.

3.

Adam, C., F. Eckstein, S. Milz, and R. Putz, The distribution of cartilage
thickness within the joints of the lower limb of elderly individuals. Journal of
Anatomy, 1998. 193: p. 203-214.

4.

Ateshian, G.A., L.J. Soslowsky, and V.C. Mow, Quantitation of Articular
Surface-Topography and Cartilage Thickness in Knee Joints Using
Stereophotogrammetry. Journal of Biomechanics, 1991. 24(8): p. 761-776.

5.

Soslowsky, L.J., E.L. Flatow, L.U. Bigliani, and V.C. Mow, Articular Geometry
of the Glenohumeral Joint. Clinical Orthopaedics and Related Research,
1992(285): p. 181-190.

31

6.

Freeman, M.A.R., Adult articular cartilage 1974, New York: Grune & Stratton.

7.

Temenoff, J.S. and A.G. Mikos, Review: tissue engineering for regeneration of
articular cartilage. Biomaterials, 2000. 21(5): p. 431-440.

8.

Goldring, M.B., Update on the biology of the chondrocyte and new approaches to
treating cartilage diseases. Best Practice & Research in Clinical Rheumatology,
2006. 20(5): p. 1003-1025.

9.

Schulz, R.M. and A. Bader, Cartilage tissue engineering and bioreactor systems
for the cultivation and stimulation of chondrocytes. European Biophysics Journal
with Biophysics Letters, 2007. 36(4-5): p. 539-568.

10.

Lin, Z., C. Willers, J.A. Xu, and M.H. Zheng, The chondrocyte: Biology and
clinical application. Tissue Engineering, 2006. 12(7): p. 1971-1984.

11.

Archer, C.W. and P. Francis-West, The chondrocyte. International Journal of
Biochemistry & Cell Biology, 2003. 35(4): p. 401-404.

12.

Aubin, J.E., F. Liu, L. Malaval, and A.K. Gupta, Osteoblast and Chondroblast
Differentiation. Bone, 1995. 17(2): p. S77-S83.

13.

Chansky, H., J.R. Robbins, S. Cha, W.H. Raskind, E.U. Conrad, and L.J. Sandell,
Expression of cartilage extracellular matrix and potential regulatory genes in a
new human chondrosarcoma cell line. Journal of Orthopaedic Research, 1998.
16(5): p. 521-530.

14.

de Crombrugghe, B., V. Lefebvre, R.R. Behringer, W.M. Bi, S. Murakami, and
W.D. Huang, Transcriptional mechanisms of chondrocyte differentiation. Matrix
Biology, 2000. 19(5): p. 389-394.

15.

Eyre, D., Collagen of articular cartilage. Arthritis Research, 2002. 4(1): p. 30-35.

16.

Wu, J.J. and D.R. Eyre, Covalent Interactions of Type-Ix Collagen in Cartilage.
Connective Tissue Research, 1989. 20(1-4): p. 241-246.

17.

Young, R.D., P.A. Lawrence, V.C. Duance, T. Aigner, and P. Monaghan,
Immunolocalization of collagen Types II and III in single fibrils of human
articular cartilage. Journal of Histochemistry & Cytochemistry, 2000. 48(3): p.
423-432.

32

18.

Aigner, T. and J. Stove, Collagens - major component of the physiological
cartilage matrix, major target of cartilage degeneration, major tool in cartilage
repair. Advanced Drug Delivery Reviews, 2003. 55(12): p. 1569-1593.

19.

Brooks, S.A., M.V. Dwek, and U. Schumacher, Functional and Molecular
Glycobiology. 2002: Bios Scientific Publishers.

20.

Roughley, P.J., The structure and function of cartilage proteoglycans. European
Cells & Materials, 2006. 12: p. 92-101.

21.

Hascall, V.C., Proteoglycans - the Chondroitin Sulfate Keratan Sulfate
Proteoglycan of Cartilage. Isi Atlas of Science-Biochemistry, 1988. 1(3): p. 189198.

22.

Lyons, T.J., S.F. McClure, R.W. Stoddart, and J. McClure, The normal human
chondro-osseous junctional region: evidence for contact of uncalcified cartilage
with subchondral bone and marrow spaces. Bmc Musculoskeletal Disorders,
2006. 7.

23.

Albright, J.A. and R.A. Brand, The Scientific basis of orthopaedics 1987,
Norwalk, Conn: Appleton & Lange.

24.

Currey, J.D., Bones: Structure and Mechanics. Vol. Princeton, NJ. 2002:
Princeton University Press.

25.

Hoehn, K. and N.E. Marieb, Human Anatomy & Physiology 7ed. 2006, San
Fransico: Benjamin-Cummings.

26.

Meyer, U., B. Kruse-Losler, and H.P. Wiesmann, Principles of bone formation
driven by biophysical forces in craniofacial surgery. British Journal of Oral &
Maxillofacial Surgery, 2006. 44(4): p. 289-295.

27.

Robling, A.G., A.B. Castillo, and C.H. Turner, Biomechanical and molecular
regulation of bone remodeling. Annual Review of Biomedical Engineering, 2006.
8: p. 455-498.

28.

Bendall, A.J. and C. Abate-Shen, Roles for Msx and Dlx homeoproteins in
vertebrate development. Gene, 2000. 247(1-2): p. 17-31.

33

29.

Ducy, P., R. Zhang, V. Geoffroy, A.L. Ridall, and G. Karsenty, Osf2/Cbfa1: A
transcriptional activator of osteoblast differentiation. Cell, 1997. 89(5): p. 747754.

30.

Glass, D.A., P. Bialek, J.D. Ahn, M. Starbuck, M.S. Patel, H. Clevers, M.M.
Taketo, F.X. Long, A.P. McMahon, R.A. Lang, and G. Karsenty, Canonical Wnt
signaling in differentiated osteoblasts controls osteoclast differentiation.
Developmental Cell, 2005. 8(5): p. 751-764.

31.

Hu, H.L., M.J. Hilton, X.L. Tu, K. Yu, D.M. Ornitz, and F. Long, Sequential
roles of Hedgehog and Wnt signaling in osteoblast development. Development,
2005. 132(1): p. 49-60.

32.

Lodish, H., A. Berk, L.S. Zipursky, P. Matsudaira, D. Baltimore, and J. Darnell,
Molecular cell biology 2000, New York: W.H. Freeman.

33.

Olszta, M.J., X.G. Cheng, S.S. Jee, R. Kumar, Y.Y. Kim, M.J. Kaufman, E.P.
Douglas, and L.B. Gower, Bone structure and formation: A new perspective.
Materials Science & Engineering R-Reports, 2007. 58(3-5): p. 77-116.

34.

Netter, F.H., Musculoskeletal system: anatomy, physiology. 1987, New Jersey:
Ciba-Geigy

35.

Holtrop, M.E. and G.J. King, Ultrastructure of Osteoclast and Its Functional
Implications. Clinical Orthopaedics and Related Research, 1977(123): p. 177-196.

36.

Vaananen, H.K., H. Zhao, M. Mulari, and J.M. Halleen, The cell biology of
osteoclast function. Journal of Cell Science, 2000. 113(3): p. 377-381.

37.

Kikuchi, M., S. Itoh, S. Ichinose, K. Shinomiya, and J. Tanaka, Self-organization
mechanism in a bone-like hydroxyapatite/collagen nanocomposite synthesized in
vitro and its biological reaction in vivo. Biomaterials, 2001. 22(13): p. 17051711.

38.

Cui, F.Z., Y. Li, and J. Ge, Self-assembly of mineralized collagen composites.
Materials Science & Engineering R-Reports, 2007. 57(1-6): p. 1-27.

39.

Keuttner, K. and V.M. Goldberg, Osteoarthritic Disorders. 1995, Rosemont:
American Academy of Orthopaedic Surgeons.

34

40.

Brandt, K.D., E.L. Radin, P.A. Dieppe, and L. van de Putte, Yet more evidence
that osteoarthritis is not a cartilage disease. Ann Rheum Dis, 2006. 65: p. 12611264.

41.

Goldring, M.B. and S.R. Goldring, Osteoarthritis. Journal of Cellular Physiology,
2007. 213(3): p. 626-634.

42.

Iannone, F. and G. Lapadula, The pathophysiology of osteoarthritis. Aging
Clinical and Experimental Research, 2003. 15(5): p. 364-372.

43.

Felson, D.T., Clinical practice. Osteoarthritis of the knee. N Engl J Med, 2006.
354: p. 841–848.

44.

Cushnaghan, J. and P. Dieppe, Study of 500 Patients with Limb Joint
Osteoarthritis .1. Analysis by Age, Sex, and Distribution of Symptomatic Joint
Sites. Annals of the Rheumatic Diseases, 1991. 50(1): p. 8-13.

45.

Sarzi-Puttini, P., M.A. Cimmino, R. Scarpa, R. Caporali, F. Parazzini, A.
Zaninelli, F. Atzeni, and B. Canesi, Osteoarthritis: An overview of the disease
and its treatment strategies. Seminars in Arthritis and Rheumatism, 2005. 35(1):
p. 1-10.

46.

Felson, D.T., A. Naimark, J. Anderson, L. Kazis, W. Castelli, and R.F. Meenan,
The Prevalence of Knee Osteoarthritis in the Elderly - the Framingham
Osteoarthritis Study. Arthritis and Rheumatism, 1987. 30(8): p. 914-918.

47.

Weiss, E. and R. Jurmain, Osteoarthritis revisited: A contemporary review of
aetiology. International Journal of Osteoarchaeology, 2007. 17(5): p. 437-450.

48.

Hunziker, E.B., Articular cartilage repair: basic science and clinical progress. A
review of the current status and prospects. Osteoarthritis and Cartilage, 2002.
10(6): p. 432-463.

49.

Hunziker, E.B. and L.C. Rosenberg, Repair of partial-thickness defects in
articular cartilage: Cell recruitment from the synovial membrane. Journal of
Bone and Joint Surgery-American Volume, 1996. 78A(5): p. 721-733.

50.

Kim, H.K.W., M.E. Moran, and R.B. Salter, The Potential for Regeneration of
Articular-Cartilage in Defects Created by Chondral Shaving and Subchondral
Abrasion - an Experimental Investigation in Rabbits. Journal of Bone and Joint
Surgery-American Volume, 1991. 73A(9): p. 1301-1315.

35

51.

Mankin, H.J., Reaction of Articular-Cartilage to Injury and Osteoarthritis .1.
New England Journal of Medicine, 1974. 291(24): p. 1285-1292.

52.

Ghadially, F.N., Fine structure of synovial joints. A text and atlas of the
ultrastructure of normal and pathological articular tissues. 1983, London:
Butterworth & Co.

53.

Hunziker, E.B., Articular cartilage repair: are the intrinsic biological constraints
undermining this process insuperable? Osteoarthritis and Cartilage, 1999. 7(1): p.
15-28.

54.

Shapiro, F., S. Koide, and M.J. Glimcher, Cell Origin and Differentiation in the
Repair of Full-Thickness Defects of Articular-Cartilage. Journal of Bone and
Joint Surgery-American Volume, 1993. 75A(4): p. 532-553.

55.

Roos, E.M., Joint injury causes knee osteoarthritis in young adults. Current
Opinion in Rheumatology, 2005. 17(2): p. 195-200.

56.

Beris, A.E., M.G. Lykissas, C.D. Papageorgiou, and A.D. Georgoulis, Advances
in articular cartilage repair. Injury-International Journal of the Care of the
Injured, 2005. 36: p. S14-S23.

57.

McLaren, A.C., C.P. Blokker, P.J. Fowler, J.N. Roth, and M.G. Rock,
Arthroscopic Debridement of the Knee for Osteoarthrosis. Canadian Journal of
Surgery, 1991. 34(6): p. 595-598.

58.

Baumgaertner, M.R., W.D. Cannon, J.M. Vittori, E.S. Schmidt, and R.C. Maurer,
Arthroscopic Debridement of the Arthritic Knee. Clinical Orthopaedics and
Related Research, 1990(253): p. 197-202.

59.

McGinley, B.J., F.D. Cushner, and W.N. Scott, Debridement arthroscopy - 10year followup. Clinical Orthopaedics and Related Research, 1999(367): p. 190194.

60.

Furukawa, T., D.R. Eyre, S. Koide, and M.J. Glimcher, Biochemical-Studies on
Repair Cartilage Resurfacing Experimental Defects in the Rabbit Knee. Journal
of Bone and Joint Surgery-American Volume, 1980. 62(1): p. 79-89.

61.

Bert, J.M., Role of Abrasion Arthroplasty and Debridement in the Management of
Osteoarthritis of the Knee. Rheumatic Disease Clinics of North America, 1993.
19(3): p. 725-739.

36

62.

Sledge, S.L., Microfracture techniques in the treatment of osteochondral injuries.
Clinics in Sports Medicine, 2001. 20(2): p. 365-+.

63.

Krishnan, S.P. and J.A. Skinner, (i) Novel treatments for early osteoarthritis of
the knee. Current Orthopaedics, 2005. 19(6): p. 407-414.

64.

Bakay, A., L. Csonge, G. Papp, and L. Fekete, Osteochondral resurfacing of the
knee joint with allograft - Clinical analysis of 33 cases. International
Orthopaedics, 1998. 22(5): p. 277-281.

65.

Chu, C.R., F.R. Convery, W.H. Akeson, M. Meyers, and D. Amiel, Articular
cartilage transplantation - Clinical results in the knee. Clinical Orthopaedics and
Related Research, 1999(360): p. 159-168.

66.

McDermott, A.G.P., F. Langer, K.P.H. Pritzker, and A.E. Gross, Fresh SmallFragment Osteochondral Allografts - Long-Term Follow-up-Study on 1st 100
Cases. Clinical Orthopaedics and Related Research, 1985(197): p. 96-102.

67.

Mahomed, M.N., R.J. Beaver, and A.E. Gross, The Long-Term Success of Fresh,
Small Fragment Osteochondral Allografts Used for Intraarticular Posttraumatic
Defects in the Knee-Joint. Orthopedics, 1992. 15(10): p. 1191-1199.

68.

Langer, F., A.E. Gross, M. West, and E.P. Urovitz, Immunogenicity of Allograft
Knee-Joint Transplants. Clinical Orthopaedics and Related Research, 1978(132):
p. 155-162.

69.

Stevenson, S., The Immune-Response to Osteochondral Allografts in Dogs.
Journal of Bone and Joint Surgery-American Volume, 1987. 69A(4): p. 573-582.

70.

Tomford, W.W., D.S. Springfield, and H.J. Mankin, Fresh and Frozen ArticularCartilage Allografts. Orthopedics, 1992. 15(10): p. 1183-1188.

71.

Stevenson, S., Q.L. Xiao, and B. Martin, The Fate of Cancellous and Cortical
Bone after Transplantation of Fresh and Frozen Tissue-Antigen-Matched and
Mismatched Osteochondral Allografts in Dogs. Journal of Bone and Joint
Surgery-American Volume, 1991. 73A(8): p. 1143-1156.

72.

Hangody, L., G. Rathonyi, Z. Duska, G. Vasarhelyi, P. Fules, and L. Modis,
Autologous osteochondral mosaicplasty. Surgical technique. J Bone Joint Surg
Am, 2004. 86-A (Suppl 1): p. 65-72.

37

73.

Girdler, N.M., Repair of Articular Defects with Autologous Mandibular Condylar
Cartilage. Journal of Bone and Joint Surgery-British Volume, 1993. 75(5): p.
710-714.

74.

Laprell, H. and W. Petersen, Autologous osteochondral transplantation using the
diamond bone-cutting system (DBCS): 6-12 years' follow-up of 35 patients with
osteochondral defects at the knee joint. Archives of Orthopaedic and Trauma
Surgery, 2001. 121(5): p. 248-253.

75.

Bentley, G. and T. Minas, Science, medicine, and the future - Treating joint
damage in young people. British Medical Journal, 2000. 320(7249): p. 15851588.

76.

Huntley, J.S., P.G. Bush, J.M. McBirnie, A.H. Simpson, and A.C. Hall,
Chondrocyte death associated with human femoral osteochondral harvest as
performed for mosaicplasty. Journal of Bone and Joint Surgery-American
Volume, 2005. 87A(2): p. 351-360.

77.

Redman, S.N.O., S.F.; Archer,C.W., Current strategies for articular cartilage
repair. Eur.Cell.Mater., 2005. 9: p. 23-32.

78.

Morrey, B.F., Joint Replacement Arthroplasty. 3rd ed. 2003: Churchill
Livingstone.

79.

Joshi, A.B., M.L. Porter, I.A. Trail, L.P. Hunt, J.C.M. Murphy, and K. Hardinge,
Long-Term Results of Charnley Low-Friction Arthroplasty in Young-Patients.
Journal of Bone and Joint Surgery-British Volume, 1993. 75(4): p. 616-623.

80.

Bohsali, K.I., M.A. Wirth, and C.A. Rockwood, Complications of total shoulder
arthroplasty. Journal of Bone and Joint Surgery-American Volume, 2006.
88A(10): p. 2279-2292.

81.

Swieszkowski, W., B.H.S. Tuan, K.J. Kurzydlowski, and D.W. Hutmacher,
Repair and regeneration of osteochondral defects in the articular joints.
Biomolecular Engineering, 2007. 24(5): p. 489-495.

82.

Langer, R. and J.P. Vacanti, Tissue Engineering. Science, 1993. 260(5110): p.
920-926.

38

83.

Rahaman, M.N. and J.J. Mao, Stem cell-based composite tissue constructs for
regenerative medicine. Biotechnology and Bioengineering, 2005. 91(3): p. 261284.

84.

Krampera, M., G. Pizzolo, G. Aprili, and M. Franchini, Mesenchymal stem cells
for bone, cartilage, tendon and skeletal muscle repair. Bone, 2006. 39(4): p. 678683.

85.

Polak, J.M. and A.E. Bishop, Stem cells and tissue engineering: Past, present,
and future, in Skeletal Development and Remodeling in Health, Disease, and
Aging. 2006. p. 352-366.

86.

Raghunath, J., H.J. Salacinski, K.M. Sales, P.E. Butler, and A.M. Seifalian,
Advancing cartilage tissue engineering: the application of stem cell technology.
Current Opinion in Biotechnology, 2005. 16(5): p. 503-509.

87.

Stocum, D.L., Stem cells in regenerative biology and medicine. Wound Repair
and Regeneration, 2001. 9(6): p. 429-442.

88.

Heng, B.C., T. Cao, and E.H. Lee, Directing stem cell differentiation into the
chondrogenic lineage in vitro. Stem Cells, 2004. 22(7): p. 1152-1167.

89.

Ornitz, D.M. and P.J. Marie, FGF signaling pathways in endochondral and
intramembranous bone development and human genetic disease. Genes &
Development, 2002. 16(12): p. 1446-1465.

90.

Fortier, L.A., A.J. Nixon, and G. Lust, Phenotypic expression of equine articular
chondrocytes grown in three-dimensional cultures supplemented with
supraphysiologic concentrations of insulin-like growth factor-I. American Journal
of Veterinary Research, 2002. 63(2): p. 301-305.

91.

Fukumoto, T., J.W. Sperling, A. Sanyal, J.S. Fitzsimmons, G.G. Reinholz, C.A.
Conover, and S.W. O'Driscoll, Combined effects of insulin-like growth factor-1
and transforming growth factor-beta 1 on periosteal mesenchymal cells during
chondrogenesis in vitro. Osteoarthritis and Cartilage, 2003. 11(1): p. 55-64.

92.

Buttery, L.D.K., S. Bourne, J.D. Xynos, H. Wood, F.J. Hughes, S.P.F. Hughes, V.
Episkopou, and J.M. Polak, Differentiation of osteoblasts and in vitro bone
formation from murine embryonic stem cells. Tissue Engineering, 2001. 7(1): p.
89-99.

39

93.

Porter, R.M., W.R. Huckle, and A.S. Goldstein, Effect of dexamethasone
withdrawal on osteoblastic differentiation of bone marrow stromal cells. Journal
of Cellular Biochemistry, 2003. 90(1): p. 13-22.

94.

Davidson, J.M., P.A. LuValle, O. Zoia, D. Quaglino, and M.G. Giro, Ascorbate
differentially regulates elastin and collagen biosynthesis in vascular smooth
muscle cells and skin fibroblasts by pretranslational mechanisms. Journal of
Biological Chemistry, 1997. 272(1): p. 345-352.

95.

Wang, X.H., S.P. Grogan, F. Rieser, V. Winkelmann, V. Maquet, M. La Berge,
and P. Mainil-Varlet, Tissue engineering of biphasic cartilage constructs using
various biodegradable scaffolds: an in vitro study. Biomaterials, 2004. 25(17): p.
3681-3688.

96.

Tuli, R., S. Nandi, W.J. Li, S. Tuli, X.X. Huang, P.A. Manner, P. Laquerriere, U.
Noth, D.J. Hall, and R.S. Tuan, Human mesenchymal progenitor cell-based tissue
engineering of a single-unit osteochondral construct. Tissue Engineering, 2004.
10(7-8): p. 1169-1179.

97.

Kandel, R.A., M. Grynpas, R. Pilliar, J. Lee, J. Wang, S. Waldman, P. Zalzal, and
M. Hurtig, Repair of osteochondral defects with biphasic cartilage-calcium
polyphosphate constructs in a Sheep model. Biomaterials, 2006. 27(22): p. 41204131.

98.

Gao, R.Z., J.E. Dennis, L.A. Solchaga, V.M. Goldberg, and A.I. Caplan, Repair of
osteochondral defect with tissue-engineered two-phase composite material of
injectable calcium phosphate and hyaluronan sponge. Tissue Engineering, 2002.
8(5): p. 827-837.

99.

Schaefer, D., I. Martin, G. Jundt, J. Seidel, M. Heberer, A. Grodzinsky, I. Bergin,
G. Vunjak-Novakovic, and L.E. Freed, Tissue-engineered composites for the
repair of large osteochondral defects. Arthritis and Rheumatism, 2002. 46(9): p.
2524-2534.

100.

Schaefer, D., I. Martin, P. Shastri, R.F. Padera, R. Langer, L.E. Freed, and G.
Vunjak-Novakovic, In vitro generation of osteochondral composites.
Biomaterials, 2000. 21(24): p. 2599-2606.

40

101.

Hung, C.T., E.G. Lima, R.L. Mauck, E. Taki, M.A. LeRoux, H.H. Lu, R.G. Stark,
X.E. Guo, and G.A. Ateshian, Anatomically shaped osteochondral constructs for
articular cartilage repair. Journal of Biomechanics, 2003. 36(12): p. 1853-1864.

102.

Chang, C.H., F.H. Lin, C.C. Lin, C.H. Chou, and H.C. Liu, Cartilage tissue
engineering on the surface of a novel gelatin-calcium-phosphate biphasic scaffold
in a double-chamber biorector. Journal of Biomedical Materials Research Part BApplied Biomaterials, 2004. 71B(2): p. 313-321.

103.

Schek, R.M., J.M. Taboas, S.J. Segvich, S.J. Hollister, and P.H. Krebsbach,
Engineered osteochondral grafts using biphasic composite solid free-form
fabricated scaffolds. Tissue Engineering, 2004. 10(9-10): p. 1376-1385.

104.

Solchaga, L.A., J.Z. Gao, J.E. Dennis, A. Awadallah, M. Lundberg, A.I. Caplan,
and V.M. Goldberg, Treatment of osteochondral defects with autologous bone
marrow in a hyaluronan-based delivery vehicle. Tissue Engineering, 2002. 8(2):
p. 333-347.

105.

Wendt, D., M. Jakob, and I. Martin, Bioreactor-based engineering of
osteochondral grafts: from model systems to tissue manufacturing. Journal of
Bioscience and Bioengineering, 2005. 100(5): p. 489-494.

106.

Vunjak-Novakovic, G.M., L.; Altman,G.; Kaplan,D., Bioreactor cultivation of
osteochondral grafts. Orthod.Craniofac.Res., 2005. 8(3): p. 209-218.

107.

Davisson, T., R.L. Sah, and A. Ratcliffe, Perfusion increases cell content and
matrix synthesis in chondrocyte three-dimensional cultures. Tissue Engineering,
2002. 8(5): p. 807-816.

108.

Mizuno, S., F. Allemann, and J. Glowacki, Effects of medium perfusion on matrix
production by bovine chondrocytes in three-dimensional collagen sponges.
Journal of Biomedical Materials Research, 2001. 56(3): p. 368-375.

109.

Vankampen, G.P.J., J.P. Veldhuijzen, R. Kuijer, R.J. Vandestadt, and C.A.
Schipper, Cartilage Response to Mechanical Force in High-Density Chondrocyte
Cultures. Arthritis and Rheumatism, 1985. 28(4): p. 419-424.

110.

Hall, A.C., J.P.G. Urban, and K.A. Gehl, The Effects of Hydrostatic-Pressure on
Matrix Synthesis in Articular-Cartilage. Journal of Orthopaedic Research, 1991.
9(1): p. 1-10.

41

111.

Mizuno, S., T. Tateishi, T. Ushida, and J. Glowacki, Hydrostatic fluid pressure
enhances matrix synthesis and accumulation by bovine chondrocytes in threedimensional culture. Journal of Cellular Physiology, 2002. 193(3): p. 319-327.

112.

Carver, S.E. and C.A. Heath, Influence of intermittent pressure, fluid flow, and
mixing on the regenerative properties of articular chondrocytes. Biotechnology
and Bioengineering, 1999. 65(3): p. 274-281.

113.

Carver, S.E. and C.A. Heath, Semi-continuous perfusion system for delivering
intermittent physiological pressure to regenerating cartilage. Tissue Engineering,
1999. 5(1): p. 1-11.

114.

Carver, S.E. and C.A. Heath, Increasing extracellular matrix production in
regenerating cartilage with intermittent physiological pressure. Biotechnology
and Bioengineering, 1999. 62(2): p. 166-174.

42

CHAPTER 2
INTERACTIONS BETWEEN SKELETAL TISSUE CELLS AND THE
EFFECTIVENESS OF CONDITIONED MEDIA TO MODULATE
MESENCHYMAL STEM CELL DIFFERENTIATION
Introduction
Osteochondral tissue engineering provides a potential way to produce similar
results as those achieved using the current treatment option of osteochondral grafting,
without the drawbacks of autologous and allogeneic grafts. While there are numerous
researchers working in the area of osteochondral tissue engineering, the optimal culture
conditions that would allow the development of a clinically viable tissue-engineered
device are yet to be determined.
While MSCs can be found in other areas of the body, the bone marrow is the most
common source [1]. Adipocytes and osteoblasts are found in abundance within the bone
marrow and research has demonstrated a complex relationship between the two [2-4]. In
the past, the prevailing theory was one that described an inverse relationship between
adipocytes and osteoblasts created in the bone marrow, i.e., if adipogenesis increased
then osteogenesis decreased, and vice versa [5, 6]. Today, while the theory of an inverse
relationship between bone and fat still provides a fundamental basis, additional studies
have shown that the relationship between osteoblasts and adipocytes is much more
complex [4, 7, 8]. The complexity of the relationship may be, in part, attributed to the
complicated cytokine and growth factor signaling pathways that exist between the two
cell populations.
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In addition, a complex relationship between chondrocytes and osteoblasts exists
in the in vivo osteochondral environment. Endochondral bone formation is a highly
regulated process involving the differentiation of mesenchymal stem cells to cartilage
forming chondrocytes, followed by the differentiation to bone forming osteoblasts [9].
During this process, which takes place during embryogenesis and fracture repair,
osteoblast differentiation and bone mineralization within the growing bone must be
coordinated with the growth and differentiation of the underlying chondrocytes [10]. The
complexity of the relationship between the two differentiating cell types is, in part,
attributed to the complicated cytokine and growth factor signaling pathways that exist
between the two cell populations. Understanding and leveraging the interactions that
regulate cell proliferation and differentiation could provide a method of optimizing
culture conditions to develop a tissue engineered osteochondral construct. Previous
studies have investigated the complex relationship between MSCs, osteoblast and
chondrocytes and have revealed that these cells can communicate via paracrine,
juxtacrine or gap-junction signaling pathways [11-14]. In addition, they have suggested
that the utilization of this cell communication can be applied to tissue engineering
applications by enhancing the tissue production of the cells [15-17]. Classical tissue
engineering research has largely focused on monoculture systems; however it is
becoming more and more evident that complex tissue can only be engineered using
systems that account for the signaling from multiple cell types [15, 16, 18].
Paracrine signaling may be modulated in vitro to find optimal culturing conditions
and improve our ability to tune MSC differentiation for tissue engineering applications.
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The goals of a first study were to determine the effect of adipocyte conditioned media
(CM) on MSC differentiation to an osteoblast phenotype and to determine the effect of
osteoblast CM on MSC‟s differentiation to an adipocyte phenotype. The goals of a
second study were to determine the effect of chondrocyte CM on MSC differentiation to
an osteoblast phenotype and to determine the effect of osteoblast CM on the
differentiation of MSCs to a chondrocyte phenotype.

Conditioned Media Cause Increases in Select Osteogenic and Adipogenic
Differentiation Markers in Mesenchymal Stem Cell Cultures
Methods and Materials
Cell Seeding
D1 murine mesenchymal stem cells (ATCC, Manassas, VA) were grown in a
standard cell culture flask (Corning, Corning, NY). After two days, the cells neared
confluence and were split into two cell culture flasks in order to grow enough cells for the
study. After another two days the cells neared confluence in both flasks. The cells were
then seeded onto 12 well plates (Corning, Corning, NY) at a concentration of 3.4x10 4
cells per well, with 2 ml of media per well. After two days, the cells neared confluence.
Up to this point, the cells were cultured in Dulbecco‟s Modified Eagle‟s Medium
(DMEM) (Invitrogen, Gibco, Carlsbad, CA) supplemented with 10% FBS (Hyclone,
Logan, UT) and 1% antibiotic/antimyocotic (Invitrogen, Gibco, Carlsbad, CA).
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Conditioned Media
The study consisted of two groups, the osteogenic group and the adipogenic
group. When the cells neared confluence in the multi-well plates, the medium was
replaced with the appropriate differentiation cocktail. The osteogenic differentiation
cocktail consisted of DMEM, 10% FBS, 1% antibiotic/antimycotic, 50 µg/ml L-ascorbic
acid 2-phosphate (Sigma, St. Louis, MO), and 3 mM β-glycerophosphate (Sigma, St.
Louis, MO). The adipogenic differentiation cocktail consisted of DMEM, 10% FBS, 1%
antibiotic/antimycotic, 10% 1BMX (50 mM) (Sigma, St. Louis, MO), 1% insulin (Sigma,
St. Louis, MO), and 0.02% dexamethasone (1 mg/ml of EtOH) (Sigma, St. Louis, MO).
Within both the osteogenic group and adipogenic group there were four control and two
experimental sets. The controls were: undifferentiated, i.e., the samples consisted of
MSCs not exposed to differentiation cocktail or CM; differentiated, i.e., the samples
consisted of MSCs exposed to either the osteogenic or adipogenic differentiation cocktail,
but no CM; and “opposite” unconditioned medium, i.e., the samples consisted of MSCs
given the appropriate differentiation cocktail as well as the “opposite” unconditioned
medium at a concentration of either 25% or 50%. For example, the 25% unconditioned
media samples in the adipogenic group were given adipogenic differentiation medium as
well as 25% osteogenic medium that was not conditioned by any cells. The
unconditioned media controls were used to establish that any changes seen in the
experimental groups were not simply due to the differentiation supplements that would
also be found in the conditioned media. The experimental sets were given either the
osteogenic or adipogenic differentiation cocktail, as well as CM from the opposite group
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at concentrations of 25% and 50%. Figure 1 outlines the experimental setup of the study.
The CM was taken from the opposite differentiated control at each media change. The
conditioned medium was removed from the well of a differentiated control sample with a
micro-pipette. Twenty-five percent was then directly administered to a 25% CM
experimental sample, 50% was directly administered to a 50% CM experimental sample
and the remaining 25% was used to test for the concentrations of lactic acid and glucose.
This process was repeated for all four samples in both the osteogenic group and
adipogenic group. The media was changed every two days and each well was given 2ml
total of the appropriate medium, differentiation cocktail, or CM/cocktail mix. The
experimental and control sets for both groups contained four samples (n=4) each for each
end point. The end points of the study were Days 5, 10, 15, and 20 for the fat cultures
and Days 7, 14, and 21 for the bone cultures. Day 0 was denoted as the day that the
differentiation cocktail was first given. Different time points were monitored for the
different groups to reflect the different key events in the differentiation of the two cell
populations.

Metabolic Activity
The metabolic activity was examined using an alamarBlueTM metabolic assay
(Invitrogen, Biosource, Carlsbad, CA) at every end point. Directly after a media change,
which includes the application of CM in the experimental groups, 150 µl of
alamarBlueTM was added to each well and the samples were incubated at 37 o C for four
hours. Aliquots of 175 µl were taken using a micro-pipette in triplicate and directly
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placed in a black sided, clear bottom 96-well plate (Corning, Corning, NY). Fluorescent
spectrometry was performed using a Fluoroskan Ascent FL (Labsystems, Finland) at an
excitation wavelength of 544 nm and a dye emission wavelength of 590 nm. Following
completion of the alamarBlueTM assay, the samples were rinsed with PBS, one milliliter
of deionized water was added to the osteogenic samples, and all the well plates were
stored in a -80o freezer until the end of the study. No water was added to the adipogenic
samples, as Triton X was added after the freeze-thaw cycles.

Osteogenic Group

MSC Control
(no cocktail or
CM)

Bone Control
(Osteogenic
cocktail, no
CM)

Differentiating Differentiating
Unconditioned Unconditioned
Osteoblasts
Osteoblasts
Media Control Media Control
w/25%
w/50%
25%
50%
adipocyte CM adipocyte CM
25%

Adipogenic Group

MSC Control
(no cocktail or
CM)

Fat Control
(Adipogenic
cocktail, no
CM)

25%
Differentiating
Adipocytes
w/25%
osteoblast CM

50%
50%

Differentiating
Unconditioned Unconditioned
Adipocytes
Media Control Media Control
w/50%
25%
50%
osteoblast CM

Figure 2.1: Outline of the experimental setup of the study. Arrows illustrate that the CM
was taken from the differentiated controls and was administered to the “opposite”
experimental groups at concentrations of 25% or 50%.

Total Protein
Three freeze-thaw cycles were performed to lyse the cell membranes. The
standard protocol for the BCA Total Protein Kit (Pierce, Rockford, IL) was followed. A
standard curve was generated using the bovine serum albumin standard and deionized
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water as the diluent. A working reagent was created by mixing reagent A, which
contains sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in
0.1 M sodium hydroxide, with Reagent B (4% cupric sulfate) at a 50:1 ratio. A volume
of 25 µl of the lysate was moved to a 96 well plate in triplicate and 200 µl of the working
reagent was added and the plate incubated at 37o C for 30 minutes. After cooling to room
temperature the absorbance was read at 563 nm using a MRX Micoplate Reader (Dynex
Technologies, Germany).

Alkaline Phosphatase (ALP) Activity
The ALP assay was conducted after the total protein assay, so the cells were
already lysed. The standard protocol for the ALP assay was followed. A standard curve
was generated using p-nitrophenol (Sigma, St. Louis, MO) standard solution with 0.02 N
NaOH. A phosphatase substrate solution was created by mixing 5ml of deionized water
with every 20 mg of phosphatase substrate (Sigma, St. Louis, MO). The phosphatase
substrate solution was mixed with an equal amount of alkaline buffer solution (Sigma, St.
Louis, MO) to create the working reagent. A volume of 500 µl of the working reagent
was placed in 24-well plates, using the same number of wells as samples; the plates were
then incubated for 15 minutes at 37o C. Subsequently, 100 µl of the sample lysate was
added to each sample well and incubated for 30 minutes at 37 o C, after which 1.5 ml of
0.25N NaOH was added to each well to stop the reaction. Aliquots in the amount of 200
µl were then moved in triplicate to a 96-well plate, and the absorbance was read at 410
nm using a MRX Micoplate Reader (Dynex Technologies, Germany). The ALP activity

49

was determined using the standard curve and measured in sigma units, which are defined
as 1μmol of p-nitrophenol converted per hour. The ALP assay is based on the ALPcatalyzed hydrolysis of p-nitrophenol phosphate in an alkaline cell lysate to generate a
yellow colored p-nitrophenol product. The results were normalized by the protein
content determined from the BCA total protein assay.

Triglyceride Production
After three freeze-thaw cycles were performed, 1 ml of 1% Triton X-100 (Sigma,
St. Louis, MO) was added to each sample and the samples were incubated at room
temperature for 30 minutes. A standard curve was generated using a glycerol standard
solution (Sigma, St. Louis, MO) and deionized water. After incubation, the wells were
scraped with a cell scraper and the triton solution and cell debris were placed in microtubes to be centrifuged at 3000rpm for 10 min. A volume of 100 µl of each sample was
placed in a 96 well plate in triplicate and 100 µl of InfinityTM triglyceride reagent (Sigma,
St. Louis, MO) was added to each sample well. After incubating at room temperature for
15 minutes the absorbance was read at 490 nm using a MRX Micoplate Reader (Dynex
Technologies, Germany).

Oil Red O Staining
Cells were rinsed twice with PBS and fixed with 2 ml of 10% formalin for 6
hours. A stock Oil Red O solution was prepared by dissolving 0.5g Oil Red O (Sigma,
St. Louis, MO) in 100 ml of deionized water. A working solution was then prepared by
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mixing 60 ml of the stock solution with 40 ml of deionized water. A volume of 500 µl of
the working solution was added to the wells and incubated at room temperature for 15
minutes. The wells were rinsed three times with water and the red staining indicating
lipid produced by the cells, was visualized using an inverted microscope and imaging
software.

Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=4). Unpaired
t tests were used to make comparisons with a significance level of p < 0.05.

Results
Metabolic Activity
The metabolic activity of both the osteogenic and adipogenic groups increased
slightly from the first end point to the last end point. There was no statistically significant
difference in the metabolic activity of any of the sets at any time point for both the
osteogenic and adipogenic groups (Figure 2).

Alkaline Phosphatase
Figure 2.3 shows the ALP activity of the cells in the osteogenic group normalized
by the total protein production. All of the samples given differentiation cocktail show a
higher ALP activity than the undifferentiated control. At Day 7 there is no statistical
difference between any of the groups except for the undifferentiated control. On Day 14
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Figure 2.2: Results from the alamarBlue assay show the metabolic activity levels of the
osteogenic group (A) and adipogenic group (B). No significant statistical differences
were seen at any time points. (Error bars represent standard error of mean)
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the ALP activity of the samples given 50% CM is higher than any of the controls and the
samples given 25% CM. The ALP activity for the 50% CM sample was .91 sigma units/
mg protein, which is 27% more than the 0.72 sigma units/ mg protein seen in the
differentiated control group that was not exposed to CM. At Day 21, the ALP production
of the samples given 50% CM was higher than any of the controls as well as the samples
given 25% CM. The ALP activity for the 50% CM sample was .86 sigma units/ mg
protein, which is 36% more ALP than the 0.63 sigma units/ mg protein seen in the
differentiated control group that was not exposed to CM.

Figure 2.3: Results from the alkaline phosphatase assay for the osteogenic group
normalized to the total protein. The set given 50% conditioned medium shows a
statistically significant higher ALP activity on Days 14 and 21. (Error bars represent
standard error of mean)
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Triglyceride
Figure 2.4 shows the triglyceride production of the cells in the adipogenic group.
All samples show a statistically higher level of triglyceride production than the
undifferentiated controls, with the exception of the differentiated control on Day 5. Both
differentiated controls that were given the opposite, unconditioned medium showed
higher triglyceride production at both 25% and 50% than the differentiated control. The
two conditioned media groups showed even higher triglyceride concentration than their
respective unconditioned media controls at every time point. By Day 20 the 25% CM set
produced a triglyceride concentration of 315 μM, which is111% more than the 150 μM
seen in the differentiated control group and the 50% CM obtained a triglyceride
concentration of 399 μM, which is160% more than the differentiated control group.

Figure 2.4: Results from the triglyceride assay for the adipogenic group. The opposite
unconditioned medium controls show increased production over the differentiated
control, while the two sets given CM show an even larger increase in triglyceride
production. (Error bars represent standard error of mean)
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Oil Red O Staining
At every time point in the study, there was no presence of lipid in the
undifferentiated control. On Day 5 there was no presence of lipid in the differentiated
control either; however a small amount of lipid was present in the opposite unconditioned
media controls and even more in the CM sets. By Day 10 lipid was produced by the
differentiated control in horseshoe shaped clusters that are very typical of the lipid
production in adipocytes, and a larger amount in the opposite unconditioned media
controls. More lipid was evident in the CM sets, but the size of some of the lipid vesicles
had also becoming larger with large individual vesicles. This trend continued through the
end of the study. Figure 2.5 shows the results of the Oil Red O staining for the
adipogenic group on Day 20, where lipid is stained red. The amount of horseshoe shaped
clusters increases in all of the sets; the largest noticeable difference seen in the CM sets
was the presence of the large individual vesicles that continued to grow in size and
number through the end of the study.

55

Figure 2.5: Micrographs of the adipogenic samples after oil red O staining on Day 20 for
(a) undifferentiated control, (b) differentiated control, (c) 25% unconditioned medium
control, (d) 50% unconditioned medium control, (e) 25% CM and (f) 50% CM. White
arrows denote the large individual lipid vesicles in the CM sets. Original total
magnification was 200X.

Conditioned Media Enhance the Osteogenic and Chondrogenic Differentiation of
Mesenchymal Stem Cells
Methods and Materials
Scaffold Construction
The porous scaffold used for the bone phase was produced using a solvent
evaporation/porogen leaching method. A copolymer of poly-L-lactide and
polycaprolactone, 75%/ 25% respectively (PL/PCL) (Alkermes Controlled Therapeutics
II, Cincinnati, OH), was added to biotech grade chloroform at a concentration of 0.15
g/mL. The as-received number average molecular weight (Mn) of the polymer was
100,074 Daltons and the as-received weight average molecular weight (Mw) was 183,032
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Daltons. The mixture was left overnight to allow the polymer to completely dissolve.
Hydroxyapatite powder (HAP) (Federal Laboratories Corp., Alden, NY) was then added
to the solution at a concentration of a 10% W/V and mixed with a magnetic stir bar. A
volume of 1 ml (0.964 g) of glucose, which had been passed through a sieve to extract
grain sizes of 250 µm – 425 µm, was added to a small glass beaker with a diameter of
approximately 22 mm. A volume of 1 ml of the PL/PCL/HAP solution was slowly added
on top of the glucose, the beaker was covered with parafilm, and two small holes were
made in the parafilm to avoid rapid evaporation of the chloroform. The beakers were left
in a chemical hood for 12 hours to allow the chloroform to evaporate. The scaffolds were
then removed from the beakers and placed in mesh containers that were suspended in 750
ml of distilled water that was continually stirred with a magnetic stir bar. The scaffolds
remained in water for 48 hours, and the water was replenished every 12 hrs. The
scaffolds were then removed from the water and allowed to dry for 24 hours. The final
product was a porous disc with an approximate 22 mm diameter and 3 mm thickness.
The scaffolds were stored in a desiccator until all of the scaffolds were produced.
Scaffolds were sterilization with ethylene oxide for 24 hours in an AN74i cabinet
sterilizer (Anprolene, Haw River, NC) with a 5 cc ampoule (Anprolene, Haw River, NC),
followed by a degassing time of 48 hours under house vacuum at ambient temperatures.
A total of 108 scaffolds were produced. Three replicates were used from each of the six
conditions for the alkaline phosphatase assay and three replicates were used from each of
the six conditions for RT-PCR, at all three time points.
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Cell Seeding and Encapsulation
D1 murine mesenchymal stem cells (ATCC, Manassas, VA) were grown in a
standard cell culture flask (Corning, Corning, NY). After three days, the cells neared
confluence and were split into two cell culture flasks in order to grow enough cells for the
study. After another three days the cells neared confluence in both flasks. The
PL/PCL/HAP scaffolds were placed in ultra low attachment 12 well plates (Corning,
Corning, NY) to prevent cell attachment to the plate and promote cell attachment to the
scaffold. The D1 cells were suspended at a concentration of 5x104 cells/ml and 5x104
cells were seeded onto each scaffold. The samples that were grown on the scaffold were
collectively referred to as the osteogenic group. The scaffolds were cultured overnight at
37o C and 5% CO2 in base medium consisting of Dulbecco‟s Modified Eagle‟s Medium
(DMEM) (Invitrogen, Gibco, Carlsbad, CA) supplemented with 10% FBS(Hyclone,
Logan, UT), 1% antibiotic/antimyocotic (Invitrogen, Gibco, Carlsbad, CA) and 0.2%
fungizone (Invitrogen, Gibco, Carlsbad, CA).
Sterile alginate (Sigma, St. Louis, MO) was mixed with sterile water to make a
2% W/V alginate solution. The D1 cells were then suspended in the alginate at a
concentration of 1x106 cells/ml. The suspension was drawn into a syringe and, using a
syringe pump, was dripped into 0.1 M CaCl2 (Fisher Scientific, Fair Lawn, NJ) to form
cross linked alginate beads. Ten beads, i.e. approximately 5x10 4 cells, were used for
each sample and placed in low attachment 12 well plates. Three replicate samples were
used from each of the six conditions for the sulfated glycosaminoglycans assay and three
replicate samples were used from each of the six conditions for RT-PCR, at all three time
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points. The samples encapsulated in the alginate beads were referred to collectively as
the chondrogenic group. The beads were cultured overnight at 37 o C and 5% CO2 in a
base medium consisting of Dulbecco‟s Modified Eagle‟s Medium (DMEM) (Invitrogen,
Gibco, Carlsbad, CA) supplemented with 10% FBS(Hyclone, Logan, UT), 1%
antibiotic/antimyocotic (Invitrogen, Gibco, Carlsbad, CA) and 0.2% fungizone
(Invitrogen, Gibco, Carlsbad, CA).

Conditioned Media
After overnight culture in the base medium, the medium was removed and
replaced with the appropriate differentiation medium. The osteogenic group (grown on
the PL/PCL/HAP scaffold) was given a differentiation medium consisting of DMEM,
10% FBS, 1% antibiotic/antimycotic, 0.2% fungizone, 50 µg/ml L-ascorbic acid 2phosphate (Sigma, St. Louis, MO), 3 mM β-glycerophosphate (Sigma, St. Louis, MO)
and 10 nM dexamethasone (Sigma, St. Louis, MO). The chondrogenic group
(encapsulated in alginate beads) was given a differentiation medium consisting of
DMEM, 1% antibiotic/antimycotic, 0.2% fungizone, 50 ug/ml L-ascorbic acid 2phosphate, 40 ug/ml L-proline (Sigma, St. Louis, MO), 10 ul/ul ITS+1 liquid media
supplement (Sigma, St. Louis, MO), and 10 ng/ml TGF-β1 (Sigma, St. Louis, MO).
After two days of culture in the differentiation media the conditioned media was
administered from that point forward and that time point was considered as Day Zero.
Both the osteogenic group and chondrogenic group contained two conditioned medium
sets. The conditioned medium sets consisted of MSCs either grown on the scaffolds
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(osteogenic group) or encapsulated in alginate (chondrogenic group) and cultured in the
appropriate differentiation medium with the addition of 25% or 50% medium that had
been conditioned by the other cell type. The CM was taken from the differentiated
controls at each medium change. For example, the 25% CM samples in the chondrogenic
group were administered 75% chondrogenic medium and 25% medium that was
conditioned by the osteogenic control. Figure 2.6 outlines the experimental setup of the
study.

Controls
In addition to the two conditioned medium sets, there were five control sets. The
first control set was the 2D control. The 2D control contained MSCs grown on the
surface of a treated well plate and cultured in base DMEM medium. The second control
set was the MSC control, which contained MSCs either grown on the scaffolds
(osteogenic group) or encapsulated in alginate (chondrogenic group) and cultured in base
Osteogenic Group
Name

2D Control

MSC Control

Osteogenic
Control

25% CM

Media

DMEM

DMEM

Osteogenic

75% Osteo
25% CM

Material
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PL/PCL/HAP

PL/PCL/HAP

50% CM

25% Uncond
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50% CM

75% Osteo
25% Chondro
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50% Chondro
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PL/PCL/HAP
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Alginate
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Figure 2.6: Outline of the experimental setup for the study. Each box represents a
different treatment with the name, medium type used and material used listed in the box.
Arrows indicate that the CM was taken from the osteogenic and chondrogenic controls
and administered to the opposite experimental sets at 25% and 50%.

60

DMEM medium. The MSC control was not administered any differentiation medium or
conditioned medium. The third control set was either the osteogenic or chondrogenic
control, which consisted of MSCs either grown on the scaffolds (osteogenic group) or
encapsulated in alginate (chondrogenic group) and only cultured in the corresponding
differentiation medium. The fourth control set was the 25% unconditioned media (UCM)
control. The 25% UCM group consisted of MSCs either grown on the scaffolds
(osteogenic group) or encapsulated in alginate (chondrogenic group) and cultured in a
75/25v/v mix of the matching differentiation media and the “opposite”, unconditioned
differentiation medium. Finally, the fifth control set was the 50% unconditioned medium
(UCM) control, consisting of MSCs either grown on the scaffolds (osteogenic group) or
encapsulated in alginate (chondrogenic group) and cultured in the appropriate
differentiation medium with 50% of the “opposite” unconditioned differentiation
medium. For example, the 25% unconditioned medium samples in the chondrogenic
group were given 75% chondrogenic differentiation medium as well as 25% osteogenic
medium that was not conditioned by any cells. The unconditioned medium controls were
used to establish that any changes seen in the experimental groups were not simply due to
the differentiation supplements that would also be found in the conditioned medium. The
medium was changed every two days and each well was given 2ml total of the
appropriate medium, differentiation cocktail, or CM/cocktail mix. The experimental and
control sets for both groups contained six samples each for each end point. The end
points of the study were Days 7, 14, and 21.
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Sulfated Glycosaminoglycans
Three of the six replicates for each treatment in the chondrogenic group were used
to assess the production of sulfated glycosaminoglycans (sGAG). At each end point the
samples that were designated for the time point were washed in PBS three times. A
volume of 1.34 ml of a papain digestion buffer (55mM sodium citrate (Research Products
International, Mt. Prospect, IL), 150 mM sodium chloride, 5mM cysteine
hydrochloride(Sigma, St. Louis, MO), 5 mM EDTA (Sigma, St. Louis, MO) and .56
units/ml papain(Sigma, St. Louis, MO)) was used to solubilize the alginate and digest the
samples. The samples were stored at 60o C for 24 hrs. Volumes of 20 μl digested
sample, 30 μl of PBE buffer (100mM Na2HPO4 (Sigma, St. Louis, MO), 5mM EDTA,
pH 7.5) and 200 μl of dimethylmethylene blue (DMB) reagent solution (40 mM NaCl, 40
mM glycine (Sigma, St. Louis, MO), 46 μM DMB (Sigma, St. Louis, MO)) were added
to each well of a 96-well plate. Chondroitin sulfate was mixed in PBE buffer and used as
a standard to create a standard curve.

The absorbance was measured at 525 nm using a

MRX Micoplate Reader (Dynex Technologies, Germany). To correct for the DMB
binding to alginate present in the samples, a control of cell free alginate beads was
measured and the results were subtracted from the results of all the samples with the
expectation of the 2D control because there was no alginate present in the 2D controls.
The amount of DNA present in each sample was determined using the standard
protocol for the DNA Quantitation Kit (Sigma, St. Louis, MO), which uses the
fluorescent dye bisBenzimide. The results from the sGAG assay were then normalized to
the DNA content.
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Alkaline Phosphatase
Three of the six replicates for each treatment in the osteogenic group were used to
assess the alkaline phosphatase (ALP) activity. The samples were washed three times
with PBS, 2 ml of deionized water were added to each sample, and three freeze-thaw
cycles were performed to lyse the cell membranes. A phosphatase substrate solution was
created by mixing 5ml of deionized water with every 20 mg of phosphatase substrate
(Sigma, St. Louis, MO). The phosphatase substrate solution was mixed with an equal
amount of alkaline buffer solution (Sigma, St. Louis, MO) to create the working reagent.
A volume of 500 µl of the working reagent was placed in 24-well plates, using the same
number of wells as samples; the plates were then incubated for 15 minutes at 37o C.
Subsequently, 100 µl of the sample lysate was added to each sample well and incubated
for 30 minutes at 37o C, after which 1.5 ml of 0.25N NaOH was added to each well to
stop the reaction. Aliquots in the amount of 200 µl were then moved in triplicate to a 96well plate, and the absorbance was read at 410 nm using a MRX Micoplate Reader
(Dynex Technologies, Germany). A standard curve was generated using p-nitrophenol
(Sigma, St. Louis, MO) standard solution diluted with 0.02 N NaOH. The ALP activity
was determined using the standard curve and measured in sigma units, which are defined
as 1μmol of p-nitrophenol converted per hour. The ALP assay is based on the ALPcatalyzed hydrolysis of p-nitrophenol phosphate in an alkaline cell lysate to generate a
yellow colored p-nitrophenol product.
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The protein content in each sample was determined by following the standard
protocol for the BCA Total Protein Kit (Pierce, Rockford, IL). The results from the ALP
assay were normalized by the protein content determined by the BCA total protein assay.

RNA Isolation and Real Time RT-PCR
The remaining three replicates from each treatment in both the osteogenic and
chondrogenic group were used for RNA analysis. The alginate beads were solubilized in
55mM sodium citrate in 0.9% NaCl for 30 minutes at 37°C and centrifuged at 2,000 rpm
for 5 min. The supernatant was removed and RNA was isolated using the RNeasy mini
kit (Qiagen AG, Switzerland). RNA was isolated directly from the 2D samples and the
osteogenic samples grown on the PLA/PLC/HAP scaffolds using the RNeasy mini kit.
The quality and concentration of total RNA was determined using the Agilent RNA 6000
Nano Kit (Agilent Technologies, Santa Clara CA) the Agilent 2100 Bioanalyzer, and the
2100 Expert software. Equal amounts of total RNA were used for real time RT-PCR
using the QuantiFast SYBR Green RT-PCR Kit (Qiagen AG, Switzerland) in the RotorGene 5.0.28 light cycler (Corbett Life Science, Sydney, Australia). The markers that
were analyzed for the chondrogenic group were aggrecan and sox9. The markers that
were analyzed for the osteogenic group were osteocalcin and bone sialoprotein. GAPDH
was used as a housekeeping gene for both groups. The primer sequences can be seen in
Table 2.1. Relative expression was determined using the ∆∆Ct method with GAPDH as
the reference gene and the Day 7 2D undifferentiated samples as the control (appendix
A).
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Statistical analysis
Averages were reported as mean values ± standard deviation (n = 3). Unpaired ttests were used to make comparisons, with a significance level of p < 0.05.

Table 2.1: Primer sequences used for RT-PCR
Tm (oC)
59.5
56.4

Primer
Aggrecan

Sequence
F 5' - AGCTGAAGTCCCTGGTCAGC - 3'
R 5' - CTGCTGTGCCTCCTCAAATG - 3'

Sox9

F 5' - AAGTCGGTGAAGAACGGACAAG - 3'
R 5' - TCTCGCTTCAGATCAACTTTGC - 3'

57.2
55.5

Osteocalcin

F 5' - AGACCGCCTACAAACGCATC - 3'
R 5' - GATCAAGTCCCGGAGAGCAG - 3'

57.8
57.4

Bone Sialoprotein

F 5' - TACGGAGCAGAGACCACACC - 3'
R 5' - CTTCCTCGTCGCTTTCCTTC - 3'

58.8
55.7

GAPDH

F 5' - GAACGGATTTGGCCGTATTG - 3'
R 5' - CGTTGAATTTGCCGTGAGTG - 3'

54.3
54.9

Results
Sulfated Glycosaminoglycans
The sulfated glycosaminoglycans (sGAG) concentrations can be seen in Figure
2.7. On Day 7 the sGAG concentration of the 2D control was significantly lower than
that of any other treatment including the MSC control. There was no difference between
any of the other treatments. On Day 14 the 2D control again had a lower sGAG
concentration than all of the other treated samples. In addition the samples given 50%
conditioned media from the osteogenic group showed a significantly higher concentration
of sGAG than the chondrogenic control samples. By Day 21 the sGAG concentration in
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the 2D control remained the lowest. The sGAG concentration also was significantly
higher in the 50% CM samples as compared to the chondrogenic control. The sGAG
concentration steadily increased in all of the samples between each time point.

Figure 2.7: The results of the DMB assay, used to determine the sGAG concentration for
the chondrogenic group. The results are normalized by the DNA content. The 2D
control showed significantly less sGAG on each day. On Days 14 and 21 the 50% CM
samples showed higher sGAG concentrations than the chondrogenic control. Error bars
represent the standard deviation (SD, n=3). Asterisks (*) signify statistically significant
differences (p< 0.05).
Alkaline Phosphatase
The results of the alkaline phophatase assay are shown in Figure 2.8. The Day 7
ALP activity is significantly less in both the 2D control and the MSC control samples as
compared to all of the other treatment samples. The Day 14 ALP activity is still
significantly less in both the 2D control and the MSC control samples as compared to all
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of the other treatment samples. Additionally, the samples given 50% CM from the
chondrogenic group show a higher ALP activity than the osteogenic control samples. On
Day 21 the ALP activity remains significantly less in both the 2D control and the MSC
control samples than in all of the other treatment samples. Both the 25% CM and 50%
CM samples show a higher ALP activiy than the osteogenic control samples. The 50%
CM samples also have higher ALP activity than the samples given 50% chondrogenic
medium that was not conditioned by the chondrogenic group.

Figure 2.8: Results of the alkaline phosphatase assay normalized by total protein for the
osteogenic group. On Day 14 the 50% CM samples had higher ALP activity than the
osteogenic group. By Day 21 both the 25% CM and 50% CM samples showed higher
ALP activity than the osteogenic group samples. Error bars represent the SD (n=3).
Asterisks (*) signify statistically significant differences (p< 0.05).
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RT-PCR
The chondrogenic group was analyzed for the expression of aggrecan and sox9.
The relative expression of those chondrogenic markers are presented in Figure 2.9. The
relative expression of aggrecan at all three time points was significantly lower in the 2D
control than the other treatments. The Day 21 expression of aggrecan in the 50% CM
samples was significantly higher than the chondrogenic control and the 50%
unconditioned medium control samples. The relative expression of sox9 was
significantly lower in the 2D control than the other treatments at all three time points.
The Day 14 and 21 sox9 expressions were higher in the 50% CM samples than the
chondrogenic control and the 50% unconditioned media control samples.
The osteogenic group was analyzed for the expression of osteocalcin and bone
sialoprotein. The relative expression of those osteogenic markers are presetned in Figure
2.10. On Days 14 and 21 the relative expression of bone sialoprotein was significantly
lower in the 2D control than the other treatments. In addition, the samples given 50%
CM from the chondrogenic group showed a significantly higher bone sialoprotein
expression than the osteogenic control and the 50% unconditioned medium control
samples on both Days 14 and 21. On Day 14 and 21 the relative expression of
osteocalcin was significantly lower in the 2D control samples than in the other treatment
samples. Both the 25% CM and 50% CM Day 21 samples showed a higher expressin of
osteocalcin than the ostesogenic control samples. Furthermore, the 50% CM samples had
a higher expression than the 50% unconditioned medium control samples.
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Figure 2.9: Results of the RT-PCR for the chondrogenic markers aggrecan (A) and
Sox9(B). The results are reported as a relative expression to GAPDH using the ∆∆Ct
method. Error bars represent the SD. Asterisks (*) signify statistically significant
differences (p< 0.05).

69

Figure 2.10: Results of the RT-PCR for the osteogenic markers bone sialoprotein (A) and
osteocalcin(B). The results are reported as relative expression to GAPDH using the
∆∆Ct method. Error bars represent the SD. Asterisks (*) signify statistically significant
differences (p< 0.05).
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Discussion
The highly interdisciplinary field of tissue engineering involves the integration of
cells, biomaterials, and signaling to repair or replace damaged tissues. Each of these
areas is of significance and a great deal of work has been accomplished in all three
general areas. Because osteoblasts and adipocytes naturally reside in the bone marrow in
close proximity, paracrine signaling between the two cell types could likely be directed in
vitro to optimize the differentiation of stem cells. This optimization is necessary in order
to reach the goal of the development of clinically viable tissue engineered devices.
The results from the alamarBlueTM assay showed no statistically significant
difference was found between the metabolic activity of any of the sets at any time point
for both the osteogenic and adipogenic groups. The alamarBlue TM assay is often used as
an indicator of cellular proliferation. The results seen in this study suggest that there is
only a low level of proliferation, likely because the cells were nearly confluent when the
study began and the cells were beginning to differentiate. However, a metabolic activity
value encompasses more than proliferation; as the reduction of the alamarBlue TM
REDOX indicator occurs in the mitochondria, a change of fluorescence could indicate
changes of events such as cell viability, intracellular signaling, or cell growth. However,
the results suggest that the CM did not affect those cellular processes.
The results of the ALP assay show that all of the samples given differentiation
cocktail had a higher ALP activity than the undifferentiated control. This study
demonstrated that the CM of D1 MSCs undergoing adipogenic differentiation,
administered at a concentration of 50%, can increase the ALP production of MSCs
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undergoing osteogenic differentiation. This finding suggests that the cells are responding
to soluble factors released by the adipogenic cells. Numerous growth factors and
cytokines are synthesized and released by adipocytes, including adiponectin, tumor
necrosis factor-α (TNF- α), interleukin-6 (IL-6) and leptin [19-21]. Logically, these
components were likely present in the adipocyte CM.
It should also be noted that dexamethasone was present in the adipogenic
differentiation medium and therefore was present in the CM that was administered to the
osteogenic group. Thus there is a possibility that the dexamethasone is responsible for
the changes that were seen; accordingly, the unconditioned medium control was included.
The samples given 50% CM (Figure 2.3) had a higher ALP activity than that of the
samples given 50% unconditioned medium, which included all of the same supplements
as the CM, but which was not conditioned by the cells in the adipogenic group. This
result suggests that the soluble factors released by the adipogenic cells, not the
dexamethasone or any other supplement in the adipogenic cocktail, were responsible for
the changes seen. The same can be said for the adipogenic group as well. The changes
were the most pronounced in the CM samples and not the unconditioned controls
(Figures 2.4 and 2.5).
Leptin receptors have been detected on marrow stromal cells, and their activation
has been shown to enhance osteoblast differentiation [8]. The general effect of TNF- α
and IL-6 in the body is to increase bone resorption [22]; however reports have indicated
TNF- α can stimulate osteoblast proliferation in conditions where osteoclasts are absent,
i.e. in tissue engineering cultures [23, 24]. This situation is evident in the described
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study, because there are no osteoclasts present in the culture. The implication is that
TNF- α possibly contributed to the changes that were seen in this study. The interactions
between the numerous ligands and receptors in bone cells are quite complex and still not
completely understood. While it is known that the interaction between RANKL and
RANK (TNF family members) is the major determinant of osteoclast formation, TNF- α
and IL-6 have also been shown to promote osteoclast formation by RANKL-independent
processes [39]. In addition, TNF - α accelerates the differentiation of osteoblasts as well
as increases their activity [40].
Past research has focused on the effect that adipocytes have on the differentiation
of osteoblasts. Some of these findings are somewhat contradictory to the findings in this
study. Benayahu and coworkers [25] reported that adipocyte CM decreased the ALP
activity of the cells and Maurin and coworkers [26] reported no significant changes in the
ALP activity . A likely explanation for these disparities is the maturity and source of the
adipocytes from which the CM was derived. Maurin utilized mature human adipocytes
from mammary adipose tissue, while Benayaha studied the 14F1.1 line of mature mouse
stromal adipocytes. The adipocytes used in this study were progressing through the
stages of adipogenesis while the CM was being collected throughout the study.
While past research has focused solely on the effect of adipocyte CM on
osteoblasts, limited, if any research has focused on the effect of osteoblast CM on
adipocytes. The paucity of results is most likely due to the relative lack of interest in
adipose tissue research and adipose tissue engineering until recent years. However,
adipose tissue is very important in many plastic and reconstructive surgeries. The study
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conducted in our laboratory showed that the CM of D1 MSCs undergoing osteogenic
differentiation can increase the triglyceride production of MSCs undergoing adipogenic
differentiation as well as increase the size of the lipid vesicles that are produced. The
triglyceride production was not normalized in this preliminary study, so it cannot be
determined if the increase is due to more cells producing triglycerides or to individual
cells producing more triglycerides. Nevertheless, these findings suggest that the cells are
responding to soluble factors released by the osteogenic cells.
Osteoblasts have been shown to produce and release several growth factors and
cytokines including bone morphogenetic protein-2 (BMP-2) and transforming growth
factor β (TGF-β) [3]; consequently they are likely present in the osteoblast CM. While
BMP-2 is generally associated with an increase in osteogenesis, studies have also shown
that it also has the ability to increase adipogenesis [7, 27].
The appearance of the single large lipid vesicles indicates that the CM is also
causing a more rapid maturation of the adipocytes. The morphology of mature
adipocytes is characterized by a large, centrally located lipid vesicle within the
cytoplasm, while immature adipocytes contain more numerous and smaller lipid vesicles
[2]. The results seen in this study could be very beneficial in adipose tissue engineering,
were it is often necessary to fill relatively large volumes of tissue.
The overall aim of this preliminary study was to determine if cellular changes
occurred in response to the CM. The goal was not to specify all of the changes, the
amount of change, or the most favorable amount of CM, but rather to determine if the
CM would elicit any changes. As changes were noted, further investigation is needed in
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order to tailor cellular systems accordingly. The next step will be to determine changes
in other differentiation markers to better elucidate the effects that CM has on the cells.
ALP is a common marker for osteogenic differentiation and was chosen for this study as
it is an early marker for osteogenic differentiation and would likely be one of the first
markers to display a change. Later events, such as osteocalcin expression, bone
sialoprotein expression, calcium deposition and mineralization should be investigated in
the future. Likewise, other adipogenic differentiation markers such as aP2 and PPAR
should be investigated. The investigation of these other markers will lend further insight
to the changes that the CM causes and will provide stronger evidence of increased
differentiation.
Additionally, the examination of other cells types will provide good insight to the
effects of CM. The cells used in this study were from a murine cell line. Further
investigation of primary cells or other cell lines from different species, including humans,
should be conducted to verify that the effect of CM is not isolated to the D1 cell line.
The objectives of the second study were to evaluate the interactions between
osteogenic differentiation and chondrogenic differentiation through paracrine signaling.
Because osteoblasts and chondrocytes naturally reside in close proximity and have
intimate interactions during bone development and regeneration, paracrine signaling
between the two cell types could likely be directed in vitro to optimize the differentiation
of mesenchymal stem cells. This optimization is necessary in order to reach the goal of
developing clinically viable tissue-engineered devices.
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The results from the DMB assay used to assess the product of sGAG and the
results from the RT-PCR for aggrecan and Sox9 support the claim that the differentiating
osteoblasts release soluble factors that affect the chondrogenic differentiation of MSCs.
The addition of the CM resulted in the 50% CM samples producing statistically
significantly higher amounts of sGAG than the chondrogenic control samples which
consisted of MSCs encapsulated in alginate beads and cultured in chondrogenic
differentiation medium. The results for the sGAG production were the only results that
did not show a significant difference between the 50% CM and the 50% unconditioned
media (UCM) groups. However, there was also not a significant difference between the
sGAG production of chondrogenic control group and the 50% UCM group, which
indicates that the osteogenic supplements did not impact the sGAG production.
Aggrecan is a late marker for chondrogenic differentiation [28]; accordingly, the relative
expression of aggrecan makes a significant jump on Day 21 in all of the samples with the
exception of the 2D control samples which were not expected to be differentiating. Sox9
is considered to be a master transcription factor that is required for chondrocyte
differentiation, and as a result is expressed earlier, followed by a reduction in its
expression [29]. The higher relative expression of aggrecan in the 50% CM samples as
compared to the chondrogenic control further suggests that the osteoblast CM affected
the chondrogenic differentiation. The higher relative expression in the 50% CM samples,
as compared to the 50% unconditioned media control, illustrates that the increase in
expression was not simply due to the components found in the osteogenic differentiation
medium, which are also found in the CM. In addition, the increased Sox9 relative
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expression in the 50% CM samples over the chondrogenic control and the 50% UCM
control adds additional evidence of the influence of osteoblast CM.
Studies have revealed that osteoblasts are capable of producing and releasing
numerous growth factors and cytokines, including bone morphogenetic protein-2 (BMP2) and transforming growth factor β1 (TGF-β1) [30]; consequently, they are likely
present in the osteoblast conditioned medium. TGF- β1 is among the most potent
inducers of chondrogenic differentiation [28]. BMP-2 is also a powerful inducer of
chondrogenic differentiation as it has been shown to stimulate the expression of type-II
collagen, aggrecan and Sox9 by MSCs cultured in alginate [31]. These two inducers are
likely present in the osteoblast CM that is responsible for the increase in chondrogenic
differentiation seen in this study. Other growth factors produced by osteoblasts or found
in bone include IGF-I, IGF-II, platelet-derived growth factor, acidic fibroblast growth
factor and bFGF [32]. It is likely that these factors are also involved in the interaction of
the two cells types and it is probable that there is a complex regulation of cellular
differentiation involving numerous factors. Future studies involving the use of CM in a
bioreactor system will investigate which growth factors and cytokines are present in the
CM.
The results from the ALP assay and the results from the RT-PCR for osteocalcin
and bone sialoprotein suggest that differentiating chondrocytes release soluble factors
that affect the osteogenic differentiation of MSC.

Soluble factors in the CM likely

contributed to the higher ALP activity of the 50% CM samples as compared with the
osteogenic control samples. Bone sialoprotein is an early marker for osteogenic

77

differentiation that first expresses in the pre-osteoblast phase [33]. Osteocalcin is a later
marker for osteogenic differentiation and is typically expressed by cells that are fully
differentiated or close to fully differentiated [33]; accordingly, there is a jump in
osteocalcin expression on Day 21.

Both of these osteogenic markers were increased by

the addition of CM, revealing the effects on chondrocyte CM on osteogenic
differentiation. Furthermore, the significantly higher expression of osteogenic markers
in the 50% CM samples over the 50% unconditioned medium samples suggests that the
changes seen were due to soluble factors in the conditioned medium and not due to the
components in the chondrogenic differentiation medium that would also be found in the
CM.
Chondrocytes have also been shown to produce and release several growth factors
and cytokines. Earlier studies have shown that chondrocytes express multiple BMPs,
including 2, 4, and 7 [9, 34]. Additionally, at least 11 other TGF-β family members are
expressed during the chondrogenic phase [9]. A previous study revealed that the
expression of IGF-1 and FGF-2 also increase during chondrogenesis of MSCs [35].
BMPs, especially BMP-2 and BMP-7, are powerful promoters of osteogenic
differentiation in MSCs [36]. BMP-2 has been shown to induce the expression of Runx2,
a master osteogenic gene. In addition, the exposure of MSCs to FGF-2 before the
induction of differentiation enhances the osteogenic differentiation potential [37].
Transglutaminase enzymes (TGases), which are Ca2+-dependent enzymes, are expressed
in chondrocytes of the growth plate [38, 39] and in articular chondrocytes [10, 40].
Research has indicated that TGase-mediated interactions are involved in differentiation
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and mineralization of the bone [10].

Again, future studies involving the use of CM in a

bioreactor system will investigate the growth factors and cytokines that are present in the
CM.
The effect of the biomaterial on the MSCs differentiation was an additional point
of interest and focus in this study. The chondrogenic differentiation was significantly
amplified in the MSC control samples (cultured in alginate without differentiation
medium) as compared to the 2D control samples (cultured on a well plate without
differentiation medium), while there was no difference between the MSC control and the
chondrogenic control samples (cultured in alginate with differentiation medium). As the
only difference between the MSC control and the 2D control was the biomaterial, this
result suggests that the alginate alone can promote chondrogenic differentiation. The
results from the experimental groups also reveal that alginate supports chondrogenic
differentiation in the presence of differentiation supplements and osteoblast CM.
Chondrocytes cultured in monolayer usually tend to dedifferentiate quickly and stem
cells cultured in monolayer do not differentiate down the chondrogenic pathway well
[41]. Hydrogels, such as alginate, are cross-linked hydrophilic polymer matrices capable
of absorbing large amounts of water. Hydrogels offer an attractive option for cartilage
tissue engineering because their crosslinked network mimics the natural structure of
extracellular matrices in vivo and their high water content facilitates the exchange of
nutrients and gases [42]. In addition, cells encapsulated in alginate tend to have a
spherical morphology, which is the morphology of chondrocytes in vivo, and contributes
to the chondrogenic phenotype in vitro. Several studies have shown that the entrapment
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of isolated chondrocytes and stem cells in hydrogels, such as alginate, agarose, and
collagen helps promote the synthesis of collagen Type II and proteoglycan, both of which
are markers of the chondrogenic phenotype [41-45]. Conversely, the osteogenic
differentiation was similar in the 2D control and the MSC control samples (cultured on
the scaffold without differentiation medium), while the osteogenic control samples
(cultured on the scaffold with differentiation medium) showed a significantly higher level
of differentiation. This result suggests that, while PL/PCL/HAP supports osteogenic
differentiation in the presence of osteogenic supplements, it does not induce it. Blending
degradable polymers, such as poly(L-lactide-co-ε-caprolactone), with hydroxyapatite can
serve as a means to improve mechanical properties as well as increase the
osteoconductive nature of the scaffold [46-48]. Previous studies have revealed that
composites of degradable polymers and hydroxyapatite of this type have the ability to
support osteogenic differentiation [49, 50]. It has also been shown that the addition of
HAP to poly- L-lactide can increase the osteoconductivity of the biomaterial [51].
Hence, one can purposefully design a biphasic scaffold to facilitate very different cellular
behaviors in the two phases – if one employs stem cells in such a system, the potential for
a simple, clinically friendly device becomes quite high.
Other researchers have also shown similar results when administering conditioned
media or performing co-culture between MSCs, osteoblasts, and chondrocytes in various
different forms. Spalazzi and coworkers [15] assessed the interaction of chondrocytes
and osteoblasts that were co-cultured on the same degradable scaffold. They found that
the chondrocytes maintained their chondrogenic morphology longer when cultured with
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osteoblasts, and the osteoblasts produced more matrix when in the presence of the
chondrocytes. Gerstenfeld and coworkers [9] assessed the effect of co-culturing
chondrocytes with MSCs using a 2D transwell system. They found that MSC osteogenic
differentiation was selectively induced by co-culture with chondrocytes. Nurminskaya
and coworkers [10] analyzed the effect that direct contact of chondrocytes and
conditioned medium from chondrocytes have on preosteoblasts in a 2D environment.
The results showed that mineralization is greatly promoted by direct interactions with
chondrocytes and by factors secreted by the chondrocytes. The results from a study by
Jiang and coworkers [52] suggest otherwise. Jiang and coworkers used a co-culture
system where a chondrocyte micromass was cultured with a monolayer of osteoblasts.
They found that GAG deposition was significantly lower in co-culture and that cellmediated mineralization in co-culture was markedly lower compared to that in osteoblast
control samples. In a study by Nakoaka and coworkers [13], the effect of chondrocyte
and osteoblast co-culture, both in direct and indirect, contact was investigated. They
found that the chondrocyte differentiation level in co-culture with osteoblasts was
dependant on the differentiation level of the co-cultured osteoblasts. In addition, the
chondrocytes regulated differentiation of the co-cultured osteoblasts using soluble factors
and direct contact. Hwang and coworkers [12] investigated the effect of chondrocyte CM
on both the chondrogenic and osteogenic differentiation of MSCs, and found that
culturing MSCs with chondrocyte-conditioned medium significantly enhanced the
production Type II collagen. In addition, culturing MSCs with chondrocyte-conditioned
medium supplemented with osteogenic factors induced more accumulation of calcium
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and increased ALP activity. A study by Thompson and coworkers [16] demonstrated that
chondrocytes encapsulated in alginate hydrogels co-culturing with MSCs can induce
osteogenic differentiation of the MSCs. Furthermore, brief exposure was sufficient to
induce early stages of differentiation, but extended exposure was necessary for mature
osteogenic development. Finally, Mo and coworkers [53] investigated the efficacy of coculturing MSCs with articular chondrocytes to promote chondrogenic and osteogenic
differentiation of MSCs. The two cell types were encapsulated in alginate hydrogels in
one of three ratios (2:1, 1:1, 1:2 of MSCs to chondrocytes). The results demonstrated that
newly synthesized cartilaginous extracellular matrix was increased with greater MSC
ratios and longer culture periods. In addition, the osteogenic phenotype was
histologically detected only in the 2:1 ratio group.
This study is one of the first reported studies to examine the interactions between
differentiating chondrocytes and differentiating osteoblasts grown on 3D degradable
materials. The conditions of this study were selected to reflect the conditions that would
likely be used in developing a clinically viable tissue engineered osteochondral construct.
It would be very advantageous to use MSCs for both the cartilage phase and the bone
phase as it only requires one cell retrieval procedure. With that point in mind, the MSCs
were used for both cell populations in this study, which is uniquely different from
previous studies. Cell culture in a 3D environment, as compared with 2D environments,
provides specific advantages to the production of osteochondral constructs. The
biomaterials that were used for this study were chosen because there are the materials that
we are currently evaluating to create an osteochondral construct. In the present study the
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biomaterials were evaluated separately in order to evaluate each phase individually.

In

the future, CM will be administered to a an osteochondral construct that contains both the
cartilage alginate phase and bone PLA/PCL/HAP phase attached to each other and
cultured in a bioreactor system that is designed such that different media can be used for
the cartilage phase and the bone phase.
The overall aim of this preliminary study was to determine whether cellular
changes occurred in response to the CM. The goal was not to specify all of the changes or
the most favorable amount of CM, but rather to determine whether the CM would elicit
any changes. As changes were noted, further investigation is needed in order to tailor
cellular systems accordingly. The use of conditioned medium of differentiating
chondrocytes and osteoblasts has potential as a method of supplying those growth factors
and signaling molecules necessary for differentiation of MSCs to create viable tissue
engineered osteochondral devices. Growth factors can be very expensive, especially in
the quantities used in bioreactors; but conditioned medium may provide a practical, costeffective method of delivering growth factors to the cells. As this was a preliminary
study, murine cells were used to gain a baseline to for future work. Future work will
involve the use of human cells to evaluate the translation of the results in this study on
murine cells into human cells.

Conclusion
In summary, the first study has shown that CM from differentiating adipocytes
can enhance the differentiation of MSCs toward osteoblasts and that CM from
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differentiating osteoblasts can enhance the differentiation of MSCs toward adipocytes.
These effects are likely due to soluble factors that are released by the cells. It is likely
that the results seen in this study are, in large part, due to the release of leptin, TNF- α
and IL-6 by the adipocytes and BMPs by the osteoblasts.
Results from the second study suggest that CM from differentiating chondrocytes
can enhance the differentiation of MSCs toward osteoblasts and that CM from
differentiating osteoblasts can enhance the differentiation of MSCs toward chondrocytes.
These effects are likely due to soluble factors that are released by the cells such as BMPs
and TGases by the chondrocytes, and BMP-2 and TGF-ß1 by the osteoblasts. In
addition, the results suggest that the encapsulation of MSCs in alginate can induce
chondrogenic differentiation, while the PL/PCL/HAP scaffold only allows osteogenic
differentiation, it does not specifically induce differentiation. Results from this work will
assist in optimizing culturing conditions of MSCs and will contribute to the development
of clinically viable tissue-engineered osteochondral devices.
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CHAPTER 3

DESIGN AND CHARACTERIZATION OF A NOVEL BIPHASIC
OSTEOCHONDRAL TISSUE ENGINEERING CONSTRUCT
Introduction
As previously discussed, osteoarthritis is a wide spread problem that affects
approximately 35% of people 65 years and older [1]. Osteochondral tissue engineering
provides a potential option for the treatment of osteoarthritis and osteochondral defects.
While a great deal of research focus has been centered on osteochondral and cartilage
tissue engineering, and considerable progress has been made toward the ultimate goal,
there are still several issues that must be addressed to make osteochondral tissue
engineering a viable option for the treatment of osteoarthritis and osteochondral injuries.
After a review of the literature and, perhaps more importantly, discussions with
orthopedic surgeons, three major limitations were identified as obstacles that must be
overcome.
The first concern with the use of engineered osteochondral tissues that was
identified was the problem of fixation to the surrounding host tissue. The means of
fixation that is used in a mosaicplasty (autologous osteochondral graft) is press fitting [2].
A plug of osteochondral tissue is removed from a non-load bearing area of the joint and
inserted into a hole that has been drilled in the load bearing area that is being repaired.
The diameter of the plug is slightly larger than that of the hole. As a result, a large
amount of friction is created between the plug and the surrounding tissue when the plug
is inserted, thereby securing the graft. The majority of researchers have also used press
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fitting as the means of anchoring a tissue engineered graft into the native tissue when
designing an osteochondral construct [3-7]. However, in order to insert the plug of
tissue, it is typically necessary to apply a large amount of force to the top of the plug.
Approximately ten impacts are needed to insert 15-mm diameter grafts. The average
force that is applied to the top of the plug is 2.4 kN, with an area-averaged compressive
stress of 13.3 MPa [8]. This insertion technique can lead to chondrocyte death, which
may diminish the performance of the graft [8]. After an injurious compression
chondrocytes undergo apoptosis, which continues to increase up to 7 days after injury [9].
The net impact force generated during an osteochondral grafting procedure could
therefore affect the viability of the chondrocytes in the osteochondral graft [10]. This
concern is especially relevant for fragile, immature tissue that may be inserted when
using a tissue engineering approach. In addition to the damage that may be created on
top of the tissue, the frictional forces that are generated along the side of the plug and the
hole can cause tissue damage as well. Histological examinations have shown that bone
resorption takes place following press fitting, both at the recipient site and along the sides
of the graft [11]. Resorption may weaken the stability of the grafts and negatively affect
the integration of the new tissue. Researchers have estimated that as high as 24% of the
grafts are nonviable after insertion due to marginal cell death [12].
The second shortcoming of osteochondral tissue engineering is that the size of the
graft that can be generated is small relative to the size of the defects that they treat.
Autologous osteochondral grafting or mosaicplasty is often referred to as the gold
standard for the treatment of cartilage defects and osteoarthritis. There are numerous
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studies that pertain to the short-term clinical experience of this procedure in human
patients [13-15]. These studies have revealed results to be good to very good, with pain
relief and improved joint functionality in 60–90% of cases. However, osteochondral plug
transplantation technique fails in the therapy of large lesions measuring more than 20–25
mms in diameter [16].
Donor-site availability and other technical considerations have limited the optimal
extent of defect coverage to 1−4 cm2 [17]. Osteochondral tissue engineering targets the
repair of tissue for smaller defects as well as larger defects that cannot be repaired by
osteochondral grafting; however, there are constraints on the size of tissue constructs that
can be created. These constraints are largely due to the non-homogeneous growth of
cells on the traditional „porous block‟ scaffolds, which prevent the formation of a
functional construct from surface to core. This is due to the mass transfer limitations of
the porous structures into which cells are expected to migrate and populate. The
movement of nutrients to cells and removal of waste products from the cells in the pores
relies on molecular diffusion. However, nutrients are depleted before reaching the inner
core of the construct, and waste products accumulate. Cells that do migrate into the core
become necrotic and so the cell population is commonly concentrated at the periphery of
the scaffold [18]. During in vitro culture, larger tissue-engineered constructs can be
supplied with nutrients, for instance in perfusion bioreactors. However, after
implantation of tissue constructs, the supply of oxygen and nutrients to the implant is
often limited by diffusion processes that can only supply cells in 100–200 μm proximity
to a capillary [19]. In order for implanted tissues of greater size to survive, additional
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strategies for enhancing the delivery of nutrients to the cells within the tissue are
necessary.
The third weakness of osteochondral tissue engineering that was identified was
the time required for engineering tissue. The typical paradigm of tissue engineering is to
isolate patient‟s cells from a biopsy, then expand and culture them in vitro. This step is
then followed by an additional surgery to implant the newly developed construct of
tissue. The only current tissue engineering approach for the treatment of cartilage defects
is the Carticel® system marketed by Genzyme. In this procedure, an initial operation is
performed to obtain a biopsy of the patient‟s cartilage. The tissue is then taken to
Genzyme‟s facilities where the chondrocytes are isolated and expanded; this step
typically takes 3-6 weeks. The cells are then sent back to the hospital and a second
procedure is performed where the chondrocytes are injected into the cartilage defect
under a periosteal graft. In discussions with orthopedic surgeons, the surgeons expressed
a need for a tissue engineering treatment that can be applied during a single surgery and
that avoids the disadvantages of multiple procedures, a wait time of up to 6 weeks, and
the risks associated with the transfer of tissue and cells from place to place.
Two different osteochondral constructs were designed with the goals of
addressing the three above current limitations of osteochondral engineering and meeting
orthopedic surgeons needs.
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Design of Novel Osteochondral Constructs
The first construct that was designed is pictured in Figure 3.1a. This design is
referred to as the barbed pin design. The barbed pin design is composed of three distinct
phases. The top phase (A), which corresponds to the cartilage phase, is composed of a
hydrogel containing mesenchymal stem cells (MSCs). The middle phase (B), which
corresponds to the bone phase, is composed of a porous scaffold of a 75:25 poly-Llactide/ polycaprolactone co-polymer containing 10% w/v hydroxyapatite
(PL/PCL/HAP). A barbed pin made of 75:25 poly-L-lactide/ polycaprolactone copolymer (PL/PCL) is attached to the bottom of the construct (C). The barbed pin serves
as a means of anchoring the construct into the surrounding bone. Within the bone
portion, a bundle of capillary channel fibers run through the diameter of the construct
(Figure 3.1b).
The design of the barbed pin osteochondral construct was intended to address the
limitations of current designs. The barbed pin that is attached to the bottom of the
construct is design to serve as a means of anchoring the construct into the surrounding
bone. With the pin creating a good attachment, the construct would not have to be press
fit and the disadvantages of press fitting can be avoided. The pin is composed of PL/PCL
in order to leverage some of the unique properties of polycaprolactone (PCL). PCL is a
semicrystalline, degradable polymer with a stable structure and reduced sensitivity to
environmental conditions. Many in vitro and in vivo biocompatibility studies have been
performed, resulting in U.S. Food and Drug Administration approval of PCL medical
drug delivery devices [6, 20, 21]. The glass transition temperature of 100% PCL is -60o
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C, while the glass transition temperature (Tg) of 75/25 PL/PCL is between 13 o and 20o C.
Due to the fact that the Tg is well below body temperature, the polymer is relatively
flexible at body temperature. The flexible nature of the polymer allows the barbed pin to
conform well to the structure and pores of the bone in which it is placed, creating good
adhesion.

Figure 3.1: Photograph of the barbed pin design (a) illustrating the hydrogel cartilage
phase (A), the PL/PCL/HAP bone phase (B), and the PCL barbed pin (C). A magnified
image of the capillary channel fibers (b) reveals the channels for fluid transportation
created by the unique geometry of the fibers cross section.

The capillary channel fibers that run through the construct are the most unique
aspect of the design and are meant to address the problem of size constraints and allow
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early implantation of the construct. The fibers are uniquely shaped with deep grooves or
channels along the longitudinal axis of the fiber (Figure 3.2). These grooves provide
unique features to the fiber and can serve as ducts to move fluid spontaneously along the
length of the fiber through capillary action. This fluid transport can provide nutrients to
cells within the construct that normally would not receive nutrients through diffusion
alone [22]. In addition, the fibers can facilitate the movement of cells into the interior of
the construct. By adding additional fibers to the design it may be possible to create large
tissue engineered constructs that would not have been viable in the past due to cell death
in the center of the tissue. The addition of capillary, or “wicking”, fibers to the design
may also allow the constructs to be implanted during the original surgery. It is possible
that the constructs could be seeded with MSCs during the first surgery and implanted
during the same procedure. The fibers can provide nutrients to the interior cells and
remove waste products, ultimately reducing the risk of necrosis. The fibers could also
provide a pathway for cytokines, thus better enabling the cells within the construct to
communicate with the native cells of the body and to recruit additional MSCs to the site
and encourage the healing response.

Figure 3.2: Schematic of the cross section of a capillary channel fiber. Fluid is
transported along the numerous groves in the fiber through capillary action.
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The second construct that was designed is pictured in Figure 3.3a. This design is
referred to as the fiber brush design. The top phase (A), corresponding to the cartilage
phase, is composed of a hydrogel containing mesenchymal stem cells (MSCs). The
bottom phase (B), corresponding to the bone phase, is composed of a large bundle of
capillary channel fibers running along the length of the bone phase. A ring of PCL (B)
surrounds the construct at the top of the fiber bundle that is used to anchor the construct
in the surrounding bone. A thin layer of porous 75:25 poly-L-lactide/ polycaprolactone
co-polymer is attached to the top of the bone phase in order to form an attachment point
for the overlying hydrogel.
The fiber brush osteochondral construct was also designed specifically to address
the limitations of current designs that were previously discussed. The ring of PL/PCL
that encircles the top of the fiber bundles is designed to serve as a means of anchoring the
construct into the surrounding bone. With the ring facilitating good attachment, the
construct does not have to be press fit and the disadvantages of press fitting can be
avoided. As with the barbed pin, the ring is composed of PL/PCL. The flexible nature of
the polymer, in combination with the large surface area of the pin, may allow the ring to
conform to the structure and pores of the bone in which it is placed, creating good
adhesion. As with the barbed pin design, the capillary channel fibers are meant to
address the problem of size constraints and allow early implantation of the construct.
The fiber brush design may also make it possible to create large tissue engineered
constructs that would not have been viable in the past due to cell death in the center of the
tissue. Since the entire bone portion of the construct is made of capillary channel fibers,
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large amounts of nutrients, waste products, and cytokines can move through the entire
construct.

Figure 3.3: Photograph (a) of the fiber brush design illustrating the hydrogel cartilage
phase (A), the PCL ring that is used to anchor the construct (B), and the large bundle of
fibers that make up the bone phase (C). A magnified image of the capillary channel
fibers (b) reveals the numerous channels for fluid transportation created by the unique
geometry of the fibers cross section.

Construction of Novel Osteochondral Constructs
The first step of the process to create the barbed pin construct was to make the
barbed pin portion of the construct. A mold in the shape of the pin was placed on a press
platen that was heated to approximately 140 o C. A copolymer of poly-L-lactide and
polycaprolactone, 75%/ 25% respectively (PL/PCL) (Alkermes Controlled Therapeutics
II, Cincinnati, OH), was placed on the two halves of the mold to allow the polymer to
melt and fill in the shape of the mold. The two halves were then placed together and
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compressed by the heated platforms and held for 1 minute. After that time the mold was
quenched in water and allowed to cool for 15 minutes. Finally, the mold halves were
separated and the pin was removed.
The second step of the process was to create the bone portion of the construct
containing the wicking fibers and attach it to the pin. First, a small fiber bundle was
formed. Tecoflex, a thermoplastic polyurethane, or polylactide was extruded through a
specially designed die to create the unique geometry of the wicking fibers. The fiber was
cut into lengths of approximately 7 mm and a group of four fibers were placed together.
To form the bundle, the four fibers were simultaneously stretched and twisted. This
action resulted in a bundle of four fibers that remain bundled together. Next, a
copolymer of 75%/ 25% PL/PCL was added to biotech grade chloroform (Sigma, St.
Louis, MO) at a concentration of 0.15 g/mL and the mixture was left overnight to allow
the polymer to completely dissolve. Hydroxyapatite powder (HAP) (Federal
Laboratories Corp., Alden, NY) was then added to the solution at a concentration of a
10% W/V and mixed with a magnetic stir bar. The pin was inserted 2 mm into the
bottom of a cylindrical Teflon mold with a diameter of approximately 7 mm. A small
bundle of wicking fibers was inserted through the diameter of the mold at the halfway
mark of the height, through holes that were drilled through the walls of the mold. A
volume of 0.5 ml (0.482 g) of glucose, which had been passed through a sieve (Fisher
Scientific Company, Waltham, MA) to extract grain sizes of 250 µm – 425 µm, was
added to the Teflon mold, on top of the pin and fibers. A volume of 0.5 ml of the
PL/PCL/HAP solution was then slowly added on top of the glucose, the mold was
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covered with parafilm, and two small holes were made in the parafilm to avoid rapid
evaporation of the chloroform. The chloroform causes the edges of the pin to solubilize,
so when the chloroform evaporates the pin is attached to the porous scaffold. The mold
was left in a chemical hood for 12 hours to allow the chloroform to evaporate. The
scaffold was then removed from the mold and placed in mesh containers that were
suspended in distilled water that was continually stirred with a magnetic stir bar. The
scaffolds remained in water for 48 hours to leach the glucose from the scaffold; the water
was replenished every 12 hrs. The scaffolds were then removed from the water and
allowed to dry for 24 hours. The final product was a porous cylinder scaffold with a fiber
bundle running the diameter and a barbed pin attached to the bottom.
The final step was to attach the hydrogel layer that was used for the cartilage
layer. Construct were sterilization with ethylene oxide for 24 hours in an AN74i cabinet
sterilizer (Anprolene, Haw River, NC) with a 5 cc ampoule (Anprolene, Haw River, NC),
followed by a degassing time of 48 hours under house vacuum at ambient temperatures.
Then a cell suspension of mesenchymal stem cells was added to the ungelled hydrogel
and mixed to create a uniform distribution of cells. The cell/ hydrogel mixture was
placed in a polystyrene 96 well plate with a diameter of 7 mm and the bone portion of the
construct that was previously constructed was inserted in the mold and extended into the
hydrogel approximately 2 mm. The hydrogel could then penetrate into the porous
scaffold, allowing the two phases to attach. The hydrogel was then gelled either by
placing the construct at 2oC for 10 minutes, in the case of agarose, or by introducing a 0.1
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M solution of CaCl2, in the case of alginate. At this point the bone portion of the
construct could be seeded with mesenchymal stem cells as well.
The first step of the process to create the fiber brush design is to form the large
fiber bundle that makes up the bone portion. Tecoflex fibers were extruded a described
above and cut into lengths of approximately 10 mm and a group of four fibers were
placed together. To form the bundle, the four fibers were simultaneously stretched and
twisted to form a small bundle. Four small bundles were then used to form a larger
bundle using the same stretching and twisting technique. This action resulted in one
large bundle composed of four bundles of four fibers.
The second step was to form the PCL/PLA ring that is used to anchor the
construct into the bone and attach the fiber brush. A small rod of PCL/PLA was formed
using compression molding techniques (as previously described). The rod was then bent
into a circle by heating the ends, adhering them to one another, and allowing the polymer
to solidify. The large fiber bundle was then inserted into the ring and the area where the
bundle and ring contact was heated, allowing the polymers to melt and attach. The third
step was to attach a small porous layer of polymer that was used to attach the hydrogel
layer for the cartilage phase. A layer of porous PLA/PCL was formed using the solvent
casting/ particle leaching method (as previously described). The bottom of the porous
layer was heated and pressed on the ring that surrounds the fiber bundle. The final step
was to attach the hydrogel layer for the cartilage phase. Construct were sterilization with
ethylene oxide for 24 hours in an AN74i cabinet sterilizer (Anprolene, Haw River, NC)
with a 5 cc ampoule (Anprolene, Haw River, NC), followed by a degassing time of 48
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hours under house vacuum at ambient temperatures. Then a cell suspension of
mesenchymal stem cells was added to the hydrogel and mixed to create a uniform
distribution of cells. The cell/ hydrogel mixture was placed in a cylindrical mold with a
diameter of 7 mm and the bone portion of the construct was inserted in the mold,
extending into the hydrogel approximately 2 mm. The hydrogel penetrated into the
porous layer, allowing good attachment between the two phases. The hydrogel was then
gelled either by placing the construct at 2oC for 10 minutes, in the case of agarose, or
introducing a 0.1 M solution of CaCl2, in the case of alginate. At this point the bone
portion of the construct could be seeded with mesenchymal stem cells as well.

Characterization of the Newly Designed Osteochondral Constructs and Evaluation
of the Stability of Anchoring Systems

Methods and Materials
Differential Scanning Calorimetry
The melting point and glass transition temperature of the PL/PCL were assessed
using differential scanning calorimetry (DSC). A mass of 5-7 mg of each sample was
placed in the pan bottom, the lid was added, and a crimper was used to seal the pan. The
three different samples were 1) the as received PL/PCL, 2) the PL/PCL that was formed
into a barbed pin using compression molding, and 3) the porous scaffold that was
produced using solvent evaporation/ particle leaching. The DSC experiments were
conducted using a Perkin Elmer DSC 7 differential scanning calorimeter in a nitrogen
atmosphere and the data was collected and analyzed with a Perkin Elmer Thermal

103

Analysis Controller 7/DX. The first scans were performed from -50 to 200 oC at a
heating rate of 10 oC/min and the temperature was held at 200 oC for 3 min. The heat
cycle was followed by quick quenching back to -50 oC and a second heat cycle from -50
to 200 oC at a heating rate of 10 oC/min.

Gel Permeation Chromatography
The molecular weight and molecular weight distribution were measured by gel
permeation chromatography using a Waters HPLC system equipped with a Model 610
HPLC pump, a Model 486 UV/Vis detector and a Model U6K injector (Waters Corp.,
Milford, MA). The four different samples were 1) the as received PL/PCL, 2) the
PL/PCL that was formed into a barbed pin using compression molding, 3) the barbed pin
that was formed using compression molding and exposed to water during the glucose
leaching process, and 4) the porous scaffold that was produced using solvent evaporation/
particle leaching. The samples were dissolved in HPLC-grade chloroform (Sigma, St.
Louis, MO) at a concentration of 3 mg/ml, allowing at least 4 h to dissolve. The solutions
were then thoroughly mixed and filtered through 0.2 μm Acrodisc syringe filters (Pall
Corp., East Hills, NY). The solutions were eluted through PLgel 5μm MIXED-C
columns (Polymer Laboratories, Amherst, MA) at a flow-rate was 1.0 ml/min at a
temperature of 30 ◦C. The weight average molecular weight (Mw) and number average
molecular weight (Mn) of the polymer were calculated using standard polystyrene
samples.
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Pull-Out Strength
Porcine hind legs were obtained from the Snow Creek slaughter house.
Each knee was separated to expose the femoral condyles, the distal portion of the femur
was removed from the rest of the bone, and excess soft tissue was removed. Recipient
sites of 10-mm depth and diameter of 7 mm were drilled on the articulating surface of the
femoral condyles. The site was then irrigated to prepare for the insertion of the
constructs. The condyles were then placed in an Instron Model 5944. To avoid external
compression to the construct, the bottom of the drill hole was placed well above the
clamp fixing the specimen in the testing machine. The graft was then inserted into the
site. To prepare for the pull-out test, a small wire was cast into the barbed pin and the top
of the wire was clamped in the upper crosshead of the Instron (Figure 3.4). A tensile load
was applied at a rate of 10 mm/minute and the pull-out strength was determined. Five
samples were tested.

Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=5). Unpaired
t tests were used to make comparisons between the barbed pin constructs and values
reported in literature for press fit grafts with a significance level of p < 0.05.
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Figure 3.4: Photograph of the setup to test the pull-out strength of the constructs.

Results
Differential Scanning Calorimetry
The DSC plots of all polymer conditions are shown in Figure 3.4. The asreceived PL/PCL did not show a peak corresponding to a melting point (T m) in the
original scan or after being quenched. The PL/PCL formed into a pin through
compression molding showed a Tm at 117 oC, but did not show a melting peak after being
quenched. Similarly the PL/PCL that was formed into a porous scaffold via a solvent
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evaporation/ porogen leaching method showed a Tm of 123oC, but did not show a melting
peak after being quenched. All polymers showed relatively low glass transition
temperatures (Tg), well below body temperature. The results from the DSC are shown in
Table 3.1.

Figure 3.5: Differential scanning calorimetry plots for the as-received pellets (A), asreceived quenched pellets (B), compression molded pin (C), compression molded pin
quenched (D), scaffold (E), scaffold quenched (F) conditions.

Table 3.1: Results from the differential scanning calorimetry
DSC
Sample
Tg (C ) Tm (C )
As-received
10.8
As-received quenched
12.9
Pin
0
117
Pin quenched
14.3
Scaffold
12.8
123
Scaffold quenched
17
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Gel Permeation Chromatography
The GPC plots of all polymer conditions are shown in Figure 3.5. The asreceived pellets had a number-average molecular weight (Mn) and a weight-average
molecular weight (Mw) that was over twice as large as the other values. The polymers
that were processed with compression molding (Pin) and solvent evaporation/ particle
leaching (Scaffold) showed similar M n and Mw values. The molecular weight of the pin
that was placed in water with the scaffold while the porogen was removed was lower than
that of the pin that was not exposed to water. The results from the GPC are shown in
Table 3.2.

Figure 3.6: Gel permeation chromatography plots for the as-received pellets,
compression molded pin, scaffold, and compression molded pin exposed to water.
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Table 3.2: Results of the gel permeation chromatography
Sample
As-received
Pin
Pin in water
Scaffold

GPC
Mn (Daltons) Mw (Daltons)
100074
183032
45965
86875
37613
75464
45473
87879

PDI
1.829
1.89
2.006
1.932

Pull-Out Test
An example of the typical load-extension curve from the pull-out tests is shown in
Figure 3.6. The average pull-out strength of the barbed pin was 37.3 ± 7.2 N (Table 3.3).
This value is not statistically different (p<0.05) than the average pull out strength of
osteochondral grafts with diameters of 8mm, i.e. 41 ± 21 N as reported by Duchow and
coworkers [22].

Figure 3.7: Typical load-extension profile of the barbed pin pull-out tests.

109

Table 3.3: Pull-out strength
Sample
Pull-Out Strength (N)
Barbed Pin
37.3 ± 7.2
8 mm osteochondral press fit graft [22]
41 ± 21
Discussion
Two osteochondral tissue engineering constructs were designed; both designs
aimed at addressing limitations of current osteochondral tissue engineering approaches.
The first weakness that was addressed with the newly developed designs was the need for
a method of anchoring the construct into the defect area while avoiding the detrimental
effects of press fitting. To meet this need, a barbed pin constructed out of a PL/PCL copolymer was incorporated into the first design to anchor the construct. The second
design included a PL/PCL ring that used the large surface area of the ring and the low
glass transition temperature of the polymer to anchor the construct in the defect area.
Another weakness that was addressed was the need for larger tissues to be developed in
order to repair large areas of damaged tissue. Both designs integrated capillary channel
fibers into the design; the intent of the incorporation of fibers is to allow better cell
infiltration into the constructs as well as provide nutrient transport and waste removal via
capillary action.
DSC was used to determine the thermal transitions of the PL/PCL used in the
constructs before and after different processing methods. The first thermal transition that
was observed for the polymer was the Tg. The Tg is the temperature where the polymer
goes from a hard, brittle state to a flexible state. When the polymer enters the rubbery
state, it tends to become softer and more flexible. This transition is due to the additional
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heat allowing the molecules to move more freely. The Tg is marked on the DSC profile
as a shift in the endothermic direction (down), representing an increase in the heat
capacity of the polymer, since polymers have a higher heat capacity above the glass
transition temperature than below. This transition is considered second order because
there is only a change in heat capacity, but there is no latent heat involved with the glass
transition. The results of the DSC showed that the T g of the PL/PCL was well below
body temperature in all forms that were tested. Most importantly the T g of the barbed pin
was 0 oC. This is important because the flexible nature of a polymer that is above its T g
will aid in the anchoring of the construct by conforming well to the defect in which it will
be placed. The melting transition is called a first order transition. This means that when
the polymer reaches the Tm, the polymer's temperature won't rise until all the crystals
have melted. Therefore additional heat will have to be introduced into the polymer in
order to melt the crystals and keep the temperature rising at the same rate as that of the
reference pan. This extra heat flow during melting is marked by a down facing peak on
the DSC plot.
GPC was used to determine the molecular weight distribution of the PL/PCL
before and after the processing techniques. The results indicated that the solvent
evaporation/ porogen leaching used to produce the scaffolds and the compression
molding used to produce the barbed pins had a similar effect on the molecular weight of
the PL/PCL. Both the MN and MW of the barbed pin and scaffold were reduced, as
compared to the as received polymer, by a similar amount. This is likely advantageous in
that both phases may have similar degradation properties. The results also indicated that
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the molecular weight of the barbed pin was reduced slightly more after being exposed to
water during the porogen leaching step, as would happen if the pin were attached to the
bottom of the scaffold.
Finally, the effectiveness of the barbed pin in anchoring the osteochondral
constructs in a defect area was tested by conducting a pull-out test. After insertion,
secure fixation of the construct is necessary to keep it in place and to maintain the proper
level of congruity until bone ingrowth and integration is completed. The current
treatment of osteochondral grafting, as well as many osteochondral tissue engineering
research options [3-7] use press fitting to secure the grafts in place. However, as
previously discussed, several problems arise from this method. The results from this
study indicated that the stability generated by the barbed pin was similar to that of press
fit osteochondral grafts of a similar size. This indicates that the barbed pin has the
potential to serve as an alternative anchoring method to press fitting.
In this experiment a porcine joint was used. The size of the joints as well as the
thickness of the cartilage are both closer to humans as compared to other animal models
such as sheep and goat [23]. In addition, mechanical tests have found no substantial
difference between the modulus of porcine and human bone [22-26]. Additionally,
porcine joints were available in a sufficient quality and quantity. Pull-out testing was
used in this study as it is commonly used to test the stability of osteochondral grafts [22,
25]. This test provides a good method of comparing the stability of osteochondral grafts
and constructs. It is important to note that the main forces that will act on an
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osteochondral implant in vivo are mainly axial compression and shear. However pull-out
testing will likely correlate to graft behavior under compression and shear forces.
The design process and basic characterization of the newly designed constructs
were discussed in this chapter. Further work is needed to further evaluate and optimize
the design. The individual components of the constructs will be evaluated and their
effects will be determined, and the optimal configurations of the construct will be
determined. Finally, studies will be conducted to test the ability of the design to generate
osteochondral tissue in a bioreactor culture.

Conclusion
Novel osteochondral tissue engineering constructs were developed, based on the
current short comings in traditional tissue engineering constructs. DSC revealed that the
Tg of the anchoring devices was below body temperature, which is beneficial to the
design. In, addition the resulting molecular weight of the polymer was similar in both
phases of the construct. Finally, the pull-out strength of the construct was similar to that
of press fit osteochondral grafts of a similar size.
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CHAPTER 4
EVALUATION AND OPTIMIZATION OF THE NEWLY DESIGNED
OSTEOCHONDRAL CONSTRUCTS
Introduction
After the design and characterization of the newly designed osteochondral
constructs it was necessary to test several individual features in order to determine if the
inclusion of specific features was in fact beneficial to the engineering of osteochondral
tissue and try to optimize the design. The first characteristic that was tested was the
inclusion of hydroxyapatite (HAP) in the polymer scaffold for the bone phase of the
barbed pin design. The hypothesis that the inclusion of HAP would enhance cell
attachment and osteogenic differentiation of MSCs was tested. The second feature that
was tested was the inclusion of the wicking fibers in the bone phase. The hypothesis that
the inclusion of the fibers would increase cell viability, especially in the interior of the
scaffold, was tested. The final characteristic that was tested was hydrogel selection for
the cartilage phase of the constructs. A comparison of the chondrogenic differentiation of
MSCs in alginate and agarose was performed.
The Effect of Hydroxyapatite on MSC Attachment and Osteogenic Differentiation
in a Bone phase Polymer Scaffold

Methods and Materials
Scaffold Construction
The study consisted of two groups: scaffolds made of PL/PCL without any HAP
and scaffolds made of PL/PCL/HAP. Two different types of porous scaffolds were
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produced using a solvent evaporation/porogen leaching method that is described on pages
57-58 in Chapter 2. The final products were porous discs with approximately 22 mm
diameter and 3 mm thickness. All scaffolds were sterilization with ethylene oxide for 24
hours in an AN74i cabinet sterilizer (Anprolene, Haw River, NC) with a 5 cc ampoule
(Anprolene, Haw River, NC), followed by a degassing time of 48 hours under house
vacuum at ambient temperatures. Table 4.1 outlines the experimental setup of the study.

Table 4.1: Outline of experimental setup displaying the number of samples used at each
end point.
ALP
Live/Dead
Histology
PL/PCL

x3

x3

x3

PL/PCL/HAP

x3

x3

x3

Cell Seeding and Culture
The PL/PCL and PL/PCL/HAP scaffolds were placed in ultra low attachment 12
well plates (Corning, Corning, NY) to prevent cell attachment to the plate and promote
cell attachment to the scaffold. Both scaffold types were soaked in base medium
consisting of Dulbecco‟s Modified Eagle‟s Medium (DMEM) (Invitrogen, Gibco,
Carlsbad, CA) supplemented with 10% FBS (Hyclone, Logan, UT), 1%
antibiotic/antimyocotic (Invitrogen, Gibco, Carlsbad, CA) and 0.2% fungizone
(Invitrogen, Gibco, Carlsbad, CA) for 24 hrs to allow protein absorption on the surface of
the scaffolds. D1 murine mesenchymal stem cells (ATCC, Manassas, VA) were grown
in a standard cell culture flask (Corning, Corning, NY). After three days the cells neared
confluence in the flask.

The D1 cells were suspended at a concentration of 7x10 5

118

cells/ml and 3.5x105 cells (0.5 mL of the cell suspension) were seeded onto each scaffold.
The scaffolds were cultured overnight at 37o C and 5% CO2 in base medium. After
overnight culture in the base medium, the medium was removed and replaced with
osteogenic differentiation medium consisting of DMEM, 10% FBS, 1%
antibiotic/antimycotic, 0.2% fungizone, 50 µg/ml L-ascorbic acid 2-phosphate (Sigma,
St. Louis, MO), 3 mM β-glycerophosphate (Sigma, St. Louis, MO) and 10 nM
dexamethasone (Sigma, St. Louis, MO). Medium was changed every two days
thereafter. End points for the study were Days 7, 14, and 21.

Cell Viability
Cell viability and attachment was assessed using a LIVE/DEAD
Viability/Cytotoxicity kit (Molecular Probes; Eugene, OR). The cells were fluorescently
labeled using calcein AM and ethidium homodimer dyes in the kit, according to the
manufacturer‟s protocol. Live cells retain a dye that produces bright green fluorescence,
with excitation and emission wave lengths of 495 nm and 515 nm, respectively. Dead
cells fluoresce a bright red, with excitation and emission wave lengths of 495 and 635,
respectively. Observations were made an inverted microscope and imaging software.

Histological Evaluation
Samples used for histological evaluation were first fixed in 10% neutral buffered
formalin for at least 24 hours. An acellular control of each scaffold type was processed
along with the cellular samples. Samples were then embedded in glycol methacrylate
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(GMA, Technovit 7100), allowed to harden, and stored in a desiccator until the time of
sectioning. Sections of 6 μm thickness were taken across the cross section of the
scaffold, offering a view of the entire thickness of the scaffold. Hematoxylin and eosin
(H&E) and Von Kossa staining were conducted. Table 4.2 outlines the protocol used for
each staining procedure.

Table 4.2: Von Kossa and H&E staining procedures for GMA embedded scaffolds
Von Kossa Staining
100% ethanol
2 min
95% ethanol
2 min
Distilled water
2 min
2% silver nitrate
30 min in UV light
Distilled water
until clear

100% ethanol
95% ethanol
Distilled water
Hematoxylin
Distilled water

Hematoxylin
Distilled water

7 min
until clear

0.25% ammonium
hydroxide
Distilled water

0.25% ammonium
hydroxide
Distilled water
0.3% eosin Y
Distilled water
95% ethanol
100% ethanol

10 sec
until clear
5 min
until clear
15 dips 2 changes
15 dips 2 changes

Xylene
Xylene
Mount with
cytoseal

0.3% eosin Y
Distilled water
95% ethanol
100% ethanol
Xylene
Xylene
Mount with
cytoseal

10 dips
1 min

H&E
2 min
2 min
2 min
7 min
until clear
10 sec
until clear
5 min
until clear
15 dips 2 changes
15 dips 2 changes
10 dips
1 min

Alkaline Phosphatase
Three replicates of each scaffold were used to assess the alkaline phosphatase
(ALP) activity of the cells. The samples were washed three times with PBS, 2 ml of
deionized water were added to each sample, and three freeze-thaw cycles were performed
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to lyse the cell membranes. A phosphatase substrate solution was created by mixing 5ml
of deionized water with every 20 mg of phosphatase substrate (Sigma, St. Louis, MO).
The phosphatase substrate solution was mixed with an equal amount of alkaline buffer
solution (Sigma, St. Louis, MO) to create the working reagent. A volume of 500 µl of
the working reagent was placed in 24-well plates, using the same number of wells as
samples; the plates were then incubated for 15 minutes at 37 o C. Subsequently, 100 µl of
the sample lysate was added to each sample well and incubated for 30 minutes at 37 o C,
after which 1.5 ml of 0.25N NaOH was added to each well to stop the reaction. Aliquots
in the amount of 200 µl were then moved in triplicate to a 96-well plate, and the
absorbance was read at 410 nm using a MRX Micoplate Reader (Dynex Technologies,
Germany). A standard curve was generated using p-nitrophenol (Sigma, St. Louis, MO)
standard solution diluted with 0.02 N NaOH. The ALP activity was determined using the
standard curve and measured in sigma units, which are defined as 1 μmol of pnitrophenol converted per hour. The ALP assay is based on the ALP-catalyzed
hydrolysis of p-nitrophenol phosphate in an alkaline cell lysate to generate a yellow
colored p-nitrophenol product.
The protein content in each sample was determined by following the standard
protocol for the BCA Total Protein Kit (Pierce, Rockford, IL). The results from the ALP
assay were normalized by the protein content determined by the BCA total protein assay.
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Mechanical Testing
Compressive mechanical testing was also conducted on PL/PCL/HAP scaffolds
and PL/PCL scaffold to determine the effect that the addition of HAP has on the
mechanical properties. The scaffolds had an approximate diameter of 20 mm and a
thickness of approximately 10 mm. The compressive modulus was obtained by
averaging values from 3 samples of each type of scaffold. Tests were run at room
temperature on an Instron Model 5944 mechanical testing system, equipped with a 50 N
load cell and using a crosshead speed of 1 mm/ min.

Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=3). Unpaired
t tests were used to make comparisons with a significance level of p < 0.05.

Results
Cell Viability
The cells formed a dense layer on the entire surface of the PL/PCL/HAP scaffold
by Day 7. The number of cells attached to the PL/PCL scaffold on Day 7 was lower as
compared to the HAP scaffold (Figure 4.1). At Days 14 and 21 there was no difference
between the levels of viable cells attached to each scaffold type. Both scaffolds
possessed a thick confluent layer of cells by the end of the study. There was a minimal
number of dead cells observed on both scaffold types on at all end points (data not
shown).
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Figure 4.1: Fluorescent microscope images following LIVE/DEAD viability/toxicity assay on Day
7. Live cells (green) are covering the entire surface of the PL/PCL/HAP (B) scaffold. The cell
layer is less confluent on the PL/PCL (A) scaffold. Dead cells were observed infrequently on
both scaffolds. Original total magnification was 100X.

Histological Evaluation
The results of the Von Kossa staining for mineralization are shown in Figure 4.2.
Calcium stains brown-black, cell nuclei stain red, and cell cytoplasm stain pink. The
images show a continuous layer of cells on the scaffold containing HAP. There was a
noticeably smaller number of cells attached to the PL/PCL scaffold as compared to the
PL/PCL/HAP scaffold. The images also show that the HAP is well dispersed throughout
the entire scaffold as evidenced by the brown-black staining seen throughout the
PL/PCL/HAP scaffold. There was minimal mineralization seen around the cells on both
scaffolds.
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Figure 4.2: Images of Von Kossa stained cell seeded PL/PCL/HAP scaffold (A), the
PL/PCL/HAP acellular control (B), the cell seeded PL/PCL scaffold (C) and the PL/PCL
acellular control (D) on Day 21. The top of each scaffold is oriented towards the top left corner
of the image. The images show significantly more cells attached to the PL/PCL/HAP scaffold
than the scaffold without HAP. Original total magnification was 100X.

Alkaline Phosphatase
There was no statistical difference (p < 0.05) in the ALP activity between the two
scaffold types on both Days 7 and 14. By Day 21 the ALP activity from the scaffold
containing 10% HAP was significantly higher that the ALP activity of the scaffold
without HAP (Figure 4.3). The ALP activity steadily increased through the course of the
study for the PL/PCL/HAP scaffolds. The ALP activity increased between Days 7 and
14, but leveled off on Day 21 for the PL/PCL scaffold.
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Figure 4.3: Results of the alkaline phosphatase assay normalized by total protein. On Day 21 the
scaffolds containing 10% HAP had higher ALP activity than the scaffolds without HAP.

Error bars represent the SD (n=3). Asterisks (*) signify statistically significant
differences (p< 0.05).

Mechanical Testing
The stress-strain curves of the compression tests are shown in Figure 4.4. The
PL/PCL/HAP scaffolds had a significantly higher compressive modulus as compared to
the PL/PCL. The compressive modulus of the scaffolds without HAP was 370 ± 63.
When 10% HAP was added to the scaffolds the compressive modulus increased to 559 ±
25 (Table 4.3).

Table 4.3: Compressive Modulus of scaffolds
Modulus
Sample
(kPa)
PL/PCL
370 ± 63
PL/PCL/HAP
559 ± 25
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Figure 4.4: Stress strain-curves from the compression testing on the scaffolds. The upper
three curves are from the PL/PCL/HAP scaffolds and the bottom curves are from the
PL/PCL scaffolds.

The Effect of Capillary Channel Fibers in the Bone Phase
Methods and Materials
Scaffold Construction
Bundles of wicking fibers made of Tecoflex, a medical grade thermoplastic
polyurethane elastomer were produced. Tecoflex beads (Lurizol Corp., Wickliffe, OH)
were loaded into the hopper of a Gottfert MP-A melt indexer (GOETTFERT Inc., Rock
Hill, SC) heated to 140o C. The indexer was maintained at 140o C for 10 minutes, the
temperature was increased to 165o C, and maintained at temperature for another 10
minutes. The polymer was then extruded through a custom machined spinneret with the
shape of the capillary channel fibers. After cooling, the fibers were placed in bundles of
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four fibers. The bundles were then simultaneously stretched and twisted in order to
create bundles.
Porous scaffolds, with or without wicking fibers, were produced using a solvent
evaporation/porogen leaching method. A copolymer of poly-L-lactide and
polycaprolactone, 75%/ 25% respectively (PL/PCL) (Alkermes Controlled Therapeutics
II, Cincinnati, OH), was added to biotech grade chloroform at a concentration of 0.15
g/mL. The mixture was left overnight to allow the polymer to completely dissolve.
Hydroxyapatite powder (HAP) (Federal Laboratories Corp., Alden, NY) was then added
to the solution at a concentration of a 10% W/V and mixed with a magnetic stir bar. A
custom designed Teflon mold was used to create the scaffolds. The mold is a cylinder
with an inside diameter of approximately 7 mm. Approximately 3.5 mm. from the bottom
of the mold a small hole was drilled through the diameter of the mold and a bundle of
fibers was inserted through the diameter of the mold. A mass of 0.5 g of glucose, which
had been passed through a sieve to extract grain sizes of 250 µm – 425 µm, was added to
the mold. A volume of 0.5 ml of the PL/PCL/HAP solution was slowly added on top of
the glucose, the mold was covered with parafilm, and two small holes were made in the
parafilm to avoid rapid evaporation of the chloroform. The beakers were left in a
chemical hood for 12 hours to allow the chloroform to evaporate. The scaffolds were
then removed from the mold and placed in mesh containers that were suspended in
distilled water and continually stirred with a magnetic stir bar. The scaffolds remained in
water for 48 hours, and the water was replenished every 12 hrs. The scaffolds were then
removed from the water and allowed to dry for 24 hours. The final product was a porous
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cylinder scaffold with an approximate 7 mm diameter and 7mm height. The fiber bundle
was surrounded by the polymer and extended through the diameter of the scaffold.
Scaffolds were also made using the same method without the inclusion of the wicking
fiber bundle. The scaffolds were stored in a desiccator until all of the scaffolds were
produced. Scaffolds were sterilization with ethylene oxide for 24 hours in an AN74i
cabinet sterilizer (Anprolene, Haw River, NC) with a 5 cc ampoule (Anprolene, Haw
River, NC), followed by a degassing time of 48 hours under house vacuum at ambient
temperatures. Four replicates of each scaffold type were produced for alamarBlue assays
and alkaline phosphatase assays, and three replicates were produced for LIVE/DEAD
staining. Finally, all of the scaffolds were sterilized using ethylene oxide gas, then
degassed for 48 hours under house vacuum.

Cell Seeding and Culture
Scaffolds with and without fibers were placed in ultra low attachment 12 well
plates (Corning, Corning, NY) to prevent cell attachment to the plate and promote cell
attachment to the scaffold. Both scaffold types were soaked in base medium consisting
of Dulbecco‟s Modified Eagle‟s Medium (DMEM) (Invitrogen, Gibco, Carlsbad, CA)
supplemented with 10% FBS(Hyclone, Logan, UT), 1% antibiotic/antimyocotic
(Invitrogen, Gibco, Carlsbad, CA), and 0.2% fungizone (Invitrogen, Gibco, Carlsbad,
CA) for 24 hrs to allow protein absorption on the surface of the scaffolds. D1 murine
mesenchymal stem cells (ATCC, Manassas, VA) were grown in a standard cell culture
flask (Corning, Corning, NY). After three days the cells neared confluence in the flask.
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The D1 cells were suspended at a concentration of 1x10 6 cells/ml and 5x105 cells (0.5 mL
of the cell suspension) were seeded onto each scaffold. The scaffolds were cultured
overnight at 37o C and 5% CO2 in base medium. After overnight culture in the base
medium, the medium was removed and replaced with osteogenic differentiation medium
consisting of DMEM, 10% FBS, 1% antibiotic/antimycotic, 0.2% fungizone, 50 µg/ml Lascorbic acid 2-phosphate (Sigma, St. Louis, MO), 3 mM β-glycerophosphate (Sigma, St.
Louis, MO) and 10 nM dexamethasone (Sigma, St. Louis, MO). Medium was changed
every two days thereafter. The end point for the study was Day 14.

Metabolic Activity
The metabolic activity was examined using an alamarBlueTM metabolic assay
(Invitrogen, Biosource, Carlsbad, CA). Directly after a medium change, 200 µl of
alamarBlueTM was added to each well and the samples were incubated at 37 o C for four
hours. Aliquots of 175 µl were taken using a micro-pipette in triplicate and directly
placed in a 96-well plate (Corning, Corning, NY) and the absorbance was read at 570 nm
and 630 nm using a MRX Micoplate Reader (Dynex Technologies, Germany). The
percent reduction of alamarBlue was then calculated by using Equation 3.3.1. Following
completion of the alamarBlueTM assay, the samples were rinsed with PBS, one milliliter
of deionized water was added to the osteogenic samples, and all the well plates were
stored in a -80o freezer until the end of the study.
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Equation 3.1
Where: A1=absorbance of test well at 570nm
A2=absorbance of test well at 630nm
N1=absorbance of negative control (media plus alamarBlue but no cells) at 570nm
N2= absorbance of negative control (media plus alamarBlue but no cells) at 630nm

Alkaline Phosphatase
Three replicates of each scaffold were used to assess the alkaline phosphatase
(ALP) activity of the cells. The samples were washed three times with PBS, 2 ml of
deionized water was added to each sample, and three freeze-thaw cycles were performed
to lyse the cell membranes. A phosphatase substrate solution was created by mixing 5ml
of deionized water with every 20 mg of phosphatase substrate (Sigma, St. Louis, MO).
The phosphatase substrate solution was mixed with an equal amount of alkaline buffer
solution (Sigma, St. Louis, MO) to create the working reagent. A volume of 500 µl of
the working reagent was placed in 24-well plates, using the same number of wells as
samples; the plates were then incubated for 15 minutes at 37 o C. Subsequently, 100 µl of
the sample lysate was added to each sample well and incubated for 30 minutes at 37 o C,
after which 1.5 ml of 0.25N NaOH was added to each well to stop the reaction. Aliquots
in the amount of 200 µl were then moved in triplicate to a 96-well plate, and the
absorbance was read at 410 nm using a MRX Micoplate Reader (Dynex Technologies,
Germany). A standard curve was generated using p-nitrophenol (Sigma, St. Louis, MO)
standard solution diluted with 0.02 N NaOH. The ALP activity was determined using the
standard curve and measured in sigma units, where each unit is defined as 1μmol of p-
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nitrophenol converted per hour. The ALP assay is based on the ALP-catalyzed
hydrolysis of p-nitrophenol phosphate in an alkaline cell lysate to generate a yellow
colored p-nitrophenol product.
The protein content in each sample was determined by following the standard
protocol for the BCA Total Protein Kit (Pierce, Rockford, IL). The results from the ALP
assay were normalized by the protein content determined by the BCA total protein assay.

Cell Viability
Cell viability and attachment were assessed using a LIVE/DEAD
Viability/Cytotoxicity kit (Molecular Probes; Eugene, OR). The cells were fluorescently
labeled using calcein AM and ethidium homodimer dyes in the kit according to the
manufacturer‟s protocol. Observations were made using an inverted microscope and
imaging software.

Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=4). Unpaired
t tests were used to make comparisons with a significance level of p < 0.05.
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Results
Metabolic Activity
The metabolic activity of the cells on the scaffold containing the wicking fiber
bundle was slightly higher than that of cells on the scaffold without the fibers (Figure
4.5). However, this difference was not statistically significant.

Figure 4.5: The results of the alamarBlue assay are presented as the percent reduction of
alamarBlue. Error bars represent the SD (n=4).

Alkaline Phosphatase
The protein production of the cells on the scaffold containing the wicking fiber
bundle was higher than that of cells on the scaffold without the fibers (Figure 4.6A).
While, the difference was not large, the different was statistically significant (p=0.0437).
The normalized ALP activity was slightly higher for scaffolds with a wicking fiber
bundle (Figure 4.6B). However, the difference was not statistically significant.
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Figure 4.6: Graphs represent the total protein production of cells on each scaffold type (A) and
the ALP activity, normalized by the total protein content. Error bars represent the SD (n=4).
Asterisks (*) signify statistically significant differences (p< 0.05).

Cell Viability
LIVE/DEAD staining revealed good cell attachment and viability on both scaffold
types. Both scaffold types contained a dense layer of viable cells throughout the entirety
of the scaffolds, with minimal numbers of dead cells. Figure 4.7 shows the interface
between the porous structure of the scaffold and the fibers. The cells can be seen
growing directly next to the fibers, while there is minimal cell attachment to the fibers
themselves.

133

Figure 4.7: Fluorescent microscopy of LIVE/DEAD viability/toxicity assay illustrating
the interface between porous scaffold and a wicking fiber. The fiber is seen in the upper
left portion of the image and the scaffold is in the lower right. The white arrow indicates
the interface between the two.

Comparison of Chondrogenic Differentiation of Mesenchymal Stem Cells in
Alginate and Agarose to Assess Potential use in Cartilage Phase
Method and Materials
Cell Encapsulation and Culture
Alginate and agarose powders were sterilized in an autoclave at 134 oC and 30 psi
prior to cell encapsulation. A mass of 0.75 g of alginate or agarose was mixed separately
with 30 ml sterile distilled water. D1 murine mesenchymal stem cells were suspended in
two 7.5 ml aliquots of medium and added to the alginate and agarose. This process
resulted in a concentration of 1x106 cells/ml in 2% alginate or 2% agarose. A volume of
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0.5 ml of each hydrogel was placed in 12 well plates. The agarose was allowed to gel at
2o C for 10 minutes. The alginate was gelled by adding 0.1 M CaCl2 on top of the
alginate and letting set for 15 minutes. This step resulted in the encapsulation of cells in
small discs of alginate and agarose with a thickness of approximately 2 mm. Table 4.4
outlines the experimental setup of the study. The group termed “DMEM” was cultured in
medium consisting of Dulbecco‟s Modified Eagle‟s Medium (DMEM) (Invitrogen,
Gibco, Carlsbad, CA) supplemented with 10% FBS (Hyclone, Logan, UT), 1%
antibiotic/antimyocotic (Invitrogen, Gibco, Carlsbad, CA) and 0.2% fungizone
(Invitrogen, Gibco, Carlsbad, CA). The group termed “TGF” was cultured in
chondrogenic differentiation medium consisting of DMEM, 1% antibiotic/antimycotic,
0.2% fungizone, 50 ug/ml L-ascorbic acid 2-phosphate, 40 ug/ml L-proline (Sigma, St.
Louis, MO), 10 ul/ul ITS+1 liquid media supplement (Sigma, St. Louis, MO), and 10
ng/ml TGF-β1 (Sigma, St. Louis, MO). The last group, termed “TGF + DEX”, was
cultured in chondrogenic differentiation medium consisting of the same medium as the
“TGF” group with the addition of 10 nM dexamethasone. Both the alginate samples and
agarose samples were cultured in the three different media. A 2D control was also
included in the study as a comparison. The 2D control contained MSCs grown on the
surface of a treated well plate and cultured in base DMEM medium. Media was changed
every three days. End points for the study were Days 7, 14, 21.
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Table 4.4: Outline of the experimental setup
DMEM

TGF

TGF +
DEX

Alginate
sGAG assay
RT-PCR
LIVE/DEAD

x3
x3
x2

x3
x3
x2

x3
x3
x2

Agarose
sGAG assay
RT-PCR
LIVE/DEAD

x3
x3
x2

x3
x3
x2

x3
x3
x2

Sulfated Glycosaminoglycans
Three samples from each treatment were used to assess the production of sulfated
glycosaminoglycans (sGAG). At each end point the samples that were designated for the
time point were washed in PBS three times. The hydrogel/cell samples were then
digested. A volume of 2 ml of a papain digestion buffer (55mM sodium citrate (Research
Products International, Mt. Prospect, IL), 150 mM sodium chloride, 5mM cysteine
hydrochloride (Sigma, St. Louis, MO), 5 mM EDTA (Sigma, St. Louis, MO) and 0.56
units/ml papain (Sigma, St. Louis, MO) was used to solubilize the alginate and digest the
samples. A volume of 2 ml of a QG digestion buffer (QG Buffer (Qiagen AG,
Switzerland), 5 mM EDTA, and 0.56 units/ml papain) was used to solubilize the agarose
samples and digest the samples. The samples were stored at 60o C for 24 hrs. Volumes
of 20 μl digested sample, 30 μl of PBE buffer (100mM Na2HPO4 (Sigma, St. Louis, MO),
5mM EDTA, pH 7.5) and 200 μl of dimethylmethylene blue (DMB) reagent solution (40
mM NaCl, 40 mM glycine (Sigma, St. Louis, MO), 46 μM DMB (Sigma, St. Louis, MO)
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were added to a 96-well plate. Chondroitin sulfate was mixed in PBE buffer and used as
a standard to create a standard curve.

The absorbance was measured at 525 nm using a

MRX Micoplate Reader (Dynex Technologies, Germany). To correct for the DMB
binding to alginate and color changes caused by the QG buffer, controls of cell free
alginate and cell free agarose were measured and the readings were subtracted from the
readings of all the samples.
The amount of DNA present in each sample was determined using the standard
protocol for the DNA Quantitation Kit (Sigma, St. Louis, MO), which uses the
fluorescent dye bisBenzimide. The results from the sGAG assay were then normalized
by the DNA content.

RNA Isolation and Real Time RT-PCR
Three other samples from each treatment were used for RNA analysis. The
alginate samples were solubilized in 55mM sodium citrate in 0.9% NaCl for 30 minutes
at 37°C and centrifuged at 2,000 rpm for 5 min. The supernatant was removed and RNA
was isolated using the RNeasy Mini Kit (Qiagen AG, Switzerland). The agarose samples
were solubilized in 600 ul of QG Buffer (Qiagen AG, Switzerland) mixed with 600 ul of
the RLT Buffer from the RNeasy Mini Kit. The solution was maintained at room
temperature until complete dissolution of the agarose, vortexing occasionally. RNA was
isolated using the RNeasy Mini Kit (Qiagen AG, Switzerland) standard protocol. The
quality and concentration of total RNA was determined using the Agilent RNA 6000
Nano Kit (Agilent Technologies, Santa Clara CA) the Agilent 2100 Bioanalyzer, and the
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2100 Expert software. Equal amounts of total RNA were used for real time RT-PCR
using the QuantiFast SYBR Green RT-PCR Kit (Qiagen AG, Switzerland) in the RotorGene 5.0.28 light cycler (Corbett Life Science, Sydney, Australia). The markers
analyzed were sox9, aggrecan, and collagen Type II. GAPDH was used as a
housekeeping gene. The primer sequences can be seen in Table 4.5. Relative expression
was determined using the ∆∆Ct method with GAPDH as the reference gene and the Day
7 alginate DMEM group as the control group (appendix A).

Cell Viability
Cell viability was assessed using a LIVE/DEAD Viability/Cytotoxicity kit
(Molecular Probes; Eugene, OR). The cells were fluorescently labeled using calcein AM
and ethidium homodimer dyes in the kit according to the manufacturer‟s protocol.
Observations were made using an inverted microscope and imaging software.

Table 4.5: Primer sequences used for RT-PCR
Primer
Aggrecan

F
R

Sequence
5' - AGCTGAAGTCCCTGGTCAGC - 3'
5' - CTGCTGTGCCTCCTCAAATG - 3'

Sox9

F
R

5' - AAGTCGGTGAAGAACGGACAAG 3'
5' - TCTCGCTTCAGATCAACTTTGC - 3'

Collagen II

F
R

5' - - 3'
5' - - 3'

GAPDH

F
R

5' - GAACGGATTTGGCCGTATTG - 3'
5' - CGTTGAATTTGCCGTGAGTG - 3'
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Melting Temp.
(oC)
59.5
56.4

57.2
55.5

54.3
54.9

Statistical Analysis
Averages were reported as mean values ± standard error of the mean (n=3).
Unpaired t tests were used to make comparisons with a significance level of p < 0.05.

Results
Sulfated Glycosaminoglycans
The sGAG concentration was significantly higher in the DMEM, TGF, and TGF
+ DEX groups as compared to the 2D controls for both hydrogels on Days 14 and 21
(Figure 4.8). There were no statistically significant sGAG differences (p < 0.05) between
the three different media types for the alginate samples. There were also no statistically
significant sGAG differences between the three different media types for the agarose
samples. When comparing the different hydrogels there were not significant sGAG
differences between the two hydrogels for any given media type.

Real Time RT-PCR
The sox9 expression reached a maximum in all groups on Day 14 and was
followed by a decrease in expression on Day 21 (Figure 4.9a). The sox9 expression of
the agarose TGF group was significantly higher than the alginate TGF group on both
Days 14 and 21. The sox9 expression of the agarose TGF + DEX group was also
significantly higher than the alginate TGF + DEX group on both Days 14 and 21. In
addition the sox9 expression was significantly higher in the agarose TGF + DEX group
than the agarose TGF group on Days 14 and 21.
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Figure 4.8: Results of the DMB assay, used to determine the sGAG concentration. The results
are normalized by the DNA content. The 2D control samples had significantly lesss GAG than all
other groups. Error bars represent the SD (n=3). Asterisks (*) signify statistically significant
differences (p< 0.05).

The aggrecan expression showed a steady increase through each time point of the
study in the agarose samples (Figure 4.9b). The aggrecan expression of the agarose TGF
group was significantly higher than the alginate TGF group on Day 21. The aggrecan
expression of the agarose TGF + DEX group was also significantly higher than the
alginate TGF + DEX group on both Days 14 and 21. In addition, the aggrecan
expression was significantly higher in the agarose TGF + DEX group than in the agarose
TGF group on Days 14 and 21.
The collagen Type II expression remained steady between Day 7 and 14, and then
markedly increased in all agarose groups on Day 21 (Figure 4.9c). The collagen Type II
expression of the agarose TGF group was significantly higher than the expression in the
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alginate TGF group on both Days 14 and 21. The collagen Type II expression of the
agarose TGF + DEX group was also significantly higher than the expression in the
alginate TGF + DEX group on both Days 14 and 21. In addition the sox9 expression was
significantly higher in the agarose TGF + DEX group than in the agarose TGF group on
Days 14 and 21.

Figure 4.9: Results of the RT-PCR for the chondrogenic markers sox9 (A), aggrecan (B) and (C)
collagen Type II. The results are reported as a relative expression to GAPDH using the ∆∆Ct
method. Error bars represent the SD. Asterisks (*) signify statistically significant differences
between the agarose TGF and TGF +DEX groups (p< 0.05). Pound symbols (#) signify
statistically significant differences between the agarose TGF + DEX and alginate TGF +DEX
groups (p< 0.05). Plus signs (+) signify statistically significant differences between the agarose
TGF and alginate TGF groups (p< 0.05).
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Cell Viability
All hydrogel and media combinations indicated a large number of live cells
distributed throughout the gels by Day 21 (Figure 4.10). There was no discernable
difference in the amount of live cells when comparing between hydrogels or between
media types. There was a noticeable difference in the amount of dead cells found in each
hydrogels by Day 21 (Figure 4.11). The images show a large number of dead cells in all
of the alginate samples as compared to the agarose samples.

Figure 4.10: Fluorescent microscope images showing results of LIVE/DEAD viability/toxicity
assay on Day 21, live cells are green. Original total magnification was 100X.
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Figure 4.11: Fluorescent microscope images showing results of the LIVE/DEAD viability/toxicity
assay on Day 21, dead cells are red. Original total magnification was 100X.

Discussion
Two novel osteochondral tissue engineering constructs were developed. After the
initial design phase, several studies were conducted to analyze the effects of individual
design characteristics and optimize the design. The first study examined the effect of
including HAP in a PCL scaffold on the attachment and osteogenic differentiation of
MSCs.
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Hydroxyapatite is the main mineral component of natural bone and, as a result, it
has received wide attention in bone tissue engineering research. Typically HAP exhibits
excellent osteoconduction and bone bonding ability to surrounding tissue [1]. However,
porous scaffolds of HAP have poor mechanical properties, which lead to structural
instability at the initial stages of implantation [2]. Therefore HAP is usually not suitable
for load-bearing sites; however, incorporation of HAP into a polymer matrix could
overcome this shortcoming. Previous studies have shown the feasibility and advantages
of combining HAP with degradable polymers for bone regeneration [3, 4]. Several
polymer/ceramic combinations have been used to control properties such as
biocompatibility, water uptake, rate of degradability, and mechanical properties, making
the materials suitable for use in a wide range of biomedical applications [5]. Moreover,
previous studies revealed that the incorporation of a ceramic phase in PCL improved the
bioactivity of the polymeric scaffold [5, 6] and that composites of HAP particles and
biodegradable polymers have good osteoconductivity [7].
The results of the cell viability assay using LIVE/ DEAD florescence staining
indicated that there was superior cell attachment on the PL/PCL/HAP scaffold as
compared to the PL/PCL scaffold. Visually, there was a very noticeable difference in the
number of cells attached to the scaffold on Day 7, and it is likely that there would have
been an even larger difference if the assay had been completed at an earlier time point.
The results of the H & E histological evaluation correlated with the results of the
LIVE/DEAD staining, as both showed a nearly continuous layer of cells was attached to
the scaffold containing HAP, while a lower number of cells were scattered on the
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PL/PCL scaffold. LIVE/DEAD and histological assays suggest that the addition of 10%
w/v HAP to PL/PCL enhances the cell attachment and distribution on porous scaffolds
produced from the material.
The results from the ALP activity assay did not show any statistically significant
differences between the two scaffold types on Days 7 and 14. However, by Day 21 there
was a significantly higher ALP activity in the PL/PCL/HAP scaffolds. ALP is often used
as a marker for osteogenic differentiation as it is expressed by maturing osteoblasts and it
is a key enzyme in the mineralization process [8]. The ALP results showing significantly
higher ALP activity in the cells grown on the scaffolds containing 10% HAP than those
grown on the scaffolds without HAP suggest that addition of HAP to the scaffold
enhances the osteogenic differentiation of MSCs.
Von Kossa staining is commonly used to demonstrate the presence of calcium in
samples, however it actually stains for presence of the anion that calcium is attached to
rather than calcium itself. In the case of bone mineralization, this anion is phosphate.
Still, Von Kossa staining has been used successfully to examine mineralization in vitro,
where calcium salts stain dark brown to black. The Von Kossa staining in this study did
not reveal any difference in mineralization on the two scaffold types. There was no
detectable mineralization seen around the cells in the PL/PCL scaffolds. The HAP that
was added to the polymer stained strongly, as would be expected. However, it was not
possible to discern any new mineralization that was created by the cells from HAP
mineralization that was already present in the scaffold, even when compared to the
acellular control. It may also be possible that the cells were not cultured long enough for
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the cells to have produced any appreciable amount of mineralization, as mineralization is
a late marker for osteogenic differentiation or the presence of the HAP particles masked
any cell generated mineralization[9].
The objective of the second study was to examine the effect of the inclusion of
capillary channel fibers in the bone phase of the osteochondral construct. A critical
obstacle in tissue engineering approaches is the ability to maintain large masses of living
cells upon transfer from the in vitro culture conditions into the host [10]. In vivo, most
cells are no more than 100 µm away from the nearest capillary, which serves to supply
oxygen and nutrients, remove waste products, and transport biochemical signals [11].
Insufficient vascularization results in hypoxic cell death of engineered tissues [12] and
consequently, implant failure [143]. In the particular case of bone grafts, the lack of a
viable blood supply is implicated as one of the major factors responsible for implant
failure [10]. Seeded cells in the middle of porous scaffolds are subject to necrosis due to
ineffective transport of oxygen, nutrients, and metabolites [13]. A cell-containing graft
larger than a few cubic millimeters demands the ingrowth of blood vessels [14].
Considering that the infiltration of blood vessels into a macroporous scaffold is a process
that occurs at a rate of <1mm per day and that it typically takes 1–2 weeks for the
vascular structure to complete the penetration into relatively thin (3mm thick) scaffolds
[10], it is crucial to facilitate fluid flow to the interior of larger scaffolds while new blood
vessels are forming.
The alamarBlue, total protein, and ALP assay results suggest that the inclusion of
capillary fibers in the scaffold may be beneficial to the development of the bone phase of
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the osteochondral construct, but the evidence is not very strong. It is likely that the
differences seen were not significant because the size of the scaffold used in this study
was small and the number of fibers that were present in the scaffolds was low. The
diameter of the scaffolds that were used was approximately 6 mm. This size is
potentially small enough to allow for nutrients to be delivered to the interior cells without
the need of wicking fibers. This diameter is comparable to the work of other researchers
attempting to engineer osteochondral tissue with bulk scaffolds without any additional
means of delivering nutrients to the interior [15-18]. It is very likely that a comparison of
larger scaffolds would show a more significant difference in metabolic activity and
differentiation of the cells. Additionally, a larger scaffold would allow for the
incorporation of more capillary channel fibers. The scaffolds in this study only had one
fiber bundle running through the diameter of the scaffold, but more fibers would allow
fluid exchange throughout the scaffold.
The final study was intended to evaluate two different hydrogels, alginate and
agarose, for use in the cartilage portion of the construct. Chondrocytes cultured in
monolayer usually tend to dedifferentiate quickly [19] ,and stem cells cultured in
monolayer do not differentiate down the chondrogenic pathway well. Hydrogels are
cross-linked hydrophilic polymer matrices capable of absorbing large amounts of water
[20]. Hydrogels offer an attractive option for cartilage tissue engineering because their
crosslinked network mimics the natural structure of extracellular matrices in vivo and
their high water content facilitates the exchange of nutrients and gases [21, 22]. Several
studies have shown that the entrapment of isolated chondrocytes and stem cells in gels,
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such as agarose, collagen, and alginate, helps promote the synthesis of collagen Type II
and proteoglycan, both of which are markers of the chondrogenic phenotype [19, 22-25].
Alginate and agarose solutions may also be injected and polymerized in situ, making
them attractive options for arthroscopic repair of lesions [26]. While alginate and agarose
have similar macroscopic properties, recent evidence suggests that cell-scaffold
interactions result in remarkably different cell behavior [22, 23, 27]. In addition to
examining the effect of the hydrogel on chondrogenic differentiation, the addition of
dexamethasone (DEX) to the culture media was also examined. The use of DEX to
promote chondrogenic differentiation is still debated as there are conflicting reports on
the subject. DEX has been shown by some researchers to cause the differentiation of
MSCs into chondrocytes [28-30], while other have shown no effect of even inhibitory
effects of DEX on chondrogenic differentiation [31]. The role of DEX‟s in
chondrogenesis is poorly understood and the secondary objective of this study was to add
to the limited knowledge on the subject.
The DMB assay and RT-PCR revealed the large, beneficial effect of culturing
MSCs in hydrogels to produce chondrogenic differentiation. When cultured in a
hydrogel, cells acquire a spherical shape rather than the spread morphology typically seen
in 2D culture. The spherical morphology is similar to what is observed by chondrocytes in vivo and this spherical morphology can aid in chondrogenic differentiation or the
preservation the chondrogenic phenotype.
Sox9 is considered to be a master transcription factor that is required for
chondrocyte differentiation, and as a result is expressed earlier, then experiences reduced
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expression [32]. Collagen Type II is typically a mid to late marker for chondrogenic
differentiation, while aggrecan is a late marker[33]. The results of the RT-PCR revealed
large differences in the RNA expression of the cells cultured in the two different
hydrogels. On Days 14 and 21 the expression of all three chondrogenic markers was
significantly higher in the agarose samples culutred in media supplemented with TGF and
TGF + DEX, as compared the alginate samples.
Large differences in chondrogenic differentiation between cells cultured in
alginate and agarose were observed in this study. A likely cause of these differences is
the physicochemical property differences in the hydrogels. The major difference between
the two is that alginate is negatively charged and agarose is neutrally charged [22]. It is
possible that alginate resists the diffusion of negatively charged particles, such as DEX,
into and out of the matrix [22]. In addition, TGF-β1 has been shown to bind to alginate
by replacing Ca2+, resulting in inactivation of the growth factor [34].

Conclusion
Two novel constructs for osteochondral tissue engineering were developed and
tested. The results of the tests revealed valuable information about the designs and were
used to hone the final design of the constructs. Based on the results, a composite of
polylactide/polycaprolactone and hydroxyapatite was used for the bone phase of the
barbed pin design to support osteogenic differentiation. In addition, capillary channel
fibers were incorporated in the bone phase of the barbed pin design to allow larger
constructs to be used. Finally, agarose was selected for use in the cartilage phase of both
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designs as it enhances chondrogenic differentiation, shows better cell viability, and has
better handling and processing properties.
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CHAPTER 5
MODIFICATION AND ADAPTATION OF CURRENT BIOREACTOR DESIGN
The primary objective of most bioreactors is to optimize the cell culture
environment by simulating the in vivo conditions pertinent to the cell type of interest. The
major functions of bioreactors include supplying metabolites, such as oxygen and
nutrients, removing waste products, maintaining temperature and pH, and applying the
appropriate mechanical stresses to stimulate the formation of the extracellular matrix
(ECM). By producing and maintaining pseudo-physiological conditions specific to and
essential for cell activities, bioreactors can lead to the culture of well differentiated 3D
tissues that can be clinically useful [1].
In native osteochondral tissue, different types of forces affect articular cartilage
and subchondral bone during joint movement and normal skeletal loading. The major
effect of all loading events is the generation of hydrostatic pressure and shear stress due
to fluid flow [2, 3]. Models have estimated the hydrostatic pressure within bone
canaliculi to be in the range of 200-300 kPa [4]. Fluid movement within the porous
structure of bone results in estimated shear stresses in the range of 0.06-30 dyne/cm2 [5,
6]. For the articular cartilage of the major weight bearing joints in the hip and the knee,
average loadings of about 0.5–7.7 MPa and average compression amplitudes of more
than 13% have been measured during normal movements like walking [7].
It is well known that physical stimuli can modulate the metabolism of
chondrocytes and osteoblasts, and may up-regulate the production of extracellular matrix
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components [8]. Mechanical stimulation such as shear stress and hydrostatic pressure
have been shown to provided significant beneficial effects on gene expression and
protein production of chondrocytes and has led to enhanced biochemical and
biomechanical properties in engineered constructs [9-13]. Furthermore, hydrostatic
pressure, especially with intermittent loading frequencies, has been shown to induce
chondrogenic differentiation of MSCs, embryonic stem cells, and dedifferentiated
chondrocytes [14]. In addition, enhanced osteogenic differentiation and mineralized
matrix deposition were reported when human bone marrow stromal cells were subjected
to physiological magnitudes of hydrostatic pressure in a bioreactor [15].
Previously in our lab a bioreactor system was developed, designed to model in
vivo loading conditions and apply mechanical stimuli to cell-seeded scaffolds/hydrogels
in an effort to enhance cell differentiation and/or tissue development [16]. The design of
the bioreactor encompassed both aspects of hydrostatic compression and perfusion fluid
flow. As this was the first generation of the bioreactor, improvements and modifications
were needed. More specifically, the means by which the hydrostatic pressure was created
needed improvement. Additionally, in order for the novel osteochondral constructs to be
cultured in the bioreactor, it was necessary to modify the design to allow biphasic
constructs to be used and hydrostatic pressure to be applied to both phases.
Figure 5.1 shows a 3D rendering of the original design of the bioreactor. The
scaffold material and cells reside within the biochamber module (A). The central
chamber of the air module (D) is in-line with the biochamber and is connected to a
pressurized air line via a barbed hose connector (E). A silicone diaphragm (C) is
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positioned between the air module and biochamber module to serve as a gasket as well as
transfer pressure from the air chamber to the medium contained in the biochamber.
Quick-disconnect luers (F) and stopcock valves (G) (Cole-Parmer, Vernon Hills, IL)
provide efficient and leak-free connection of the bioreactor and medium perfusion tubing.
Bioreactor modules were machined out of Lexan®. The bioreactor design provided a
means of applying both perfusion flow and hydrostatic compression to the biochamber
environment (Figure 5.2). The valves remain open during perfusion flow to allow a
peristaltic pump (Cole-Parmer) to drive medium through the biochamber. Conversely,
the pump is turned off and valves are closed prior to commencing hydrostatic
compression to develop a fixed fluid volume of medium within the biochamber. The
introduction of sterile pressurized air within the air chamber deflects the silicone
diaphragm that, in turn, transfers the pressure to the fixed fluid volume of medium to
create a hydrostatic compressive load [16].

Figure 5.1: Expanded view of the original bioreactor design [16].
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Figure 5.2: Illustration of original bioreactor demonstrating perfusion flow (a) and hydrostatic
compression (b). Solenoid valves (not shown) are connected in-line with the medium perfusion
tubing on both sides of the bioreactor. The valves are opened during perfusion flow and closed
during hydrostatic compression to provide a fixed fluid volume within the cell-scaffold chamber
[16].

While in use, after numerous cycles, the silicone diaphragm would often begin to
weaken. This led to the diaphragm making contact with the sample in the bioreactor and
eventually rupturing. This would ultimately destroy the samples in the bioreactor. On
average, this would occur in about 50% of the bioreactors, resulting in a loss of half of
the tissue samples. An alternative method of creating hydrostatic pressure was needed.
The new method needed to be integrated easily with the current system, maintain sterile
conditions, and use the controlled pressurized air system.
Consequently, a pneumatically controlled syringe was implemented to create the
hydrostatic pressure. Figure 5.3 shows a 3D rendering of the expanded design. The
controlled pressurized air line is connected to the (A) pneumatic adaptor assembly (B)
(Zephyrtronics, Pomona, CA). The heads of the adaptor assembly fits inside a 5 ml
syringe (D) and forms a tight seal with an o-ring placed around the head of the adaptor
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assembly. The adaptor is attached to the syringe by two notches on the sides of the
assembly that attach to the tabs on the syringe. Inside the syringe is a small rubber piston
(C) that is free to move up and down in the syringe. The end of the syringe is attached to
a luer to threading adaptor (E) by the luer end. The adaptor passes through a metal and
facet washer (F) to prevent leaks and is screwed into the air module (G) of the bioreactor
which contains a hole in the center of the module that extends through the entire
thickness. The pressure module is in line with the biochamber (I) that contains the
sample. An O-ring (H) is placed between the two modules to form a tight seal and the
modules are held together using four socket screws and nuts (J). The adapter assembly
connects the syringe to the controller and delivers the air supply to the piston inside the
syringe. Air is pulsed into the syringe by the adapter assembly which pressed on the
piston within the barrel. The piston presses down on the fluid within the syringe, creating
a hydrostatic pressure in the biochamber.
When the system was first tested, cracks formed in the Lexan® air module. The
cracks radiated out from the threaded hole that adaptor used to connect the syringe
screwed into. It was necessary to screw the adaptor on very tightly to avoid a leak when
the hydrostatic pressure was created. It is likely that the crack formed because of the
high loads generated from attaching the adaptor as well as the stress concentrations that
are formed by the machined threads along the wall of the hole. In addition, Lexan® has
been shown to weaken after repeated autoclaving. The cracks caused leaks in the system,
resulting in the hydrostatic pressure drop. New air modules were fabricated by Clemson
Machining and Technical Services. Instead of making the modules out of Lexan®, they
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were made out of aluminum 6061. Aluminum 6061 was chosen due to its excellent
corrosion resistance, relatively high strength, good machinablilty, and its relatively low
cost and wide availability.

Figure 5.3: 3D rendering of the new bioreactor design incorporating a pneumatic syringe to
create the hydrostatic pressure.
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The generation of hydrostatic pressure using the new design was verified using a
simple yet effective setup (Figure 5.4). The bioreactor (A) was assembled as described
above with the syringe loaded with water (B) attached to a pressurized air supply. A
solenoid valve (C) was attached to one of the ports on the side of the bioreactor and
closed to create a closed volume of fluid in the bioreactor. A pressure gauge (D) was
attached to the other port in order to record the pressure within the bioreactor. The
biochamber was prefilled with water to avoid any air bubbles in the system. The
pressurized air was set at varying pressures from 5-60 psi at increments of 5 psi, and
several cycles were run and the readings on the pressure gauge were recorded. Figure 5.5
show the results of the test. There is a linear relationship between the air pressure that is
applied to the piston in the syringe and the hydrostatic pressure that is created in the
bioreactor. The line is shifted approximately 2.5 psi to the right on the graph, indicating
that there is a difference of 2.5 psi between the two pressures. This shift is likely due to a
small amount of deformation in the pressurized system as well as a small amount of
friction between the piston and the wall of the syringe that must be overcome. The
equation generated (Figure 5.5) by the test serves as a means of determining the pressure
in the bioreactor based on the pressure to which the air delivery system is set.
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Figure 5.4: Setup of bioreactor with the inclusion of a pressure gauge to evaluate the hydrostatic
pressure that is generated in the bioreactor with the new design.

Figure 5.5: Graph showing the relationship between the pressure that is exerted on the piston by
the pressurized air system and the hydrostatic pressure that is actually created in the biochamber
of the bioreactor.
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The second modification of the original bioreactor system that was needed was to
enable a biphasic construct to be cultured in the bioreactor while allowing hydrostatic
pressure to be applied to both sides. It was possible to culture a biphasic construct in the
original design by placing two of the biochamber modules face to face, creating an area
into which both phases would fit. The configuration would allow the culture of a
biphasic construct with different medium supplied to each phase; however this
configuration did not allow hydrostatic pressure to be applied to either phase. As it was
desirable to culture the newly developed osteochondral construct in the bioreactor and
examine the effect of hydrostatic pressure conditioning, the bioreactor was modified.
Figure 5.6 shows a 3D rendering of the modified setup of the bioreactor. New
biochamber modules were fabricated by Clemson Machining and Technical Services out
of aluminum 6061. The new modules (A) are similar to the old biochamber with the
difference that the sample cavity extends through the entire thickness of the chamber.
Two of the modified modules are placed together with pressure chambers on the opposite
sides of each module. The two biochamber modules being placed together create an area
in which a biphasic construct (B) can be cultured. This new design allows fluid flow and
hydrostatic pressure to be applied to each phase, with the potential of different
magnitudes and frequencies that may be implemented in the future. In addition, each
phase can be cultured in different medium to optimize the differentiation and growth of
different tissues.
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Figure 5.6: 3D rendering of the new bioreactor design in a configuration to allow hydrostatic
pressure to be applied to both sides of a biphasic construct.
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CHAPTER 6
SYNERGISTIC EFFECTS OF CONDITIONED MEDIA AND HYDROSTATIC
PRESSURE ON THE CHONDROGENIC AND OSTEOGENIC
DIFFERENTIATION OF MESENCHYMAL STEM CELLS
Introduction
A successful tissue engineering solution for osteochondral repair will likely
require a combination of several components, including the appropriate cells, a scaffold
to contain the cells and to mimic the mechanical function of the native tissue, chemical
signals to encourage and maintain the appropriate cell phenotype, and mechanical signals
to accelerate and enhance differentiation and tissue regeneration [1].
A complex relationship between chondrocytes and osteoblasts exists in the in vivo
osteochondral environment. The complexity of the relationship between the two
differentiating cell types is, in part, attributed to the complicated cytokine and growth
factor signaling pathways that exist between the two cell populations. Previous work
(Chapter 2) has demonstrated that it is possible to leverage the interactions that regulate
cell proliferation and differentiation to help optimize culture conditions to develop a
tissue engineered osteochondral construct.
Hydrostatic pressure (HP) provides a robust method of stimulation, because it can
be applied to cells in monolayer, three-dimensional (3-D) engineered constructs, as well
as explants [2]. Various regimens of HP can be potent stimulators of ECM synthesis and
have been demonstrated as such in different culture systems, including cartilage explants
[3], high-density monolayers [4], agarose gels [5], and collagen sponges [6]. It has been
demonstrated that chondrocyte responses to HP can induce changes in the gene
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expression, protein synthesis, matrix composition, and, ultimately, biomechanical
competence of the tissue [7].
The objective of this study was to investigate the effect of mechanical stimuli, in
combination with conditioned media (CM), on the osteogenic and chondrogenic
differentiation of mesenchymal stem cells. It was hypothesized that an additive, or
synergistic, effect would exist between the HP treatment and the administration of CM.
Osteogenic samples were cultured in bioreactors with and without chondrocyte CM and
with and without the application of hydrostatic pressure. In addition, chondrogenic
samples were cultured in bioreactors with and without osteoblast CM and with and
without the application of hydrostatic pressure.

Methods and Materials
Experimental Setup
Two groups were designated for this study. The first group, termed the bone
group, was produced by culturing MSCs on PL/PCL/HAP scaffolds in the bioreactor and
facilitating their differentiation to osteoblasts.

The conditioned medium that was used

was taken from MSCs encapsulated in low gelling temperature agarose hydrogel (Sigma,
St. Louis, MO) and cultured in chondrogenic medium to induce chondrogenic
differentiation. The four different treatments that were tested are outlined in Table 6.1.
This setup allowed for the effects of CM and HP to be assessed alone and in combination
with each other. The second group, termed the cartilage group, was produced by
culturing MSCs encapsulated in agarose in the bioreactor and facilitating their
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differentiation to chondrocytes. The CM that was administered was taken from MSCs
seeded on PL/PCL/HAP scaffold and cultured in osteogenic medium to induce
osteogenic differentiation. The four treatments for this group are very similar to those
applied to the bone group and are also outlined in Table 6.1.

Table 6.1: Outline of the experimental setup
Bone Group
Treatment
Name
Osteo NoP
Osteo HP
CM NoP
CM HP

Chondrocyte
CM

Cartilage Group
Hydrostatic
Pressure

+
+
+

+

Treatment
Name
Chondro
NoP
Chondro HP
CM NoP
CM HP

Osteoblast
CM

Hydrostatic
Pressure

+
+
+

+

Conditioned Media
To generate chondrocyte CM to be used in the bone group, D1 murine MSCs
were expanded in standard cell culture flasks to produce enough cells for the study. Cells
were trypsinized and suspended in sterile 2% agarose at a concentration of 2x10 6
cells/ml. A volume of 0.5 ml of the cell suspension was placed in the wells of a 12 well
plates. The agarose was then placed at 40 C for 10 minutes to allow the agarose to gel.
Chondrogenic medium consisting of DMEM, 1% antibiotic/antimycotic, 0.2% fungizone,
50 ug/ml L-ascorbic acid 2-phosphate, 40 ug/ml L-proline (Sigma, St. Louis, MO), 10
ul/ml ITS+1 liquid media supplement (Sigma, St. Louis, MO), and 10 ng/ml TGF-β1
(Sigma, St. Louis, MO) was then added to the cultures. The cells were cultured at 370 C
and 5% CO2 in static conditions for the entire study. CM was collected at Days 7, 14,
and 21 and administered to the appropriate samples in the bone group. CM from all
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agarose samples were mixed together to form one sample of CM and passed through a
0.2 μm filter to remove any cells. In addition, 1 ml samples were taken at Days 3, 7, 10,
14, 18, 21 to be used for ELISA analysis.
To generate osteoblast CM to be used in the cartilage group, D1 murine MSCs
were seeded on sterilized porous PL/PCL/HAP scaffolds at a concentration of 2x10 6 cells
per scaffold. Seeding took place in low attachment 12 well plates and the plates were
placed on an orbital shaker for the first 12 hours. Osteogenic medium consisting of
DMEM, 10% FBS, 1% antibiotic/antimycotic, 0.2% fungizone, 50 µg/ml L-ascorbic acid
2-phosphate (Sigma, St. Louis, MO), 3 mM β-glycerophosphate (Sigma, St. Louis, MO)
and 10 nM dexamethasone (Sigma, St. Louis, MO) was then added to the cultures. The
cells were cultured at 370 C and 5% CO2 in static conditions for the entire study. CM
was collected at Days 7, 14, and 21 and administered to the appropriate samples in the
cartilage group. CM from all osteogenic samples were mixed together to form one
sample of CM and passed through a 0.2 μm filter to remove any cells. In addition, 1 ml
samples were taken at Days 3, 7, 10, 14, 18, 21 to be used for ELISA analysis.

Bioreactor Culture
All parts of the bioreactor were sterilized in an autoclave at 134 OC and 30 psi for
45 minutes with the exception of the solenoid valves and scaffolds, which were sterilized
using ethylene oxide followed by a 48 hour degassing time under house vacuum. For the
bone group, PL/PCL/HAP scaffolds were manufactured in the shape of cylinders with a
diameter of approximately 6 mm and a height of approximately 6 mm, sized to fit the
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biochamber of the bioreactor. After sterilization, the scaffolds were soaked in medium
containing FBS for 24 hours to allow proteins to attach to the surface. D1 murine MSCs
were then seeded on the scaffolds at a concentration of 2x10 6 cells per scaffold. Seeding
took place in low attachment 24 well plates and the plates were placed on an orbital
shaker for the first 12 hours. The seeded scaffolds were then placed in the biochamber of
the bioreactor and the entire system was assembled under sterile conditions. Half of the
scaffolds were placed in bioreactors capable of creating hydrostatic pressure, comprising
the “Osteo HP” and “CM HP” treatment groups, while the other half was placed in
bioreactors unable to create hydrostatic pressure, comprising the “Osteo NoP” and “CM
NoP” treatment groups. The media reservoirs feeding the samples in the “Osteo NoP”
and “Osteo HP” treatments were each filled with 40 mL of osteogenic medium consisting
of DMEM, 10% FBS, 1% antibiotic/antimycotic, 0.2% fungizone, 50 µg/ml L-ascorbic
acid 2-phosphate (Sigma, St. Louis, MO), 3 mM β-glycerophosphate (Sigma, St. Louis,
MO), and 10 nM dexamethasone (Sigma, St. Louis, MO). The media reservoirs feeding
the samples in the “CM NoP” and “CM HP” were each filled with 20 ml of osteogenic
medium and 20 ml of chondrocyte CM, resulting in a CM concentration of 50%.
For the cartilage group, D1 murine MSCs were suspended in 2% agarose at a
concentration of 2x106 cells/ml. The cell suspension was placed in a cylindrical mold
with a diameter of 6 mm and a height of 6 mm. The molds were then placed at 4o C for
10 minutes to allow the agarose to gel. The gel cylinders that resulted were placed in the
biochamber of the bioreactors and the entire system was assembled under sterile
conditions. Again, half of the samples were placed in bioreactors capable of creating
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hydrostatic pressure, comprising the “Chondro HP” and “CM HP” treatment groups,
while the other half was placed in bioreactors unable to create hydrostatic pressure,
comprising the “Chondro NoP” and “CM NoP” treatment groups. The media reservoirs
feeding the samples in the “Chondro NoP” and “Chondro HP” treatments were each
filled with 40 ml of chondrogenic medium consisting of DMEM, 1%
antibiotic/antimycotic, 0.2% fungizone, 50 ug/ml L-ascorbic acid 2-phosphate, 40 ug/ml
L-proline (Sigma, St. Louis, MO), 10 ul/ml ITS+1 liquid media supplement (Sigma, St.
Louis, MO), and 10 ng/ml TGF-β1 (Sigma, St. Louis, MO). The media reservoirs
feeding the samples in the “CM NoP” and “CM HP” were each filled with 20 ml of
chondrogenic medium and 20 ml of osteoblast CM, resulting in a CM concentration of
50%.
The perfusion rate for all treatment groups in both the bone and cartilage groups
was 0.7 ml/min throughout the study. For the treatment groups that were subjected to
hydrostatic pressure, the schedule was 2.5 hours of perfusion flow followed by 30
minutes of intermittent hydrostatic pressure at a magnitude of 300 kPa and a frequency of
0.5 Hz. This pattern resulted in a 3 hour cycle that was repeated continuously for a total
of 8 cycles per day and a total of 4 hours of intermittent hydrostatic pressure per day.
The perfusion flow to the samples in the treatment groups that were not subjected to
hydrostatic pressure was suspended during the 30 minute period when hydrostatic
pressure was be administered to the hydrostatic pressure samples.
Complete media changes were performed on Days 7 and 14. The study was timed
such that the CM that was administered on Day 0 was from chondrocytes or osteoblasts
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at Day 7, the CM administered on Day 7 was from cells at Day 14 and CM administered
on Day 14 was from cells at Day 21. The study was conducted through Day 21, at which
point the samples were removed from the bioreactors and assessed for osteogenic and
chondrogenic differentiation.

Alkaline Phosphatase
Three replicates for each treatment in the bone group were used to assess the
alkaline phosphatase (ALP) activity. The samples were removed from the bioreactors,
washed three times with PBS, 2 ml of deionized water were added to each sample, and
three freeze-thaw cycles were performed to lyse the cell membranes. A phosphatase
substrate solution was created by mixing 5ml of deionized water with every 20 mg of
phosphatase substrate (Sigma, St. Louis, MO). The phosphatase substrate solution was
mixed with an equal amount of alkaline buffer solution (Sigma, St. Louis, MO) to create
the working reagent. A volume of 500 µl of the working reagent was placed in 24-well
plates, using the same number of wells as samples; the plates were then incubated for 15
minutes at 37o C. Subsequently, 100 µl of the sample lysate was added to each sample
well and incubated for 30 minutes at 37o C, after which 1.5 ml of 0.25N NaOH was
added to each well to stop the reaction. Aliquots in the amount of 200 µl were then
moved in triplicate to a 96-well plate, and the absorbance was read at 410 nm using a
MRX Micoplate Reader (Dynex Technologies, Germany). A standard curve was
generated using p-nitrophenol (Sigma, St. Louis, MO) standard solution diluted with 0.02
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N NaOH. The ALP activity was determined using the standard curve and measured in
sigma units, which are defined as 1μmol of p-nitrophenol converted per hour.
The protein content in each sample was determined by following the standard
protocol for the BCA Total Protein Kit (Pierce, Rockford, IL). The results from the ALP
assay were normalized by the protein content determined by the BCA total protein assay.

Sulfated Glycosaminoglycans
Three samples from each treatment in the cartilage group were used to assess the
production of sulfated glycosaminoglycans (sGAG). The samples were removed from
the bioreactors and washed in PBS three times. The hydrogel/cell samples were then
digested. A volume of 2 ml of a QG digestion buffer (QG Buffer (Qiagen AG,
Switzerland), 5 mM EDTA, and 0.56 units/ml papain) was used to solubilize and digest
the agarose samples. The samples were stored at 60 o C for 24 hrs. Volumes of 20 μl
digested sample, 30 μl of PBE buffer (100mM Na2 HPO4 (Sigma, St. Louis, MO), 5mM
EDTA, pH 7.5) and 200 μl of dimethylmethylene blue (DMB) reagent solution (40 mM
NaCl, 40 mM glycine (Sigma, St. Louis, MO), 46 μM DMB (Sigma, St. Louis, MO))
were added to each well of a 96-well plate. Chondroitin sulfate was mixed in PBE buffer
and used as a standard to create a standard curve.

The absorbance was measured at 525

nm using a MRX Micoplate Reader (Dynex Technologies, Germany). To correct any
color changes caused by the QG buffer, controls of cell free agarose were measured and
the readings were subtracted from the readings of all the samples.
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The amount of DNA present in each sample was determined using the standard
protocol for the DNA Quantitation Kit (Sigma, St. Louis, MO), which uses the
fluorescent dye bisBenzimide. The results from the sGAG assay were then normalized to
the DNA content.

RNA Isolation and Real Time RT-PCR
The three remaining samples from each treatment in both the bone and cartilage
groups were used for RNA analysis. The agarose samples were solubilized in 600 µl of
QG Buffer (Qiagen AG, Switzerland) mixed with 600 µl of the RLT Buffer from the
RNeasy Mini Kit (Qiagen AG, Switzerland). The solution was left at room temperature
until complete dissolution of the agarose, vortexing occasionally. RNA was isolated
using the RNeasy Mini Kit standard protocol. RNA was isolated directly from the bone
samples grown on the PL/PCL/HAP scaffolds using the RNeasy mini kit. The quality
and concentration of total RNA was determined using the Agilent RNA 6000 Nano Kit
(Agilent Technologies, Santa Clara CA), the Agilent 2100 Bioanalyzer, and the 2100
Expert software. Equal amounts of total RNA were used for real time RT-PCR using the
QuantiFast SYBR Green RT-PCR Kit (Qiagen AG, Switzerland) in the Rotor-Gene
5.0.28 light cycler (Corbett Life Science, Sydney, Australia). The markers that were
analyzed for the bone group were osteocalcin (OC) and bone sialoprotein (BSP). The
markers that were analyzed for the cartilage group were sox9, aggrecan, and collagen
Type II. GAPDH was used as a housekeeping gene. The primer sequences can be seen
in Table 6.2. Relative expression was determined using the ∆∆Ct method with GAPDH
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as the reference gene and the samples not administered hydrostatic pressure or CM in
both the bone and cartilage group were used as control samples (appendix A).

Table 6.2: Primer sequences used for RT-PCR
Primer
Aggrecan

Melting Temp.
(oC)
59.5
56.4

F
R

Sequence
5' - AGCTGAAGTCCCTGGTCAGC - 3'
5' - CTGCTGTGCCTCCTCAAATG - 3'

Sox9

F
R

5' - AAGTCGGTGAAGAACGGACAAG - 3'
5' - TCTCGCTTCAGATCAACTTTGC - 3'

57.2
55.5

Collagen II

F
R

5' - CAGATGGGAGTCATGCAAGG - 3'
5' - CATGGGACCAGAGACACCAG - 3'

55.7
57.4

Osteocalcin

F
R

5' - AGACCGCCTACAAACGCATC - 3'
5' - GATCAAGTCCCGGAGAGCAG - 3'

57.8
57.4

Bone Sialoprotein

F
R

5' - TACGGAGCAGAGACCACACC - 3'
5' - CTTCCTCGTCGCTTTCCTTC - 3'

58.8
55.7

GAPDH

F
R

5' - GAACGGATTTGGCCGTATTG - 3'
5' - CGTTGAATTTGCCGTGAGTG - 3'

54.3
54.9

Measurement of TGF-β1 and BMP-2
The amount of transforming growth factor beta one (TGF-β1) and bone
morphogenetic protein-2 (BMP-2) present in both the chondrocyte CM and the osteoblast
CM were assessed using a quantitative sandwich ELISA. The Mouse/Rat/Porcine/Canine
TGF-beta 1 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN) and the
Human/Mouse/Rat BMP-2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN)
were used and the standard protocols were followed. Briefly, samples were collected
from each conditioned media at Days 3, 7, 10, 14, 18, and 21 and stored at -20o C until
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the assay was run. Standards, controls, and samples were pipetted into the wells which a
monoclonal antibody specific for TGF-β1 or BMP-2 had been pre-coated, and any TGFβ1 or BMP-2 present were bound by the immobilized antibody. After washing away any
unbound substances, an enzyme-linked polyclonal antibody specific for TGF-β1 or BMP2 was added to the wells to sandwich the TGF-β1 or BMP-2 immobilized during the first
incubation. Following a wash to remove any unbound antibody-enzyme reagent, a
substrate solution was added to the wells and color developed in proportion to the amount
of TGF-β1 or BMP-2 bound in the initial step. The color development was stopped and
the optical density measured at 450 nm with a wavelength correction at 540 nm. The
TGF-β1 or BMP-2 concentration was determined by comparing the results to a standard
curve generated by a dilution series of a standard stock solution. Three CM samples from
each cell type and time point were run in duplicate. The fresh chondrogenic medium and
osteogenic medium were also tested and the results were subtracted from the results of
the CM.

Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=3). Unpaired
t tests were used to make comparisons with a significance level of p < 0.05.
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Results
Alkaline Phosphatase
The results of the ALP activity assay are shown in Figure 6.1. The samples that
were administered both CM and hydrostatic pressure showed a slightly higher ALP
activity as compared to any other samples, however the difference was not statistically
significant (p<0.05). There were no statistical differences in the ALP activity between
any of the treatments.

Sulfated Glycosaminoglycans
The results of the sGAG assay using DMB are shown in Figure 6.2. The samples
that were cultured in chondrogenic medium and were subjected to hydrostatic pressure
showed a higher sGAG concentration than the samples that were only cultured in only
chondrogenic medium. In addition, the samples that were cultured in 50% osteoblast CM
without hydrostatic pressure also had a higher sGAG concentration than the samples that
were only cultured in chondrogenic medium. The samples that were cultured in 50%
osteoblast CM and subjected to hydrostatic pressure had a significantly higher
concentration (p<0.05) of sGAG as compared to both the samples cultured under one of
the variables of CM or hydrostatic pressure.
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Figure 6.1: Results of the alkaline phosphatase assay normalized by total protein for the bone
group. There were no statistically significant differences between any of the groups (p<0.05).
Error bars represent the SD (n=3).

Figure 6.2: Results of the DMB assay, used to determine the sGAG concentration for the
cartilage group. The results are normalized by the DNA content. Error bars represent the SD
(n=3). Asterisks (*) signify statistically significant differences (p< 0.05).
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RT-PCR
The results of the real time RT-PCR for the bone group are shown in Figure 6.3.
The samples that were cultured in 50% chondrocyte CM and subjected to hydrostatic
pressure had a significantly higher bone sialoprotein expression than the samples only
cultured in 50% chondrocyte CM as well as the samples that were subjected to
hydrostatic pressure without CM. The same behavior was evident for the osteocalcin
expression. In addition, the samples cultured in osteogenic medium and administered
hydrostatic pressure had a significantly higher osteocalcin expression than the samples
only cultured in osteogenic medium and not administered hydrostatic pressure.
The results of the real time RT-PCR for the cartilage group are shown in Figure
6.4. The samples that were cultured in chondrogenic medium and were subjected to
hydrostatic pressure showed a higher sox9, aggrecan, and collagen Type II expression
than the samples that were only cultured in chondrogenic medium. In addition, the
samples that were cultured in 50% osteoblast CM without hydrostatic pressure also
showed a higher sox9, aggrecan, and collagen Type II expression than the samples that
were only cultured in chondrogenic medium. Also, the samples that were cultured in
50% osteoblast CM and subjected to hydrostatic pressure showed a significantly higher
collagen Type II expression than the samples cultured in 50% osteoblast CM without
hydrostatic pressure.
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Measurement of TGF-β1 and BMP-2
Both the chondrocyte CM and the osteoblast CM contained TGF-β1. The
chondrocyte CM contained significantly more TGF-β1 than the osteoblast CM
throughout the study. The chondrocyte CM contained 1825 pg/ml (± 259 pg/ml) of TGFβ1 on Day 3 and the value steadily increased throughout the study to 3832 pg/ml (± 97
pg/ml) on Day 21. The osteoblast CM contained 700 pg/ml (± 67 pg/ml) of TGF-β1 on
Day 3 and this value also steadily increased throughout the study to 2960 pg/ml (±338
pg/ml) by Day 21.
In addition, both the chondrocyte CM and the osteoblast CM contained BMP-2.
The osteoblast CM contained slightly more BMP-2 as compared to the chondrocyte CM,
but the difference was not statistically significant. The chondrocyte CM contained 164
pg/ml (± 5 pg/ml) of BMP-2 on Day 3 and the value increased to 229 pg/ml (± 40 pg/ml)
by Day 14. Between Day 14 and Day 21 the BMP-2 concentration leveled out in the
chondrocyte CM. The osteoblast CM contained 178 pg/ml (± 21 pg/ml) on Day 3 and the
value increased to 315 pg/ml (± 63 pg/ml) on Day 21. The TGF-β1 and BMP-2
concentration of the fresh medium (not exposed to cells) was subtracted from the
concentration for the CM, so the concentrations reported are only for TGF-β1 and BMP-2
that was produced by the cells.
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Figure 6.3: Results of the real time RT-PCR for the osteogenic markers bone sialoprotein (A) and
osteocalcin (B). The results are reported as relative expression to GAPDH using the ∆∆Ct
method. Error bars represent the SD. Asterisks (*) signify statistically significant differences
(p< 0.05).

181

Figure 6.4: Results of the real time RT-PCR for the chondrogenic markers sox9 (A), aggrecan
(B) and collagen Type II. The results are reported as relative expression to GAPDH using the
∆∆Ct method. Error bars represent the SD. Asterisks (*) signify statistically significant
differences (p< 0.05).

Figure 6.5: Results from the ELISAs detailing the amount of TGF-β1 (A) and BMP-2 (B) present
in the chondrocyte CM and osteoblast CM. Error bars represent the SD(n=3).
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Discussion
The objective of this study was to investigate the effect of mechanical stimuli in
combination with CM on the osteogenic and chondrogenic differentiation of
mesenchymal stem cells. Osteoblasts and chondrocytes naturally reside in close proximity and
have intimate interactions during bone development and regeneration, so paracrine signaling
between the two cell types may be directed in vitro to optimize the differentiation of
mesenchymal stem cells. In addition, mechanical stimuli can enhance the production of

extra cellular matrix from osteoblast and chondrocytes. It follows that these two stimuli
could have a synergistic effect on the osteogenic and chondrogenic differentiation of
MSCs and lead to a superior tissue engineered construct. Osteogenic samples were
cultured in bioreactors with and without chondrocyte CM and with and without the
application of HP. In addition, chondrogenic samples were cultured in bioreactors with
and without osteoblast CM and with and without the application of HP.
The sGAG production in the CM samples and the HP samples each showed
significantly higher production of sGAG as compared to the samples without any CM or
HP. However, they did not show any significant difference between each other,
suggesting that neither stimulus had a greater effect than the other. In addition, the
samples that were administered CM and HP showed a higher sGAG production as
compared to CM samples and HP samples, suggesting that there is a synergistic effect
between osteoblast CM and HP. The results of the RT-PCR for sox9, aggrecan, and
collagen type II also had similar results. The results of the RT-PCR showed an obvious
synergistic effect when both CM and HP are combined.
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Some of the results seen for the chondrogenic differentiation are somewhat
contradictory. The sGAG production and the collagen Type II expression both showed a
synergistic effect between CM and HP, while the expression of sox9 and aggrecan were
not significantly increased when CM and HP were applied together. A logical
explanation for this discrepancy is the time point at which the assays were performed.
The endpoint for the study was Day 21, which was chosen to determine the more long
term effects of CM and HP. However, this time point may have been too late to detect
changes seen in earlier markers. The nuclear transcription factor Sox9, is one of earliest
markers expressed in cells undergoing chondrogenesis, and the expression has been
shown to decrease later in the differentiation process [8, 9]. Conversely, collagen Type II
and sGAG are components of the cartilage extra cellular matrix and are markers for the
middle to late stages of chondrogenic differentiation [10]. Similar comments can be
made about the osteogenic samples as well. There was no significant difference between
the ALP activity of any of the groups, but the expression of both osteocalcin and bone
sialoprotein was significantly increased when CM and HP were combined. ALP is an
early marker for osteogenic differentiation, and the Day 21 time point again may have
been too late to detect any effects of the CM and HP.
The ELISA results agree with previous studies that have shown that both
chondrocytes and osteoblasts produce TFG-β1 [11-13]. TGF- β1 is among the most
potent inducers of chondrogenic differentiation [10] and likely the TGF- β1 produced by
the osteoblasts contributed to the changes seen when CM was administered. In addition
there is evidence that TGF- β1 is important in osteogenic differentiation as well [14, 15].
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Both conditioned media also contained BMP-2 and the production increased throughout
the study. Again these results support other studies that have shown that both osteoblasts
and chondrocytes produce BMP-2 [16-18]. It is well known that BMP-2 has strong
osteogenic effects on MSCs, but BMP-2 is also a powerful inducer of chondrogenic
differentiation and has been shown to stimulate the expression of Type-II collagen,
aggrecan and sox9 by MSCs cultured in alginate [19]. While TGF- β1 and BMP-2 were
both present in the CM and known to affect osteogenic and chondrogenic differentiation,
they are certainly only two of the soluble factors present in the CM affecting the
chondrogenic and osteogenic differentiation of the MSCs. There is likely a complex
relationship between numerous soluble factors that is yet to be determined.
The results suggested that intermittent hydrostatic pressure enhanced the
chondrogenic differentiation of the MSCs encapsulated in agarose. In human joints,
cartilage is exposed to stresses between 0.1 and 10 MPa depending on the location, and
the human walking cadence generally is between 0.5 to 1 Hz [2]. The HP and frequency
used in this study are both within those ranges. Several studies have focused on the
effect of HP on the chondrogenic differentiation of MSC and the maintenance of
chondrocytes. Overall, it has been demonstrated that dynamic HP is typically beneficial
with increases in Type II collagen, GAG content and chondrogenic RNA expression [1,
20], whereas static HP has been found to have no effect or a suppressive effect [2, 21].
Additionally, studies have shown that multiple days of HP application are required for an
effect, and the maximum effects of HP may be delayed until several weeks after removal
of the stimulus [22]. In comparison, little has been written on the effect of hydrostatic
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pressure on the osteogenic differentiation of MSCs. The majority of studies have focused
on the application of mechanical strain and fluid shear stress. However, Liu and
coworkers [23] did investigate the effect of HP on the early osteogenic differentiation of
MSCs. They showed that hydrostatic pressure strongly stimulated the expression of
osteogenic-related factors of totally undifferentiated MSCs. Furthermore, the
undifferentiated MSCs were highly sensitive to pressure exposure; whereas after
osteoinduction the cells were not as sensitive to pressure. This finding may shed some
light on our finding that HP alone did not significantly increase osteogenic
differentiation. In our study the cells were also receiving osteogenic medium and the
samples were assessed at later time points, which may explain the lack of significant
differences seen.
The combination of hydrostatic pressure and conditioned media that contains
cytokines, such as TGF-β1 and BMP-2, may stimulate similar down-stream pathways
leading to additive or synergistic effects. For example, both HP and TGF- β1 have been
shown to increase tissue inhibitors of metalloproteinase (TIMP) expression in
chondrocytes [24]. HP is known to alter the conformation of cell membrane ion transport
pathways thereby influencing other down-stream processes [25] and a recent study has
shown that intracellular Ca2+ mobilization can significantly affect cell response to TGFβ1 [26]. Ultimately, several different cell-signaling pathways are likely involved, with
feedback loops either complementing or antagonizing the final downstream effect.
Though the exact mechanism is not clear, the results suggest that for the pressure and CM
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used in this study (300 kPa at 0.5 Hz and 50% CM) there was a synergistic effect on
chondrogenic and osteogenic differentiation.
To the best of our knowledge, this is the first study that has investigated the
synergistic effects of conditioned media and hydrostatic pressure on the chondrogenic
and osteogenic differentiation of mesenchymal stem cells. However, some investigators
have examined the synergistic effect of HP and soluble growth factors, which can provide
some useful comparisons. Gunja and coworkers [27] evaluated the combined effects of
TGF-β1 and HP on meniscus cells seeded on polylactide constructs. They found that the
combination of 10 ng/ml of TGF-β1 and 10 MPa, 0 Hz of HP generated the highest
overall biochemical and biomechanical properties. In a study by Miyanishi and
coworkers [28], the effects of intermittent hydrostatic pressure and TGF-β3 on
chondrogenesis of adult human mesenchymal stem cells was investigated. HP was
applied to MSCs in pellet culture at a level of 10 MPa and a frequency of 1 Hz for 4 h per
day. MSCs responded to the addition of TGF-β3 and HP individually by increased
expression of sox9, Type II collagen, and aggrecan during a 14-day culture period.
Applying HP in the presence of TGF-β3 further increased the expression of sox9, Type II
collagen, and aggrecan. In a study by Kim and coworkers [29], the effects of mechanical
stimulation on chondrogenesis of MSCs in a 3D co-culture system was evaluated.
Chondrocytes and MSCs were cultured in chondrogenic differentiation medium
containing 10 ng/mL TGF-β1. MSCs and chondrocytes were suspended in different
alginate beads with the different beads being separated by a membrane and HP was
applied for 3 days. The differentiation of the MSCs and chondrocytes were affected by
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the mechanical stimulation on Day 14 day, as determined by an increase in GAG
production and expression of chondrogenic markers. The results suggested that during
co-culture, secretion from chondrocytes, which are fully developed, tended to promote
differentiation of MSCs when stimulated with mechanical stimulation. On the other
hand, Zeiter and coworkers [30] found some contradictory results when they investigated
the hypothesis that TGF-β1, BMP-2 and hydraulic pressure may act synergistically on
chondrogenic differentiation of MSCs. Aggregates of MSC were cultured in the presence
of 10 ng/ml TGF-β1, 50 ng/ml BMP-2 or both. Half of the samples were loaded for 4
hours per day with 0.5-3 MPa cyclic hydraulic pressure at 1 Hz. Cells responded to the
presence of TGF-β1 with an up-regulation of chondrogenic genes and GAG content.
However, the concentrations of BMP-2 and parameters for pressure did not induce or
modulate chondrogenesis of the MSCs.
Future work is needed for more in-depth evaluation of different parameters of
hydrostatic pressure. Variables such as magnitude, frequency, and duration may have an
impact on the reaction of the MSCs. In addition, earlier time points need to be examined
to better evaluate the effects on earlier differentiation markers. As this was a preliminary
study, murine cells were used to gain a baseline for future work. Future work will
involve the use of human cells to evaluate the translation of the results in this study from
murine cells to human cells. Finally, these results will also be translated into the creation
of an osteochondral construct cultured with HP and CM to enhance the generation of
engineered osteochondral tissue.
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Conclusion
In conclusion, both osteoblast CM and intermittent HP individually enhanced the
chondrogenic differentiation of MSCs. In addition, there is evidence that there is a
synergistic interaction between CM and HP on chondrogenic differentiation. The results
also suggest that the combination of chondrocyte CM and HP significantly enhanced the
osteogenic differentiation of MSCs, while the individual stimuli did not have a significant
effect. Both the chondrocyte CM and osteoblast CM contained considerable amounts of
TGF-β1 and also contained BMP-2 that were generated by the cells. These cytokines, in
addition to others, likely contributed to the effects of the CM.
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CHAPTER 7
CELL INFILTRATION, VIABILITY AND OSTEOGENIC DIFFERENTIATION
IN LARGE TISSUE ENGINEERING SCAFFOLDS CONTAINING
CAPILLARY CHANNEL FIBER BUNDLES
Introduction
Osteochondral tissue engineering targets the repair of cartilage and bone tissue
that has been damaged either by trauma or osteoarthritis. However, the size of tissue
constructs that can be created is limited, and a major shortcoming of osteochondral tissue
engineering is that the size of the grafts that can be generated is small relative to the size
of the defects that they are meant to treat. In addition, autologous osteochondral grafting
or mosaicplasty, often referred to as the gold standard for the treatment of cartilage
defects and osteoarthritis, fails in the therapy of large lesions measuring more than 20–
25 mms in diameter [1]. Thus there is a need for a tissue engineering approach that can
address large osteochondral defects that currently typically need unicompartmental or
total arthroplasty.
The size constraints that osteochondral tissue engineering currently faces are
largely due to the non-homogeneous growth of cells on the traditional „porous block‟
scaffolds, which prevents the formation of a functional construct from surface to core.
This outcome is due to two major limiting factors: lack of uniform cell seeding through
the entire thickness of the scaffold and the limited mass transfer of nutrients and removal
of waste. Because of the complex architecture of many 3D scaffolds, dispersing a high
density of cells with high efficiency and uniformity throughout the scaffold volume is
difficult [2]. Initial cell number and cell spatial distribution play an important role in
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determining subsequent cellular processes critical for tissue development, including
proliferation and differentiation, which in turn determine the properties of the final
construct. A high number of seeded cells can improve structural stability and biochemical
composition of the engineered tissues [3, 4]. Furthermore, uniform cell distribution
throughout the scaffold is critical for the regeneration of tissues [5]. An additional factor
in the survival of thick 3D tissues is the delivery of oxygen and nutrients to the entire
construct, and waste removal from the construct [6]. The movement of nutrients to cells
and removal of waste products from the cells in the pores is dependent on molecular
diffusion, due to the lack of a vascular system. However, nutrients can be depleted
before reaching the inner core of the construct, and waste products can accumulate. Cells
that do migrate into the core can become necrotic, and so the cell population is commonly
concentrated at the periphery of the scaffold [7]. During in vitro culture, larger tissueengineered constructs can be supplied with nutrients, for instance in perfusion
bioreactors. However, after implantation of tissue constructs, the supply of oxygen and
nutrients to the implant is often limited by diffusion processes that can only support cells
in 100–200 μm proximity of a blood supply [8]. In order for implanted tissues of greater
size to survive, additional strategies for improving the cellular distribution upon seeding
and enhancing the delivery of nutrients to the cells within the tissue are necessary.
The design of the novel osteochondral construct that was discussed in Chapter 3 is
aimed at addressing the current size constraints of osteochondral tissue engineering. The
design incorporates bundles of capillary channel or “wicking” fibers that run through the
thickness of the scaffold. It is hypothesized that the capillary action in the fiber bundles
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will pull cells into the interior of the scaffold and facilitate fluid movement to provide the
cells with nutrients once they have reached the interior. The objective of the study was to
evaluate if larger constructs are feasible when incorporating capillary channel fibers
within the scaffold. The study was also conducted in a newly developed bioreactor test
system that can accommodate larger constructs and can be used to evaluate cell seeding
and infiltration.
The study was split into two different phases, the first focused on evaluating the
initial cell infiltration into the scaffold, and the second focused on investigating the
cellular viability and osteogenic differentiation after 3 weeks of culture. The study
assessed three different scaffold types: 1) porous PL/PCL/HAP scaffolds 2) porous
PL/PCL/HAP scaffolds containing capillary channel fibers and 3) large capillary channel
fiber bundles. The PL/PCL/HAP scaffold without fibers served as a control, while the
other two designs correspond to the two osteochondral constructs that were designed and
discussed in Chapter 3. The diameter of the scaffolds was approximately 20 mm, which
is at least twice the size of current successfully seeded osteochondral tissue engineered
devices in the literature [9-13]. For the purpose of this study, the fibers within the
PL/PCL/HAP scaffolds were oriented along the long axis of the cylinder. Pictures of the
preliminary design of the construct in Chapter 3, in contrast, show the fibers running
across the diameter of the cylinder. The orientation of the fibers was modified for three
reasons. First, the mechanical integrity of the construct is improved with the fibers
running parallel to the cylinder axis. Second, this orientation can allow better
communication between the bone phase and the cartilage phase, which can be
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advantageous as demonstrated by the previous conditioned media studies in Chapter 2.
Finally, as the diameter of the construct increases, additional fibers can be added if they
are oriented along the axis.

Methods and Materials
Bioreactor Design
The study was conducted in a newly developed bioreactor test system that can
accommodate larger constructs and can be used to evaluate cell seeding and infiltration
(Figure 7.1). The test system is composed of a cylindrical chamber (PN-16-P, Parker
Hannifin Corp., Tucson, AZ) in which the construct is cultured. The construct is
surrounded by numerous small polypropylene tubes with a diameter of approximately 1
mm that are also contained within the chamber. The ends of the chamber are threaded to
attach a compression fitting (GAFS-816, Parker Hannifin Corp., Tucson, AZ)that
connects to tubing running through a peristaltic pump. The chamber and compression
fittings are made of perfluoroalkoxy (PFA), a type of fluoropolymer with properties
similar to Teflon® (polytetrafluoroethylene). The chamber has an inside diameter of 1
in. and a length of 2 in. The small tubes that surround the construct within the chamber
serve as an alternate path for the cells to follow. In most bioreactors that are used to seed
a scaffold, the cells are forced into the scaffold and the scaffold acts like a filter, simply
catching the cells as they have no other place to go. The newly designed setup allows
cells to attach to the scaffold, or to flow past the scaffold and interact with the scaffold
again when the cells are pumped through the system again. This configuration enables
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Figure 7.1: 3D rendering of the newly developed test system used to test cellular infiltration. The
constructs are placed in the middle (A) and surrounded by small tubes (B) within the chamber.
The ends of the chamber are threaded (C) to attach to compression fittings (D) that are then
connected to tubing.

evaluation of the effect of the wicking fibers on cellular infiltration during the seeding
process.

Scaffold Production
Three different scaffold configurations were tested in this study (Figure 7.2). The
first configuration was a porous scaffold made of poly-L-lactide/
polycaprolactone/hydroxyapatite (PL/PCL/HAP) that did not contain any bundles of
capillary channel fibers. The second was a porous scaffold made of PL/PCL/HAP that
contained seven bundles of four capillary channel fibers. The pattern in which the fiber
bundles were arranged resulted in a distance of approximately 6 mm between the center
of each fiber bundle and between the center of the outer bundles and the edge of the
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Figure 7.2: Pictures of the three scaffold configurations that were compared.

scaffold. The last configuration was a large bundle of capillary channel fibers. The
entire scaffold was a bundle of 50 fibers. The fibers embedded in the scaffold and used
in the large bundle were made of Tecoflex, a thermoplastic polyurethane. Each scaffold
type had a diameter of approximately 20 mm and a thickness of approximately 10 mm.
Four samples (n=4) were used for each assay in the study.
As with the previous studies, the porous scaffolds were produced using a solvent
evaporation/porogen leaching method. However due to the size of the scaffolds and the
inclusion of numerous fiber bundles, the procedure was adapted. In the original
procedure, as described in Chapters 2 and 3, the 75:25 poly-L-lactide/ polycaprolactone
co-polymer (PL/PCL) was dissolved in chloroform, mixed with hydroxyapatite (HAP),
and then poured on top of the glucose porogen inside the mold. However, when this
procedure was used to create the large scaffolds it resulted in scaffolds that were
collapsed in the middle (Figure 7.3A). When the scaffolds were cut in half it was
revealed that the scaffolds contained a large hole in the middle where the dissolved
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polymer had not reached (Figure 7.3B). To correct this problem, the procedure was
adapted as follows. PL/PCL was dissolved overnight in biotech grade chloroform
(Sigma, St. Louis, MO) at a concentration of 0.15 g/mL. HAP (Federal Laboratories
Corp., Alden, NY) was then added to the solution at a concentration of a 10% W/V and
mixed with a magnetic stir bar. The PL/PCL/HAP mixture was then mixed with an equal
volume of glucose, which had been passed through a sieve to extract grain sizes of 250
µm – 425 µm. The resulting slurry was then poured into 22 mm diameter molds made
from Teflon piping and the molds were covered with parafilm, and two small holes were
made in the parafilm to avoid rapid evaporation of the chloroform. The molds were left
in a chemical hood for 12 hours to allow the chloroform to evaporate. The scaffolds were
then removed from the molds and placed in mesh containers that were suspended in 750
ml of distilled water that was continually stirred with a magnetic stir bar. The scaffolds
remained in water for 48 hours, and the water was replenished every 12 hrs. The
scaffolds were then removed from the water and allowed to dry for 24 hours. By mixing
the dissolved PL/PCL with the glucose before it was poured into the mold, the polymer
filled the entire mold, resulting in quality scaffolds (Figure 7.3C). To embed capillary
channel fibers in the scaffolds, a very similar process was used (Figure 7.4). A thin
circular piece of Teflon (diameter=22 mm, thickness=1 mm) with holes drilled in it in the
pattern that the fibers were to be arranged in (as seen in Figure 7.2) was attached to the
top and bottom of the mold. The fiber bundles were then run through the holes in the top
piece through the mold and out the bottom piece of Teflon. This allowed the fiber
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bundles to be held in place in the mold and the slurry of PL/PCL/HAP was then poured
around the fibers. The same procedures as above were then followed.

Figure 7.3: The scaffolds on the left and middle demonstrate the limitations resulting
from pouring dissolved polymer on top of the glucose in the mold. The scaffolds were
collapsed (A) and contained a large hole in the middle of the scaffold (B). Mixing the
dissolved polymer with the glucose before pouring into the mold produced quality
scaffolds (C).
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Figure 7.4: Schematic of the production process used to produce the large scaffold with
bundles of embedded capillary fibers.
Cell Seeding and Bioreactor Culture

The study was split into two different phases, the first focused on evaluating the
initial cell infiltration into the scaffold, the second focused on investigating the cell
viability and osteogenic differentiation after 3 weeks of culture. For the first phase, all
scaffold types were sterilization with ethylene oxide for 24 hours in an AN74i cabinet
sterilizer (Anprolene, Haw River, NC) with a 5 cc ampoule (Anprolene, Haw River, NC),
followed by a degassing time of 48 hours under house vacuum at ambient temperatures.
All parts of the bioreactor were sterilized in an autoclave at 134 OC and 30 psi for 45
minutes. After sterilization, the scaffolds were soaked in medium containing FBS for 24
hours to allow proteins to attach to the surface. The scaffolds were then placed in the
middle of the bioreactor chambers surrounded by the small tubes. The bioreactors were
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then connected to the tubing running through a peristaltic pump and the entire system was
filled with base medium consisting of Dulbecco‟s Modified Eagle Medium (DMEM)
(Invitrogen, Gibco, Carlsbad, CA), 10% fetal bovine serum (FBS) (Invitrogen, Gibco,
Carlsbad, CA), 1% antibiotic/antimycotic (Invitrogen, Gibco, Carlsbad, CA), 0.2%
fungizone (Invitrogen, Gibco, Carlsbad, CA). A volume of 1 ml of medium containing
1.5x107 cells was then injected into each bioreactor through a three-way stop cock valve
(Cole-Parmer, Vernon Hills, IL). The cell suspension was then pumped through the
system at rate of approximately 0.3 ml per minute. The scaffolds were removed from the
bioreactor after 2 days to assess the initial cellular infiltration. When the scaffolds were
removed they were cut in half as shown in Figure 7.5. The half of the scaffold in the
upstream position was defined as the “top” and the half in the downstream position was
defined as the “bottom”. Cutting the scaffolds in half allowed us to determine if the fiber
bundles resulted in a more uniform cellular distribution.
For the second phase the setup was the same and the same number of cells were
used. The samples were cultured in base medium for 24 hrs to allow the cells to attach.
The medium was then replaced with osteogenic differentiation medium consisting of
DMEM, 10% FBS, 1% antibiotic/antimycotic, 0.2% fungizone, 50 µg/ml L-ascorbic acid
2-phosphate (Sigma, St. Louis, MO), 3 mM β-glycerophosphate (Sigma, St. Louis, MO),
and 10 nM dexamethasone (Sigma, St. Louis, MO). The samples were cultured for 21
days and the long term cell viability and osteogenic differentiation was assessed. As with
the 2 day samples the scaffolds were cut in half and the top and bottom were defined as
described in Figure 7.5.
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Figure 7.5: When the scaffolds were removed from the bioreactors they were cut at the
indicated line. The “top and “bottom” were then defined as shown with relation to the
flow direction in the bioreactor.

Cell Number
The number of attached cells was quantified using the CytoTox 96® NonRadioactive Cytotoxicity Assay (Promega, Madison, WI) that facilitates the measurement
of lactate dehydrogenase (LDH) that is released upon cell lysis, which is proportional to
the number of cells. The samples were removed from the bioreactors, cut in half, washed
three times with phosphate buffered saline (PBS) (Sigma, St. Louis, MO), 2 ml of
deionized water were added to each sample, and three freeze-thaw cycles were performed
to lyse the cell membranes. Volumes of 50 μl were removed from each sample in
triplicate and transferred to a 96 well plate. A volume of 50 μl of reconstituted substrate
mix was added to each well and incubated for 30 minutes at room temperature. A
volume of 50 μl of stop solution was then added to each well. Samples positive for LDH
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are cherry red. The absorbance was then read at 490 nm. A standard curve was produced
prior to the study to correlate the absorbance reading to the cell number. To generate the
standard curve, the assay was conducted using cell populations of known quantity
ranging from 0 to 1 million cells. The resulting equation is shown in equation 7.1. The
absorbance values from the scaffolds were plugged into the equation to determine the
number of cells attached to the top and bottom of the scaffolds

Cell number = 276,908*(absorbance) – 167,627

Equation 7.1

ALP Activity and Total Protein Content
Scaffolds from the 21 day periods of the study were used to assess the alkaline
phosphatase (ALP) activity. The samples were removed from the bioreactors, cut in half,
washed three times with PBS, then 2 ml of deionized water was added to each sample,
and three freeze-thaw cycles were performed to lyse the cell membranes. A phosphatase
substrate solution was created by mixing 5ml of deionized water with every 20 mg of
phosphatase substrate (Sigma, St. Louis, MO). The phosphatase substrate solution was
mixed with an equal amount of alkaline buffer solution (Sigma, St. Louis, MO) to create
the working reagent. A volume of 500 µl of the working reagent was placed in 24-well
plates, using the same number of wells as samples; the plates were then incubated for 15
minutes at 37o C. Subsequently, 100 µl of the sample lysate was added to each sample
well and incubated for 30 minutes at 37o C, after which 1.5 ml of 0.25N NaOH (Fisher
Scientific Company, Waltham, MA) was added to each well to stop the reaction.
Aliquots in the amount of 200 µl were then moved in triplicate to a 96-well plate, and the
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absorbance was read at 410 nm using a MRX Micoplate Reader (Dynex Technologies,
Germany). A standard curve was generated using p-nitrophenol (Sigma, St. Louis, MO)
standard solution diluted with 0.02 N NaOH. The ALP activity was determined using the
standard curve and measured in sigma units, which are defined as 1μmol of p-nitrophenol
converted per hour.
The protein content in each sample was determined by following the standard
protocol for the BCA Total Protein Kit (Pierce, Rockford, IL). The results from the ALP
assay were normalized by the protein content determined by the BCA total protein assay.

RNA Isolation and Real Time RT-PCR
After the Day 21 scaffolds were cut in half, the samples being used for RT-PCR
were further reduced and cut into small pieces to aid the lysing buffer in contacting all of
the cells on the scaffold. RNA was isolated directly from the PL/PCL/HAP scaffolds
using the RNeasy mini kit (Qiagen AG, Switzerland). The quality and concentration of
total RNA was determined using the Agilent RNA 6000 Nano Kit (Agilent Technologies,
Santa Clara CA), the Agilent 2100 Bioanalyzer, and the 2100 Expert software. Equal
amounts of total RNA were used for real time RT-PCR using the QuantiFast SYBR
Green RT-PCR Kit (Qiagen AG, Switzerland) in the Rotor-Gene 5.0.28 light cycler
(Corbett Life Science, Sydney, Australia). The markers that were analyzed were
osteocalcin and bone sialoprotein. GAPDH was used as a housekeeping gene. The
primer sequences can be seen in Table 7.1. Relative expression was determined using the
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∆∆Ct method with GAPDH as the reference gene and undifferentiated D1 cells grown on
a 2D surface were used as control samples (Appendix A).

Table 7.1: Primer sequences used for RT-PCR

F
R

Sequence
5' - AGACCGCCTACAAACGCATC - 3'
5' - GATCAAGTCCCGGAGAGCAG - 3'

Melting Temp.
(oC)
57.8
57.4

Bone Sialoprotein

F
R

5' - TACGGAGCAGAGACCACACC - 3'
5' - CTTCCTCGTCGCTTTCCTTC - 3'

58.8
55.7

GAPDH

F
R

5' - GAACGGATTTGGCCGTATTG - 3'
5' - CGTTGAATTTGCCGTGAGTG - 3'

54.3
54.9

Primer
Osteocalcin

Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=4). Unpaired
t tests were used to make comparisons, with a significance level of p < 0.05.

Results
Cell Number
The results of the CytoTox 96 assay, conducted to determine the number of cells
attached to top and bottom halves, of the scaffolds are shown in Figure 7.6. On Day 2,
there was a dramatic difference between the number of cells that were attached to the top
and bottom of the scaffolds without any fibers. The bottom of the scaffolds had nearly no
cells attached, while approximately 615,000 ± 9400 cells attached to the top of the
scaffolds. A fairly uniform distribution of cells attached to the scaffolds with fiber
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bundles was evident. No statistical difference was noted between the number of cells
attached to the top and bottom of the scaffolds with fibers. Cells were uniformly
distributed and attached to the large fiber bundles; no significant difference in cell
number was detected between the top and bottom of the large bundles. The number of
cells attached to each half of the large fiber bundles was lower than those attached in the
scaffold with fibers. In addition, there were significantly more cells attached to the
bottom of the scaffolds with fibers as compared to the bottom of the scaffolds without
fibers. On Day 21 similar patterns were seen. There was a significant difference
between the number of cells attached to the top and bottom of the scaffolds without
fibers. The distribution of cells in the scaffolds with fibers was still uniform, and there
was no statistical difference between the cell number in the top versus the bottom of the
scaffold. The distribution on the large fiber bundles was also still uniform and there was
no statistical difference between the top and bottom. There were still significantly more
cells attached to the bottom of the scaffolds with fibers than the bottom of the scaffolds
without fibers.
The number of cells attached to the top and bottom of the scaffolds was added
together to obtain the total number of cells attached to the entire scaffold (Figure 7.7).
The total number of cells attached to the scaffolds with fibers on both Day 2 and Day 21
was significantly higher as compared to both the scaffolds without fibers and the large
fiber bundles. There was no difference between the number of cells attached to the
scaffolds without fibers and the large fiber bundles on either day.

207

Figure 7.6: Results of the CytoTox 96 assay to determine cell number. Values represent
the number of cells attached to only the top half or bottom half of the scaffold. Error
bars represent the standard deviatioin (SD). Asterisks (*) signify statistically significant
differences (p< 0.05) between top and bottom in scaffolds without fibers. Pound symbols
(#) signify statistically significant differences (p<0.05) between the bottom of scaffolds
with fibers and scaffolds without fibers.

Total Protein Content and ALP Activity
The results of the BCA Total Protein assay are shown in Figure 7.8. The protein
content was only determined on Day 21. The protein content was significantly higher on
the top of the scaffolds without any fibers as compared to the bottom. The protein
content was similar between the top and bottom of the scaffold with fibers as there was
no statistical difference. The protein content for the large fiber bundles was also even
and there was no statistical difference between the top and bottom. Additionally, there
was significantly more protein in the bottom of the scaffold with fiber bundles than the
bottom of the scaffold without fibers.
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Figure 7.7: Results of the CytoTox 96 assay to determine total cell number. Values
represent the total number cells attached to the entire scaffold. Error bars represent the
SD. Asterisks (*) signify statistically significant differences (p< 0.05) between scaffolds
without fibers and scaffolds with fibers. Pound symbols (#) signify statistically significant
differences (p<0.05) between the scaffolds with fibers and the large fiber bundles.

The results of the ALP assay normalized by the total protein content are shown in
Figure 7.9. There was no statistically significant difference in the normalized ALP
activity of the cells attached to the top and bottom of the samples for any of the scaffold
types. In addition, there was no statistically significant difference in the normalized ALP
activity between each scaffold type.
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Figure 7.8: Results of the BCA Total Protein assay on Day 21. Error bars represent the
SD. Asterisk (*) signify statistically significant differences (p< 0.05) between top and
bottom in scaffolds without fibers. Pound symbol (#) signify statistically significant
differences (p<0.05) between the bottom of scaffolds with and without fibers.

Figure 7.9: Results of the alkaline phosphatase assay normalized by the total protein
content on Day 21. Error bars represent the SD.
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Real Time RT-PCR
The bone sialoprotein expression (BSP) and osteocalcin (OC) expression are
shown in Figure 7.10. Cells attached to both the top and bottom of the scaffolds with and
without fibers showed high levels of BSP and OC expression. However, there was not a
statistically significant difference between the top and bottom for any of the scaffold
types. BSP and OC was being expressed in the large fiber bundle on Day 21, however
the expression was lower as compared to the other two scaffolds.

Figure 7.10: Results of the RT-PCR for bone sialoprotein expression (A) and osteocalcin
expression (B). The results are reported as relative expression to GAPDH using the
∆∆Ct method. Error bars represent the SD.
Discussion
The objective of this preliminary study was to evaluate the feasibility of creating
large tissue engineering constructs with the use of capillary channel fiber bundles. The
initial cell infiltration and distribution was first assessed followed by the long term cell
viability and osteogenic differentiation. Both a uniform cell seeding distribution and the
delivery of oxygen and nutrients to support the long term viability of cells in the interior
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of the construct are vitally important to the success of large tissue engineered constructs.
However, these issues have been limiting factors in the engineering of large tissue and
there is an obvious need for strategies to improve cell distribution and viability in large
scaffolds.
At the study end points, the large scaffolds used in this study were cut in half,
creating a top portion, which was in the upstream position in relation to the flow of
medium and cells, and a bottom portion, which was in the downstream position in
relation to the flow of medium and cells. This process allowed investigation of the ability
of cells to infiltrate the entire thickness of the scaffolds. The Day 2 time point was used
to evaluate the initial cell infiltration and seeding distribution. As seen in Figure 7.6,
cells were not able to reach the entire thickness of the fiber-less scaffold as there was a
large number of cells attached to the top of the scaffold while there were almost no cells
attached to the bottom half of the scaffold. Conversely, cells were able to reach the entire
thickness of the scaffolds containing fiber bundles as there was an even distribution of
cells between the top and bottom of the scaffold. In addition, the cells attached to the
large fiber bundles were also evenly distributed between the top and bottom of the
construct. These results suggest that the fiber bundles are providing a means for the cells
to penetrate into the large scaffold that is not possible without the fibers. The total
number of cells attached to each scaffold type (Figure 7.7) on Day 2 suggests that the
fiber bundles not only enhanced the cell distribution, but also enhanced the cell seeding
efficiency. There were over twice as many cells attached to the scaffolds containing
fibers as the fiber-less scaffold. The total number of cells attached to the large fiber
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bundles, was also significantly lower than the scaffold containing fibers. This is likely
due to the biomaterial of the constructs and the surface area available for cellular
attachment. The fibers used in this proof of principle study were made of polyurethane,
which has been shown to have relatively low cell attachment levels [14, 15]. The
scaffolds containing fiber bundles contain HAP which shows good cell attachment levels
and a large surface area created by the numerous pores in the scaffold. However, the
important result seen with the large fiber bundle was the even distribution of cells.
The Day 21 end point was used to evaluate the long term viability of the cells and
osteogenic differentiation on each scaffold type. There were still a large number of
viable cells attached to both the top and bottom of the scaffold with fibers by Day 21
(Figure 7.6). While there was an increase in the number of cells attached to the bottom of
the scaffold without fibers, the number was still significantly lower than the number
attached to the top of that scaffold as wells as the bottom of the scaffolds with fibers.
These results suggest that the bundles of capillary fibers were also able to provide
nutrients to the cells that reached the entire scaffold, with nutrients allowing for them to
stay viable throughout the thickness of the scaffold for at least 21 days. ALP activity and
the expression of BSP and OC were used to assess the osteogenic differentiation of the
cells in the constructs. The ALP activity (Figure 7.9) was relatively low on both sides of
all of the scaffold types on Day 21 and there were no significant differences between any
of the groups. This is likely due to the fact that ALP activity is an early marker for
osteogenic differentiation and will decrease in later stages of differentiation [16]. The
ALP activity was tested on Day 21 and it is likely that the expression had already

213

decreased. There were high levels of BSP and OC in all of the scaffold types indicating
osteogenic differentiation for all constructs, but there were no significant differences
between the top and bottom of any of the scaffolds, nor was there a significant difference
between the scaffolds with and without fibers. This result indicates that the fiber bundles
did not influence the osteogenic differentiation of the cells that were present in the
constructs. However, it is important to realize the values that are reported in Figure 7.10
are relative expressions of the osteogenic markers. The same amount of total RNA was
used from each sample to run the RT-PCR and the expression of the osteogenic genes
were normalized to the GAPDH expression using the ∆∆Ct method. This means that the
expression of BSP and OC per cell was not influenced by the fiber bundles. However,
there were more cells and a better distribution of cells in the scaffold with fiber bundles;
thus, there were more osteogenic cells in the scaffold with fibers as well as a better
distribution.
Total protein production often correlates to cell number, but this correlation
cannot always be assumed since differentiated cells can produce extracellular matrix,
resulting in an increase in protein content without an increase in cell number. However,
it is still useful to normalize the ALP results by the total protein as it gives a ratio of the
osteogenic protein ALP that is being produced to the overall protein production.
Furthermore, this study confirmed the correlation between cell number and total protein
production (Figure 7.11). The total protein content on Day 21 followed the same patterns
as the cell numbers on Day 21. There was a linear relationship between the total protein
content and the cell number, with the best fit equation shown in Figure 7.11,
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corresponding to an R2 value of 0.9924. This result also provides some validation for the
use of the total protein content to normalize the ALP activity that was reported in
previous chapters.

Figure 7.11: Relationship between the total protein content and cell number was linear.
Perfusion bioreactors have been developed in various forms to aid the movement
of nutrients, waste products, and the initial seeding process in three dimensional culture
systems [2, 7, 17, 18]. In this study perfusion flow was used, but was not the focus of the
study and was not intended to aid in the cell infiltration. The perfusion rate that was
applied was only 0.3 ml/min which, using Equation 7.2, equates to an approximate
velocity of 10 μm/s in the bioreactor chamber. This velocity is very slow compared to
velocities used by others who have used perfusion flow to seed cells in a 3D scaffold.
Typically the velocities ranges from 500 μm/s – 10 mm/s [2, 7, 17, 18]. Since the
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velocity was so slow, the perfusion flow would have a minimal effect on the infiltration
of the cells into the constructs. While the application of a driving force on the media has
lead to some success in homogeneous scaffold populations, the design of the bioreactor in
this study was intended to serve as a model for the conditions that a construct may
experience when implanted into the body, rather than a method to seed the scaffolds.
This model allowed us to evaluate the effectiveness of the fiber bundles to draw cells into
the interior of the constructs.
v = 1.274 q / d2

Equation 7.2

where:
v = velocity (m/s)
q = volume flow (m3/s)
d = pipe inside diameter (m)
This proof of concept study showed the potential of using capillary channel fibers
to develop large tissue engineering constructs. The uniform distribution of cells within
the large scaffolds generated by the capillary channel fibers is an important factor that
contributes to the success of large tissue engineered constructs [4, 5]. A uniform cell
seeding has been shown to lead to a more uniform generation of tissue throughout
engineered tissues [2, 19]. Future studies will be needed to evaluate different
arrangements of fiber bundles within the scaffolds. Different patterns, different numbers
of fibers within the bundles, and different spacing between the bundles will likely have
an effect on the cellular distribution and viability. In addition, future studies should look
at not only the distribution of cells through the thickness of the scaffold, but also look at
the distribution of cells through the diameter of the scaffold. It would be constructive to
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determine if there were a similar number of cells attached to the outside of the scaffold as
compared to the inside. Finally, additional studies should evaluate constructs that contain
both the cartilage and bone phase of the construct together. This study focused on the
bone phase, as it is important to have a thick bone portion to anchor the construct in the
defect area, while the thickness of the cartilage is limited by the thickness of native
cartilage. However, it will be necessary to determine if the larger diameter of both
tissues together is feasible when the capillary channel fibers are present.

Conclusion
The results suggest that bundles of capillary channel fibers embedded in large
tissue engineering scaffolds as well as large fiber bundles can produce a uniform cell
distribution through the thickness of the scaffold. The total number of cells attached to
the entire scaffold was also increased with the presence of fiber bundles. In addition, the
cells are able to remain viable after 21 days of culture. Osteogenic differentiation
occurred in all scaffold types; however, it was not affected by the capillary channel
fibers. Yet the total number of cells undergoing osteogenic differentiation was higher in
the scaffolds containing fiber bundles.
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CHAPTER 8
OSTEOCHONDRAL TISSUE ENGINEERING WITH A NOVEL BIPHASIC
CONSTRUCT IN A BIOREACTOR SYSTEM SUPPLEMENTED WITH
CONDITIONED MEDIA
Introduction
Human articular cartilage and osteochondral defect repair is a challenging clinical
problem, because the ability of hyaline cartilage to respond to injury is poor [1]. Once
cartilage damage has occurred, an irreversible degenerative process can occur and will
often lead to osteoarthritis [2]. While current treatment options, including autologous
chondrocyte implantation (ACI) and autologous osteochondral grafting, have produced
some favorable results, they will often not produced consistent and reproducible
successes [3, 4]. The repair tissues have limited durability and show degeneration after
long-term follow-up [5]. Thus tissue engineering has developed as a prospective
approach for the repair of articular cartilage and osteochondral defects. Engineered
osteochondral implants may facilitate the fixation and integration with host tissue, and
therefore promote the regeneration of osteochondral defects. It is important to note that
articular osteochondral injury involves damage to both bone and cartilage. These tissues
have different intrinsic structures and properties and tissue engineering techniques should
mimic this physiological structure. A biphasic implant design would allow adequate
subchondral bone repair to subsequently support regeneration of the overlying cartilage.
Therefore, fabricating composite scaffolds with layers of different materials that can
benefit both bone and cartilage regeneration is potentially an advantageous technique for
osteochondral repair. Accordingly, a biphasic scaffold with a stratified two-layer
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structure for osteochondral tissue engineering was developed from biodegradable
synthetic and naturally derived polymers.
Although tissue engineering is an exciting potential treatment for osteochondral
defects, the quality of in vitro generated tissues is currently limited. This limitation is due
to an insufficient understanding of the impacts of specific biological, chemical and
physical parameters on tissue development. With the exception of clinical studies, in
vivo animal studies may provide the best method of evaluating tissue engineering
strategies. However, this approach is extremely costly and time consuming, and it is
often difficult to isolate and control individual stimuli [6]. Bioreactor systems can
provide reliable model systems for fundamental studies of cell biology and will play a
key role in improving the quality of engineered tissues, as they can allow researchers to
control the physical and chemical culture environment under defined conditions [7].
Thus far, the studies described in previous chapters have focused on the
individual aspects of developing a novel osteochondral tissue engineered construct. The
studies in Chapters 2 and 6 were focused on using conditioned media (CM) to enhance
mesenchymal stem cell (MSC) differentiation, while Chapters 3, 4 and 7 were focused on
the design and characterization of the construct itself. Finally, Chapters 5 and 6 were
focused on the use of a bioreactor system to provide appropriate culture conditions for the
cells. The objective of this final study was to combine the information that has been
gained in the previous studies about the three different areas of focus, in an effort to
generate and characterize a tissue engineered osteochondral construct. The study
consisted of stem cells cultured on the newly designed osteochondral construct, focusing
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on the barbed pin design due to the results of previous studies that revealed superior cell
attachment and differentiation as well as better mechanical properties. The biphasic
constructs were cultured in the modified bioreactor that is able to apply fluid flow and
hydrostatic pressure to each phase of the construct. In addition, the bone phase was
cultured with chondrocyte CM and the cartilage phase was cultured with osteoblast CM.
Furthermore, human mesenchymal stem cells (hMSCs) were used in this study to
determine if the findings from the murine studies would translate to human cells.

Methods and Materials
Construct Preparation
The porous scaffolds that were used for the bone phase were produced using a
solvent evaporation/porogen leaching method as described in Chapter 7. The resulting
porous PL/PCL/HAP scaffolds were in the shape of cylinders with a diameter of
approximately 6 mm and a height of approximately 6 mm, sized to fit the biochamber of
the bioreactor and contained a bundle of fibers embedded in the middle of the scaffold.

Conditioned Media
To generate chondrocyte CM to be used with the bone phase of the constructs,
human mesenchymal stem cells (hMSCs) (PT-2501; Lonza, Hopkinton, MA) were
expanded in standard cell culture flasks to produce enough cells for the study. Cells were
trypsinized and suspended in sterile 2% agarose at a concentration of 5x10 5 cells/ml. A
volume of 0.5 ml of the cell suspension was placed in the wells of a 12 well plates. The
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agarose was then placed at 40 C for 10 minutes to allow the agarose to gel. Chondrogenic
differentiation medium (PT-3003, Lonza, Hopkinton, MA) containing dexamethasone,
ascorbate, ITS+ supplement, GA-100, sodium pyruvate, proline, L-glutamine, and 10
ng/ml TGB-β1 was then added to the cultures. The cells were cultured at 37 0 C and 5%
CO2 in static conditions for the entire study. CM was collected at Days 7, 14, and 21 and
administered to the media reservoirs supplying the bone phases of the constructs. CM
from all agarose samples were mixed together to form one sample of CM and passed
through a 0.2 μm filter to remove any cells.
To generate osteoblast CM to be used with the cartilage phase of the constructs,
hMSCs were seeded on sterilized porous PL/PCL/HAP discs at a concentration of 5x105
cells per scaffold. Seeding took place in low attachment 12 well plates and the plates
were placed on an orbital shaker for the first 12 hours. Osteogenic differentiation
medium (PT-3002, Lonza, Hopkinton, MA) containing dexamethasone, L-glutamine,
ascorbate, pen/strep, and β-glycerophosphate was then added to the cultures. The cells
were cultured at 370 C and 5% CO2 in static conditions for the entire study. CM was
collected at Days 7, 14, and 21 and administered to the media reservoirs supplying the
cartilage phases of the constructs. CM from all osteogenic samples were mixed together
to form one sample of CM and passed through a 0.2 μm filter to remove any cells.

Cell Seeding and Construct Assembly
All scaffolds were sterilization with ethylene oxide for 24 hours in an AN74i
cabinet sterilizer (Anprolene, Haw River, NC) with a 5 cc ampoule (Anprolene, Haw
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River, NC), followed by a degassing time of 48 hours under house vacuum at ambient
temperatures. After sterilization, the scaffolds were soaked in medium containing FBS
for 24 hours to allow proteins to attach to the surface. Then hMSCs were seeded on the
scaffolds at a concentration of 5x105 cells per scaffold. Seeding took place in low
attachment 24 well plates and the plates were placed on an orbital shaker for the first 12
hours. Next, hMSCs were suspended in 2% low melting temperature agarose (Sigma, St.
Louis, MO) at a concentration of 5x105 cells/ml. The cell suspension was placed in a
polystyrene 96 well plate with a diameter of 7 mm to a height of 6 mm. The cell seeded
scaffolds for the bone phase were inserted in the agarose filled molds to an approximate
depth of 2 mm. The molds were then placed at 4o C for 10 minutes to allow the agarose
to gel. This resulted in a 4 mm cell seeded agarose phase representing the cartilage phase
on top of 4 mm cell seeded porous PL/PCL/HAP scaffold separated by the 2 mm
agarose/scaffold interface region, all with a diameter of 7 mm.

Bioreactor Culture
After assembly, the constructs were placed in the biochambers of the bioreactor
and the entire system was assembled under sterile conditions. The bioreactor used was
the newly modified version as described in Chapter 5 and pictured in Figure 5.6. The
bioreactor consists of two biochambers, one corresponding to the cartilage phase and one
to the bone phase. A pressure chamber is connected to each biochamber with a syringe
attached to the top of each pressure chamber. The syringes are then connected to a
computer controlled pressurized air supply. The bioreactor design provided a means of
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applying both perfusion flow and hydrostatic compression to the biochamber
environment (Figure 8.1). Solenoid valves attached to the inlet and outlet of both phases
remain open during perfusion flow to allow a peristaltic pump (Cole-Parmer, Vernon
Hills, IL) to drive medium through the biochamber. Conversely, the pump is turned off
and the solenoid valves are closed prior to commencing hydrostatic compression to
develop a fixed fluid volume of medium within the biochamber. The introduction of
sterile pressurized air into the top of the syringes by the adapter assembly presses on the
piston within the syringe. The piston presses down on the fluid within the syringe,
creating a hydrostatic pressure in the biochamber. The perfusion rate for both the bone
and cartilage phases was 0.7 ml/min throughout the study. The hydrostatic pressure
schedule consisted of 2.5 hours of perfusion flow followed by 30 minutes of intermittent
hydrostatic pressure at a magnitude of 300 kPa and a frequency of 0.5 Hz. This pattern
resulted in a 3 hour cycle that was repeated continuously for a total of 8 cycles per day
and a total of 4 hours of intermittent hydrostatic pressure per day. The cartilage phase of
each bioreactor was connected to a medium reservoir containing 30 ml of chondrogenic
medium and 30 ml of osteoblast CM. The bone phase of each bioreactor was connected
to a medium reservoir containing 30 ml of osteogenic medium and 30 ml of chondrocyte
CM. Pictures of the bioreactor setup can be seen in Figure 8.2
Complete media changes were performed on Days 7, 14 and 21. The study was
timed such that the CM that was administered on Day 0 was from chondrocytes or
osteoblasts at Day 7, the CM administered on Day 7 was from cells at Day 14, the CM
administered on Day 14 was from cells at Day 21 and the CM administered on Day 21
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was from cells at Day 28. This schedule was applied to allow the cells that were
producing the CM to start the progression through differentiation before the CM was
collected from.

Figure 8.1: Schematic of the bioreactor used in the study. During the perfusion phase
(A) the solenoid valves on each side of the bioreactor are opened and media is pumped
through the biochamber with tubing and a peristaltic pump. During the compression
phase (B) the solenoid valves are closed, creating a closed volume of media surrounding
the construct. Air pressure is then introduced into the top of the syringes, pressing down
on the plunger and creating hydrostatic pressure on each phase of the construct.
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Figure 8.2: The upper picture shows the bioreactor setup with the media reservoirs on
the left and the bioreactor chambers on the right. The lower image shows a clearer
picture of a group of bioreactor chambers. A set of three chambers are connected to two
pairs of solenoid valves (A), one pair for the bone phases and a pair for the cartilage
phases. The valves are connected to tubing (B) that runs through a peristaltic pump and
connects to the media reservoirs. The syringes are connected to a pressurized air supply
that ultimately generates the hydrostatic pressure (C).
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RNA Isolation and Real Time RT-PCR
At Day 28, three constructs were used for RNA analysis. The samples were
removed from the bioreactors and the cartilage phase was separated from the bone phase.
In addition, samples that were producing osteoblast CM and chondrocyte CM were used
for RNA analysis as static comparisons. The agarose of the cartilage phases were
solubilized in 600 µl of QG Buffer (Qiagen AG, Switzerland) mixed with 600 µl of the
RLT Buffer from the RNeasy Mini Kit (Qiagen AG, Switzerland). The solution was left
at room temperature until complete dissolution of the agarose, and vortexed occasionally.
RNA was isolated using the RNeasy Mini Kit standard protocol. RNA was isolated
directly from the PL/PCL/HAP scaffolds of the bone phase using the RNeasy mini kit.
The quality and concentration of total RNA was determined using the Agilent RNA 6000
Nano Kit (Agilent Technologies, Santa Clara CA), the Agilent 2100 Bioanalyzer, and the
2100 Expert software. Equal amounts of total RNA were used for real time RT-PCR
using the QuantiFast SYBR Green RT-PCR Kit (Qiagen AG, Switzerland) in the RotorGene 5.0.28 light cycler (Corbett Life Science, Sydney, Australia). The markers that
were analyzed for the bone phase were runt-related transcription factor 2 (Runx2),
osteocalcin (OC) and bone sialoprotein (BSP). The markers that were analyzed for the
cartilage phase were sox9, aggrecan, and collagen Type II. GAPDH was used as a
housekeeping gene. The primer sequences can be seen in Table 8.1. Relative expression
was determined using the ∆∆Ct method with GAPDH as the reference gene and
undifferentiated hMSCs cells grown on a 2D surface were used as control samples
(appendix A).
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Table 8.1: Primer sequences used for RT-PCR
Primer
GAPDH

Sequence
F 5' - GGGCTGCTTTTAACTCTGGT - 3'
R 5' - GCAGGTTTTTCTAGACGG - 3'

Melting Temp (OC)
55.3
56

RunX2

F 5' - GACGAGGCAAGAGTTTCACC - 3'
R 5' - ATGAAATGCTTGGGAACTGC - 3'

54.6
55.5

Bone Sialoprotein

F 5' - AATGAAAACGAAGAAAGCGAAG - 3'
R 5' - ATCATAGCCATCGTAGCCTTGT - 3'

52.1
50.6

Osteocalcin

F 5' - ATGAGAGCCCTCACACTCCTC - 3'
R 5' - GCCGTAGAAGCGCCGATAGGC - 3'

58.3
62.8

Sox9

F 5' - ATCTGAAGAAGGAGAGCGAG - 3'
R 5' - TCAGAAGTCTCCAGAGCTTG - 3'

53.7
53.8

Aggrecan

F 5' - TGAGGAGGGCTGGAACAAGTACC - 3'
R 5' - GGAGGTGGTAATTGCAGGGAACA - 3'

60.6
59.3

Collagen Type II

F 5' - CAGGTCAAGATGGTC - 3'
R 5' - TTCAGCACCTGTCTCACCA - 3'

55.5
56.2

Histological Evaluation
Although protocols have been established for sectioning most types of natural
tissue, difficulties arise upon applying standard histological techniques to synthetic
polymer scaffolds infused with cells such as used in the present study. An additional
complicating factor is the fact that the hydrogel for the cartilage phase and polymer for
the bone phase are very different and finding a technique that is appropriate for both
phases can be difficult. Paraffin embedding is a widely used technique in histology,
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though it usually requires the use of organic solvents such as xylene as clearing agents for
the paraffin. These clearing agents also dissolve many solvent-soluble polymers like PL
and PCL. In addition, high temperatures are often involved in the embedding process that
can melt the polymer. Glycol methacrylate (GMA) embedding is another method that
could be used and was even used with the PL/PCL/HAP scaffolds in Chapter 3.
However, some immunohistochemical stains cannot be performed on samples embedded
in GMA. Cryosectioning is another possible method that can be used, though two
obstacles arise with this technique: poor infiltration of the viscous optimal cutting
temperature (OCT) embedding media into the construct and low adherence between the
section and slide after mounting.
After testing several different methods a modified cryosectioning protocol was
used. After 28 Days of culture in the bioreactor three samples were removed and used
for histological evaluation. Acellular control constructs were processed as well. Samples
were infiltrated with a series of diluted OCT (Tissue-Tek, Sakura; Torrance, CA) as
outlined in Table 8.2. After the infiltration process, the samples were placed in
disposable molds with OCT. The molds were left at -80 OC over night to freeze. Frozen,
OCT-embedded specimens were secured to cryostat chucks with OCT and sectioned at a
10 μm thickness at -26 OC. Sections were mounted on NewSilane adhesive coated slides
(Newcomer Supply Inc., Middleton, WI) and allowed to air dry for 2 h before staining.
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Table 8.2: Infiltration schedule for samples used for histological evaluation
Concentration Time
Vacuum/ Pressure
5% OCT

1 hour

Vacuum

25% OCT

1 hour

Vacuum

50% OCT

1 hour

Vacuum

75% OCT

1 hour

Vacuum

100% OCT

4 hours

Vacuum

The sections were stained with Safranin O (Poly Scientific, Bay Shore, NY) to
detect the presence of glycosaminoglycans (GAGs), a key component of cartilage. The
staining procedure is outlined in Appendix B. This stain results in glycosaminoglycans
being stained orange to red.

In addition, the sections were stained using the Dahl‟s

method for calcium (Poly Scientific, Bay Shore, NY) to visualize the presence of
mineralization. The staining procedure outlined in Appendix C. This stain results in
calcium being stained red to orange. Finally, a Masson's trichrome stain (Poly Scientific,
Bay Shore, NY) was also used to detect collagen that has been produced by the cells.
This stain results in collagen being stained blue. The staining procedure is outlined in
Appendix D.

Mechanical Testing
Viscoelastic mechanical testing was performed on the constructs after 43 days in
culture in the bioreactors. Mechanical testing was also performed on acellular constructs
to serve as a Day 0 control in order to assess any mechanical improvements resulting
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from ECM production from cells encapsulated in the agarose. In addition, the
mechanical testing was performed on porcine osteochondral tissue samples from the
femoral condyles of the hind limbs in order to benchmark the results.
Indention creep tests were performed on all samples using an Instron Model 5944
mechanical testing system (Instron, Norwood, MA) equipped with a 50 N load cell.
Samples were submerged in PBS and a tare load of 0.05 N was applied to ensure full
contact between the cartilage sample and the indentor tip. A 1.5 mm radius spherical tip
indentor was used for the test. After the samples came to equilibrium under the tare load,
a constant test load of 1N was then applied for 60 minutes and the sample displacement
was recorded.
Indentation compression stress relaxation testing was also performed on the
samples using an Instron Model 5944 mechanical testing system (Instron, Norwood, MA)
equipped with a 50 N load cell. Samples were placed in PBS and a tare load of 0.05 N
was applied to ensure full contact between the cartilage sample and the indentor tip. A
1.5 mm radius spherical tip indentor was used for the test. A 3% strain was held on the
specimen and the tissue was allowed to relax for 60 minutes.
Statistical Analysis
Averages were reported as mean values ± standard error of mean (n=3). Unpaired
t tests were used to make comparisons with a significance level of p < 0.05.
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Results
Real Time RT-PCR
The results of the real time RT-PCR for the expression of chondrogenic markers
are shown in Figure 8.3. All of the cartilage samples showed high levels of expression of
the chondrogenic markers. The static cartilage samples showed significantly higher
expression of all three markers, sox9, aggrecan, and collagen type II, than the static bone
samples. The cartilage phase of the constructs cultured in the bioreactor showed a higher
expression of all three markers, sox9, aggrecan, and collagen type II, than the bone phase
of the constructs cultured in the bioreactor. In addition, the cartilage phases cultured in
the bioreactor showed higher aggrecan and collagen type II expression as compared to
the static cartilage samples.
The results of the real time RT-PCR for the expression of osteogenic markers are
shown in Figure 8.4. All of the bone samples showed high levels of expression of the
osteogenic markers. The static bone samples showed significantly higher expression of
all three markers, RunX2, BSP, and OC, than the static cartilage samples. The bone
phase of the constructs cultured in the bioreactor showed a higher expression of all three
markers than the cartilage phase of the constructs cultured in the bioreactor. In addition,
the bone phases cultured in the bioreactor showed higher RunX2, BSP, and OC
expression as compared to the static bone samples.
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Figure 8.3: Results of the real time RT-PCR for the chondrogenic markers sox9,
aggrecan and collagen Type II. The results are reported as relative expression to
GAPDH using the ∆∆Ct method. Error bars represent the SD. Pound symbols (#)
signify significant differences (p< 0.05) between relative expressions of chondrogenic
markers in the static cartilage samples and the static bone samples. Asterisks (*) signify
statistically significant differences (p< 0.05) between relative expressions of
chondrogenic markers in the cartilage phases and bone phases cultured in the
bioreactors. Squares and diamonds (□, ◊) signify statistically significant differences (p<
0.05) between relative expressions of chondrogenic markers in the static cartilage
samples and the cartilage phase of the constructs cultured in the bioreactors.
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Figure 8.4: Results of the real time RT-PCR for the osteogenic markers RunX2, bone
sialoprotein and osteocalcin. The results are reported as relative expression to GAPDH
using the ∆∆Ct method. Error bars represent the SD. Pound symbols (#) signify
significant differences (p< 0.05) between relative expressions of osteogenic markers in
the static bone samples and the static cartilage samples. Asterisks (*) signify statistically
significant differences (p< 0.05) between relative expressions of osteogenic markers in
the bone phases and cartilage phases cultured in the bioreactors. Squares, diamonds,
and triangles (□, ◊, Δ) signify statistically significant differences (p< 0.05) between
relative expressions of osteogenic markers in the static bone samples and the bone phase
of the constructs cultured in the bioreactors.

Histological Evaluation
The results of the safranin-O staining for glycosaminoglycans are shown in Figure
8.5. The cartilage phase showed strong red-orange staining indicating the presence of
GAGs throughout the entire phase. The red-orange staining was present in the agarose
through the entire cartilage phase and was not present in the bone phase (Figure 8.5B).
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Figure 8.5: Results of the safranin-O staining for GAGs in the cartilage phase (A), the
interface of the bone and cartilage phases (B), acellular agarose control (C), and the
interface of the acellular control (D). Original total magnification of all micrographs
was 50X. Blue arrows indicate cartilage phase and black arrows indicate bone phase.

The results of the Dahl‟s staining method for calcium to visualize the presence of
mineralization are shown in Figure 8.6. The HAP particles that are part of the scaffold
were stained red throughout the PL/PCL matrix (black arrows). Red staining indicated
that mineralization only occurred along the edges of the pores of the scaffolds cultured in
the bioreactor.
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Figure 8.6: Results of the Dahl’s staining method for mineralization in the bone phase at
5OX original total magnification (A) and 100X original total magnification (B) and the
acellular control at 50X (A) and 100X (B). Black arrows indicate HAP particles that are
part of the scaffold. Blue arrows indicate mineralization generated by the cells.

The results of the Masson‟s trichrome stain are shown in Figure 8.7. The
presence of collagen is indicated by blue staining. Collagen fibers were attached to the
PL/PCL/HAP scaffolds and extended into the pores of the structure.
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Figure 8.7: Results of the Masson’s trichrome staining. Collagen fibers, indicated by
blue staining and black arrow, were seen attached to the PL/PCL/HAP scaffolds in the
bone phase. Original total magnification was 200X.

Mechanical Testing
The typical results of the indentation creep test are show in Figure 8.8. The initial
indentation due to the 1 N load and total creep over the 60 minute test are shown in Table
8.3. The initial indentation decreased from 0.95 ± 0.22 mm in the acellular agarose
controls to 0.77 ± 0.23 mm in the constructs cultured in the bioreactor. The initial
indentation of articular cartilage was 0.68 ± 0.18 mm. The total creep decreased from
0.60 ± 0.17 mm in the acellular agarose controls to 0.51 ± 0.20 mm in the constructs
cultured in the bioreactor. The total creep in the articular cartilage was 0.31 ± 0.12.
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Figure 8.8: Typical creep profiles of the acellular agarose controls, articular cartilage,
and the experimental samples.

Table 8.3: Results of indentation creep test
Sample
Acellular agarose control
Articular cartilage
Experimental sample

Initial
Indentation (mm)
0.95 ± 0.22
0.68 ± 0.18
0.77 ± 0.23

Total Creep
(mm)
0.6 ± 0.17
0.31 ± 0.12
0.51 ± 0.20

The typical results of the stress relaxation test are show in Figure 8.9. The initial
stress required for the initial 3% strain and the total stress relaxation over the 60 minute
test are shown in Table 8.4. The initial stress increased from 680 ± 180 kPa in the
acellular agarose controls to 820 ± 290 mm in the constructs cultured in the bioreactor.
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The initial stress of articular cartilage was 1330 ± 270 kPa. The total relaxation increased
from 370 ± 130 kPa in the acellular agarose controls to 630 ± 240 mm in the constructs
cultured in the bioreactor. The total stress relaxation in the articular cartilage was 1190 ±
320.

Figure 8.9: Typical stress relaxation profiles of the acellular agarose controls, articular
cartilage, and the experimental samples.

Table 8.4: Results of indentation stress relaxation test

Sample
Acellular agarose control
Articular cartilage
Experimental sample

Initial Stress (kPa)
680 ± 180
1330 ± 270
820 ± 290
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Total Relaxation (kPa)
370 ± 130
1190 ± 320
630 ± 240

Discussion
Previous work on the development on a biphasic osteochondral tissue engineered
construct has demonstrated the advantages of incorporating CM in the culture, the
advantages of a construct design consisting of a agarose cartilage phase on top of a
PL/PCL/HAP bone phase, and the advantages of using bioreactor technology to
administer physical stimuli. These three areas have already been investigated
individually. Now this combinatory study brought together all three of areas in an effort
to generate and characterize a biphasic tissue engineered osteochondral construct. The
study involved seeding of hMSCs on the newly designed biphasic osteochondral
construct and culturing the constructs in the modified bioreactor, while applying fluid
flow and hydrostatic pressure to each phase of the construct. In addition, the bone phase
was cultured with chondrocyte CM and the cartilage phase was cultured with osteoblast
CM. Ultimately, the combination of all these factors in this study generated a biphasic
construct with a cartilage like upper phase attached to a bone like bottom phase.
The results of the RT-PCR, histology and viscoelastic mechanical testing
illustrated the differentiation of the hMSCs and production of cartilage-like extracellular
matrix (ECM). The cartilage phase showed high expression of all three of the
chondrogenic markers tested for in this study, sox9, aggrecan, and collagen Type II. The
nuclear transcription factor sox9 is one of earliest markers expressed in cells undergoing
chondrogesis. The marker sox9 is required for the expression of the Type II collagen
gene and certain other cartilage-specific matrix proteins [8]. The expression of sox9 is
typically transient with a peak expression during the chondroprogenitor stage, followed
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by a decrease in expression as the cells reach terminal differentiation [8]. As a result, the
expression of sox9 in the cartilage phase of the construct was the lowest of all markers
since the end point of the study was at Day 28. Collagen Type II and aggrecan are the
two major component of the ECM of articular cartilage. In articular cartilage, 90–95%
of the collagen in the ECM is formed by collagen Type II fibrils, which provide the
tensile strength of the tissue [9]. The proteoglycan (PG) aggrecan is the most abundant
PG in articular cartilage and the high content is often used to characterize articular
cartilage. Aggrecan molecules do not exist in isolation within the extracellular matrix,
but as proteoglycan aggregates [10]. The RNA expression of both collagen Type II and
aggrecan was high in the cartilage phase of the constructs, as well as the chondrogenic
samples that are producing chondrocyte CM. However, the expression of both markers
was significantly higher in the cartilage phase of the constructs as compared to the
chondrocyte CM samples. This illustrates that combination of the osteoblast CM,
bioreactor culture, and the biphasic scaffold enhance the chondrogenic differentiation.
The results of the safranin-O staining for GAGs also demonstrated the production of a
cartilage-like ECM. The strong red-orange staining indicated the presence of GAGs
throughout the agarose hydrogel in the cartilage phase that was not present in the
acellular controls. This results shows that, not only are the cells expressing the RNA of
the chondrogenic markers, but the GAGs are being produced and retained in the
biomaterial.
Indentation experiments are the most frequently used method for studying the
biomechanical properties of articular cartilage [11]. An advantage of this method is that
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the mechanical properties of cartilage are determined on the bone, a condition more
closely resembling the physiological situation [11]. The results of the viscoelastic
indentation mechanical testing in this study indicated that the experimental constructs
showed an improvement in mechanical properties over the controls and approached the
properties of articular cartilage. The dominant physical mechanism affecting the
viscoelastic responses of cartilage is the frictional drag caused by interstitial fluid flow
through the porous-permeable solid matrix [12]. A faster decay of stress indicates a
faster loss of the fluid content, suggesting an inferior ability of the tissue or material to
trap fluid, or a higher permeability. The acellular agarose control group depicted a very
rapid stress decay and large depth of indentation. However, after 43 days of culture in
the bioreactor, the experimental sample showed a slower stress relaxation rate closer to
the profile that was seen by the articular cartilage. In addition, the experimental samples
showed a smaller indentation depth than the acellular control and approached the
properties of the articular cartilage. These results indicate that during the 43 days of
culture a cartilage-like tissue was generated with mechanical properties that approached
those of articular cartilage.
The RT-PCR and histology results also indicated the hMSCs in the bone phase of
the constructs underwent osteogenic differentiation and produced a bone-like ECM. The
bone phase of the constructs showed higher expression of all three osteogenic markers
RunX2, BS, and OC. Runx2 is one of the earliest and most specific markers of osteoblast
differentiation. It is a master transcription factor and a key activator of osteogenic
differentiation [13]. Runx2‟s main role is in the initiation of osteogenic differentiation
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during osteogenic commitment of an osteogenic precursor and as a result is expressed at
its highest levels during the early stages of osteogenic differentiation [14]. Consequently,
the Runx2 expression of the bone phase of the constructs was lower than that of the other
markers since the RT-PCR was run on Day 28. OC induction is initiated at middle to late
stages of osteogenic differentiation, at the very beginning of extracellular matrix
mineralization, where it plays a key role in the normal completion of osteogenic
differentiation [13]. BSP appears to be involved with the formation of the initial
hydroxyapatite crystals at collagen fibril sites and serves as a nucleation site for
hydroxyapatite [15]. The RNA expression of both OC and BSP was high in the bone
phase on the constructs, as well as the osteogenic samples that are producing osteoblast
CM. Yet, the expression of both markers was significantly higher in the bone phase of
the constructs as compared to the osteoblast CM samples. This demonstrates that
combination of the chondrocyte CM, bioreactor culture, and the biphasic scaffold
enhance the osteogenic differentiation.
The results of the Dahl‟s method of staining for calcium revealed some very
interesting patterns of mineralization in the bone phase. The HAP particles that were part
of the scaffold appeared as red spots throughout the polymer scaffold in both the
experimental samples and the acellular controls. Mineralization generated by the
osteoblasts within the scaffold was observed around the edges of the pores of the
scaffold. This is a similar pattern to that which can be seen during in vivo bone
remodeling. The results of the Masson‟s trichrome staining also showed the presence of
newly formed collagen fibers that likely correlate to newly formed, unmineralized ECM.
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One of the shortcomings seen in this study was the lack of a clearly defined
separation of the cartilage and bone phases. While there did appear to be a good
integration of the two phases, the interface lacked the appearance of the natural
osteochondral junction. The osteochondral junction between cartilage and bone in
diarthrodial joints is a complex region that includes a sharp boundary between calcified
and non-calcified articular cartilage matrices, often referred to as the tidemark, and a less
distinct boundary between calcified cartilage and subchondral bone [16]. It has been
hypothesized that the stepwise transition in stiffness from cartilage to bone is important
for the distribution of forces across the joint without allowing failure at the cartilage–
bone junction [17]. Therefore the strength of the interface in the tissue engineered
construct must also be sufficient to avoid detachment of the newly formed cartilage tissue
from the underlying bone phase. However, it is possible that an osteochondral junction
more similar to one typically seen in vivo could be generated with a longer culture time or
in an in vivo study. The tidemark is formed through endochondral ossification, which
involves terminal differentiation of chondrocytes to the hypertrophic phenotype, cartilage
matrix calcification, and ossification [8]. With more time the cells may undergo this
process, generating a stronger junction.
The combination of CM, bioreactor cultivation, and the unique construct design
generated a biphasic tissue engineered osteochondral construct. However, future studies
are needed to further the development of the construct to a clinically viable application.
Primary cells will need to be used to replicate the scenario seen in the clinical setting. In
addition, shear testing should be conducted on the constructs. This method of mechanical

245

testing is rarely seen in the literature; however it is important as that is often a form of
failure in osteochondral grafts. Finally, in vivo studies will have to be conducted to
assess the functionality of the engineered tissue as well as the long term results.

Conclusion
In this study we were able to form a biphasic construct with a top phase having
cartilage-like phenotype and genotype characteristics attached to a phase with bone-like
phenotype and genotype characteristics from hMSCs. A cartilage phase was formed that
expressed sox9, collagen type II, and aggrecan at high levels. The cartilage phase also
stained strongly for the presence of GAGs throughout the agarose hydrogel. In addition,
the mechanical properties were improved after 43 days in culture. Similarly, the bone
phase showed high levels of expression of runx2, OC, and BSP. Finally, the bone phase
showed mineralization along the edges of the pores and the presence of collagen fibers.
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CONCLUSIONS
Three different areas of focus significant to the development of a tissue
engineered mesenchymal stem cell (MSC) based osteochondral construct were explored
in these works. The use of conditioned media (CM) to examine cellular interactions and
enhance stem cell differentiation was investigated. The construct design itself and the
biomaterials selection were evaluated. Finally, bioreactor technology was employed to
generate an in vitro modeling system and provide advantageous culturing environments.
The following conclusions were extracted from the work on the development of the
osteochondral tissue engineering construct.


CM from differentiating adipocytes can enhance the osteogenic differentiation of
MSCs.



CM from differentiating osteoblasts can enhance the adipogenic differentiation of
MSCs.



CM from differentiating chondrocytes can enhance the osteogenic differentiation
of MSCs.



CM from differentiating osteoblasts can enhance the chondrogenic differentiation
of MSCs.



The encapsulation of MSCs in alginate can induce chondrogenic differentiation.



While PL/PCL/HAP scaffolds support osteogenic differentiation, they do not
specifically induce differentiation.



Osteochondral constructs were designed to address some of the current limitations
that osteochondral tissue engineering currently faces, including an alternative
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method of anchoring the construct and possessing the ability to generate large
viable constructs.


The barbed pins designed for anchoring the constructs into the defect area
provided a pull-out strength similar to that of press fit osteochondral grafts.



The addition of hydroxyapatite improves the mechanical properties and enhances
the cellular attachment and osteogenic differentiation of porous
polylactide/polycaprolactone scaffolds.



The incorporation of capillary channel fibers does not have a significant effect on
small PL/PCL/HAP scaffolds.



MSCs encapsulated in agarose showed superior cell viability and chondrogenic
differentiation as compared to cells encapsulated in alginate.



The addition of dexamethasone to culture medium was shown to increase
chondrogenic differentiation.



Modifications made to the bioreactor system generated a more reliable method of
producing hydrostatic pressure on 3D samples.



Modifications made to the bioreactor system also allowed for a biphasic construct
to be cultured with perfusion flow and hydrostatic pressure applied to both
phases.



Both osteoblast CM and intermittent hydrostatic pressure individually enhance the
chondrogenic differentiation of MSCs.



There is evidence of a synergistic interaction between CM and hydrostatic
pressure on chondrogenic differentiation.
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Individually, chondrocyte CM and hydrostatic pressure do not have a significant
effect of osteogenic differentiation in the bioreactor system.



The combination of chondrocyte CM and hydrostatic pressure significantly
enhance the osteogenic differentiation of MSCs.



Both the chondrocyte CM and osteoblast CM contained considerable amounts of
TGF-β1 and also contained BMP-2 that were generated by the cells. These
cytokines likely contributed to the effects of the CM.



Bundles of capillary channel fibers embedded in large tissue engineering
scaffolds, as well as large fiber bundles can produce a uniform cell distribution
through the thickness of large scaffolds.



Cells that infiltrated into large scaffolds containing capillary channel fibers were
able to remain viable after 21 days of culture.



A linear relationship between total protein content and cell number was
demonstrated in cells undergoing osteogenic differentiation.



The combination of CM, bioreactor cultivation, and the unique construct design
generated a biphasic construct with a top phase having cartilage like phenotype
and genotype characteristics attached to a phase with bone like phenotype and
genotype characteristics from hMSCs.
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RECOMMENDATIONS FOR FUTURE WORK


Additional in vitro studies should be conducted to evaluate the effects of
administering CM from MSCs at different stages of differentiation. In addition,
studies should be conducted to evaluate the effect of administering CM in varying
concentrations other than 25% and 50% as presented in Chapter 2.



Future studies should evaluate a variety of different HAP concentrations in the
scaffolds to further optimize the design of the constructs. Different HAP
concentrations will likely affect the processing, cellular viability, cellular
attachment, differentiation and mechanical properties.



The next generation design of the constructs should include replacement of the
polyurethane fibers with fibers made of a degradable polymer. PCL or a PCL copolymer are good candidates as their flexibility allow for easier bundle formation
than does a PL fiber. It may also be beneficial to include a coating on the fiber
bundles which may enhance the fluid transport.



Future work is needed for more in-depth evaluation of different parameters of
hydrostatic pressure and peristaltic flow. Variables such as magnitude, frequency,
and duration may have an impact on the cellular differentiation and tissue
formation.



Additional studies should be conducted to evaluate different arrangements of fiber
bundles within the large scaffolds. Different patterns, different numbers of fibers
within the bundles, and different spacing between the bundles will likely have an
effect on the cellular distribution and viability.
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The orientation of the fiber bundles within the constructs was changed to run
along the longitudinal axis of the constructs, partially to address the idea that
growth factors and cytokines that the cells are producing could be transported via
the fibers instead of administering CM. This hypothesis needs testing in future
studies.



The bioreactor needs to be further improved by simplifying the design. The
current embodiment involves many different connections, each one an
opportunity for leaking and contamination. In addition, the biochambers are held
together with nuts and bolts. Both of these issues result in the assembly of the
bioreactors being cumbersome, time consuming, and full of potential
contamination opportunities.



In addition to the mechanical properties that were already tested, the shear
properties should be tested as that is a common form of failure for an
osteochondral graft.



After further in vitro testing, in vivo implantation studies should be conducted.
The integration of the constructs with the native cartilage and bone should be a
major point of emphasis of those studies as well as long term results.



Future work should also include in vivo studies to investigate what maturation
level of the engineered tissue is appropriate at the time of implantation to generate
the best results. It could be advantages to implant tissues that are well developed
as it could allow for early post-operative rehabilitation and enhance support of
physiological mechanical loads. Conversely, less mature grafts may be able to

253

integrate better with the native tissue and perhaps allow for implantation during
the initial surgery.
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APPENDICES
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Appendix A
ΔΔCt Method for Determining Relative Quantitation of RT-PCR Results
Definitions
Control = Samples used as control condition (i.e. undifferentiated, 2D, static)
Experimental = Samples cultured under experimental conditions (i.e. CM, bioreactor, 3D)
Target = Gene that the expression is being evaluated (i.e. sox9, runx2, aggrecan,
osteocalcin)
Reference = Housekeeping gene (i.e. GAPDH)
ΔCt(control) = Ct(target) – Ct(reference)
ΔCt(sample) = Ct(target) – Ct(reference)
ΔΔCt = Ct(sample) – Ct(control)
Relative Expression = 2 -ΔΔCt

Example
Ct Values

sox9 (target)
GAPDH (reference)

Undifferentiated
(control)
12
8

Bioreactor
(experimental)
10
8

ΔCt(control) = 12 – 8 = 4
ΔCt(sample) = 10 – 8 = 2
ΔΔCt = 2 - 4
Relative Expression = 2 –(-2) = 4
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Appendix B
Safranin O Staining Procedure for Frozen Sections
Solutions:
1% Safranin O (Stock)
Safranin O ……………………………………….1.0 gm
Distilled Water…………………………………100.0 ml
1% Glacial Acetic Acid
Glacial acetic acid………………………………...1.0 ml
Distilled water………………………………….100.0 ml
0.1% Safranin O Solution (Working)
1% safranin O (stock)……………………………10.0 ml
1% glacial acetic acid…………………………..100.0 ml
5% Phosphotungstic acid
Phosphotungstic acid……………………………….5.0 g
Distilled water………………...………………..100.0 ml
2% Light Green SF Yellowish
Light green SF yellowish……..…………………....2.0 g
Distilled water……………………..…………...100.0 ml
Staining Procedure:
1. Soak in Acetone at -20o C for 10 minutes
2. Rinse in tap water for 1 minute
3. Safranin O working solution for 8 minutes
4. Rinse in tap water – 1 quick dip
5. Soak in 5% Phosphotungstic acid for 1 minute.
6. Tap water rinse for 3 dips
7. Soak in 2% Light Green for 1 minute
8. Gently rinse in running tap water until no stain bleaches out
9. Dehydrate in 95% alcohol, absolute alcohol
Results
Proteoglycans – reddish orange
Collagen – green
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Appendix C
Dahl’s Method for Calcium Staining Procedure for Frozen Sections
Solutions
Ammonium Hydroxide 0.1% Aqueous
Alizarin Red S working solution
Ammonium Hydroxide 0.1%...........................10 ml
Alizarin Red S 1%..........................................100 ml
Fast Green substitute for Light Green 1%
Staining Procedure
1. Soak in Acetone at -20o C for 10 minutes
2. Rinse in tap water for 1 minute
3. Stain in Alizarin Red S working solution for 2 minutes
4. Rinse in distilled water for 5-6 rinses
5. Fast green substitute for light green 1% for 1 minute
6. Rinse in distilled water for 5-10 seconds
7. Dehydrate in 95% alcohol, absolute alcohol

Results
Calcium salts – intense reddish orange
Background – pale green
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Appendix D
Masson’s Trichrome Staining Procedure for Frozen Sections
Solutions
Bouin’s Fixative
Weigert’s Iron Hematoxylin working solution
Equal parts solution A & B
Biebrich Scarlet – Acid Fuschsin Solution
Phosphotungstic – Phophomolybdic Acid
Aniline Blue Masson’s Trichrome
Acetic Acid 1% Aqueous
Staining Procedure
1. Soak in Acetone at -20o C for 10 minutes
2. Rinse in tap water for 1 minute
3. Mordant in Bouin‟s fixative for 1 hour at 56o C
4. Cool and wash in running water until yellow color disappears
5. Rinse in distilled water
6. Weigert‟s Iron Hematoxylin working solution for 10 minutes
7. Running water for 10 minutes
8. Rinse in distilled water
9. Biebrich Scarlet – Acid Fuchsin for 2 minutes
10. Rinse in distilled water
11. Phosphotungstic – Phophomolybdic Acid for 10 minutes
12. Aniline Blue solution for 5 minutes
13. Rinse in distilled water
14. Acetic acid 1% for 3 minutes
15. Dehydrate in 95% alcohol, absolute alcohol
Results
Collagen – blue
Nuclei – black
Cytoplasm - red
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